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Chapter 1: Introduction  
Metal complex-peptide conjugates have been extensively explored in bioorganic 
chemistry, catalysis and de novo peptide and protein design. Metal complex-peptide 
conjugates are often used as radiopharmaceuticals1,2, imaging agents3-5, DNA/protein 
inactivating agents6-10 as well as anticancer and antibacterial agents.11 In such examples 
peptide motifs often serve as delivery vectors and carry the metal complexes to biological 
targets. With the advent of de novo designed metallopeptides, applications of metal complex-
peptide conjugates have advanced beyond the biomedicine regime. The metal-assisted 
stabilization of peptide-microstructure is now being used in molecular recognition motifs, 
catalysis, light harvesting systems and material science.12,13  
Considering the plethora of applications for metal complex-peptide conjugates, 
methods for their syntheses have been widely investigated. Methods for the synthesis of 
metal complex-peptide conjugates can be divided into two categories. The first method is 
called pre-conjugation, in which metals are coordinated to ligands prior to their incorporation 
into peptide chains. In the second method, metals are coordinated to ligands after they have 
been conjugated to peptide chains, hence this is called the post-conjugation method. Among 
these methods, the post-conjugation method is more frequently used since it allows the 
incorporation of sensitive/reactive metal complexes into the peptide during the final steps of 
the synthesis. Indeed several ligands containing N-, O-, P- and S-donor atoms have been 
successfully appended into the peptide chain at various positions. Using these peptide-ligand 
conjugates, sensitive, reactive or toxic metal complexes such as those used in 
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radiopharmaceutical, imaging and catalysis applications have been incorporated into peptide 
chains.  
Despite all of the applications of peptide-ligand conjugates, methods for 
incorporating polydentate nitrogen-rich ligands into peptides are limited. In particular, 
divergent methods, where libraries of these chelators are built on a peptide scaffold were not 
known. Given the utility of such ligands in biology and bioinorganic chemistry, this was an 
area of research that needed to be explored. For example, high valent iron-oxo complexes, 
also called ferryl complexes, can be built from such ligands and have been thoroughly 
investigated as oxidants and enzyme models.14,15 The Kodanko group has recently 
demonstrated the application of non-heme ligands and their ferryl complexes in cancer cell 
cytotoxicity16 and protein inactivation.17 Considering these results, incorporation of such 
non-heme ligands into peptides and understanding the chemistry of ferryl-peptide conjugates 
would be very critical for their applications as site selective anticancer agents. In addition 
this knowledge would be beneficial for the synthesis of artificial oxygenases. Unfortunately 
there is no divergent strategy available for the incorporation of non-heme ligands that support 
ferryl complexes into peptides. Moreover chemistry of ferryl-peptide conjugates is 
unexplored. This lack of information motivated us to develop a divergent strategy for the 
synthesis of non-heme ligand-peptide conjugates and explore its applications. 
This dissertation will discuss my contribution towards efforts in the Kodanko group 
to explore the applications of non-heme transition metal complexes in targeting proteins, in 
metal-chelators mediated cancer therapy and in de novo protein design for artificial 
oxygenases as well as in intracellular localization of metal complexes. The first chapter will 
provide an overview of the research pertaining to my work in the Kodanko group. The first 
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section of this chapter will survey the existing strategies for the synthesis of peptide-ligand 
conjugates and discuss where our strategy fits with respect to other methods in the literature. 
The second section will include the applications of metal complex-ligand conjugates derived 
from peptide-ligand conjugates. In the subsequent section the chemistry of ferryls will be 
discussed in the context of the development of ferryl-peptide conjugates. The chapter will 
end with the thesis statement where the research goals and their importance will be 
discussed. 
1.1 Synthesis Strategies for Peptide-Ligand Conjugates 
In this section the strategies for the synthesis of peptide-ligand conjugates are 
described. This section has been limited to only post-conjugation labeling methods. Ligands 
have been incorporated into peptides via N- and/or C-terminus conjugation, within the 
backbone or through a side chain. Therefore these synthetic strategies are discussed 
according to these three major categories (Figure 1.1).  
Peptide CONH2 PeptideH Peptide
Peptide CONH2 Peptide CONH2HPeptideH
Ligands at N– and/or C– terminal
Ligands in backbone Ligands in side chain
= Metal binding 
   ligand
 
Figure 1.1: Types of peptide-ligand conjugates 
1.1.1 Ligands at N- and/or C-termini of peptides 
1.1.1.1 Ligand conjugation at the N-terminus 
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Since peptide synthesis is usually performed from C- to N-terminus via solid-phase 
peptide synthesis (SPPS), the most simple, convenient and widely used method to construct 
peptide-ligand conjugates is to attach ligands at the N-terminus.18-32 For conjugation at the N-
terminus, it is a common practice to include a linker between the metal-binding moiety and 
the peptide chain. In several instances, these spacers are found to be very critical to maintain 
the biological activity of the resulting metal complex-peptide conjugates.32,33 Typical 
procedures include the synthesis of a desired peptide sequence followed by the attachment of 
linkers at the N-terminus through an amide bond formation. Upon cleavage of the Fmoc 
group from the linker, the amine functionality is exposed through which the ligands are 
attached (Figure 1.2, Mode A).27,34 Alternatively, such linkers can be coupled first to ligands 
via solution phase synthesis, which can then be tethered at the N-terminus of the peptide 
chain (Figure 1.2, Mode B).18-20,25,26 In addition to the traditional amide bond formation, 
ligands bearing activated esters and isocyanates groups could also be used as a mode of 
conjugation.35,36 
PeptideFmocHN R
Linker X
Peptide RLinker
Linker COOHFmocHN
FmocHN Peptide RLinker
X
Mode A
Mode B
 
Figure 1.2: Modes of ligand conjugation at the N-terminus of peptides 
Alternative to the standard coupling methods, click chemistry has also been used to 
construct peptide-ligand conjugates. For instance, the azide linker has been appended at the 
N-terminus of somatostatin 2 and a click reaction has been used to tether the alkyne-bearing  
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Scheme 1.1: Conjugation of DOTA at the N-terminus of octreotide via (a) copper catalyzed 
click reaction and (b) copper free click reaction 
DOTA 1 with peptide 2 (Scheme 1.1a).34 The use of an unprotected peptide demonstrates the 
remarkable chemoselectivity of this method. Despite such remarkable functional group 
compatibility, copper accumulation within the resulting peptide-ligand conjugates 3 limited 
the use of this strategy. To overcome this drawback, a sulfo-click reaction was developed in 
which alkyne containing thioester 4 was conjugated to the azido somatostatin analogue 2 via 
a traditional copper catalyzed click reaction (Scheme 1.1b).37 Acidolytic cleavage of the 
  
 
6 
resulting thioester 5 unmasked the corresponding thioacid, which upon reaction with the 
DOTA bearing sulfonyl azide 6 furnished a sulfonamide linkage that conjugates DOTA with 
somatostatin. Mechanistic investigation suggested that the reaction proceeds via formation of 
a thiatriazoline and not via acyl substitution.38,39 This is important since the later mechanism 
would not be chemoselective due to the presence of nucleophilic side chains in the 
unprotected peptide. 
N
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N
H
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P P
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    resin
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Scheme 1.2: Dithia-bisphosphine (P2S2) chelating agents at the N-terminus of the bombesin 
analogue 
Although phosphine ligands are extensively used in organometallic complexes, their 
incorporation into peptides has been challenging due to the oxidation prone nature of alkyl 
phosphines, particularly in acidolytic cleavage conditions that are used to cleave peptides 
from resin. Such phosphine-ligand conjugates have been constructed in a stepwise fashion 
via solution as well as solid phase synthesis as described in Scheme 1.2.40 Unlike alkyl 
phosphines, phosphorous hydrides (PH2) have remarkable stability towards oxidation and 
other chemical reactions. Hence a straightforward incorporation into peptides was possible. 
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After conjugation of (PH2)2S2-ligand at the N-terminus of the BBN analogue, the formylation 
of the phosphorous hydride moiety of 8 and cleavage of the peptide from resin yielded 
oxidatively stable phosphonium salt 9. Treatment of the resulting phosphinium salt with 1M 
NaHCO3 exposed the reactive bis(hydroxymethyl) phosphine 10 in situ, which was 
eventually transformed into the corresponding metal complexes. Using this method, P2S2-
ligands were also incorporated at the Nε-lysine of the LHRH analogue. 
The stepwise ligand synthesis method has also been applied to the synthesis of N- and 
O-donor ligands. As shown in Scheme 1.3, NOTA-Aoc-BBN[6-14] (Where NOTA = 1,4,7-
triazacyclononane-N,N’,N”-triacetic acid) was synthesized on NovaSyn TGR resin.41 Upon 
synthesis of the desired peptide sequence 12, α-bromo acetic acid was coupled at the N-
terminus to obtain 13. A two-step N-alkylation sequence followed by cleavage from resin 
gave the NOTA-peptide conjugate 15. It is important to note that only one peptide was 
coupled per molecule of 1,4,7-triazacyclononane in the first alkylation (13 to 14). The NOTA 
ligand has also been attached to Nε-amino of lysine using this strategy (vide infra). 
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Scheme 1.3: Stepwise synthesis of NOTA on peptide bound resin 
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1.1.1.2 Ligand conjugation at the C-terminus 
Ligand conjugation at the C-terminus of a peptide is the most challenging since 
peptides are usually synthesized via SPPS where C-terminus is attached to the solid support 
and a peptide chain is elongated from C- to N-terminus. An obvious method to conjugate 
ligands at the C-terminus is to attach ligands directly to the resin through a reactive 
functionality of a ligand (16) prior to elongation of the peptide chain (Scheme 1.4).42 Finally 
the conjugate is cleaved from resin in a separate step or through in situ cleavage followed by 
complex formation (18 to 19). Unlike the example shown in Scheme 1.4, if a ligand has 
amino acid functionality it could be directly attached to the resin prior to the incorporation of 
the first amino acid residue in SPPS.43 
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Scheme 1.4: Incorporation of monoamide monoamine (MAMA) ligands at the C-terminus of 
the peptide chain 
A creative approach for ligand conjugation at the C-terminus involves the use of 
safety-catch linkers. A representative example is shown in Scheme 1.5 where a peptide 20 
was built on the resin 19 containing a sulfonamide linker.44 Upon completion of the desired 
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sequence, alkylation of the N-acylsulfonamide with iodoacetonitrile generated a highly 
reactive N,N-cyanomethyl-acylsulfonamide 21. Displacement of the activated linker by 
nucleophilic propargyl amine furnished the peptide-ligand conjugate 22 where propargyl amine 
was tethered to the C-terminus. The alkyne moiety served as a ligand in the formation of 
hexacarbonyl cobalt complex. In another example, hydrazyl amide linker was used as a safety-
catch linker in SPPS (vide infra). 
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Scheme 1.5: Use of safety catch linker for incorporation of dicobalthexacarbonyl-alkyne at 
the C-terminal of enkephaline 
1.1.1.3 Ligand conjugation at both termini 
An obvious method to adjoin ligands at both termini involves the ligand conjugation 
at the N-terminus using standard methods, followed by cleave the peptide-ligand conjugate 
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from resin and attachment of the ligand at the C-terminus via solution phase synthesis.45 As 
shown in Scheme 1.6, a substitution reaction between ligands carrying the benzyl halide 
linker and a C-terminus acid could be used as a conjugation method (24 to 25). Although no 
side chain protecting groups were present in the example shown here, the use of Sasrin resin 
is noteworthy because the side chain protecting groups of a peptide are retained when it is 
cleaved from Sasrin. This is important since the peptide side chains are expected to remain 
protected during the subsequent solution phase reaction. An apparent drawback of this 
method is that the final step has to be performed via solution phase synthesis, which is 
usually associated with insolubility and purification issues. In addition, if side chain 
protecting groups are present on the final conjugate, then a separate deprotection step is 
necessary. 
R
CO-NH-(Gly)2-Val-(Gly)3-Pro-(Gly)4-COO-CH2N N
N
N
N
N
CO-NH-(Gly)2-Val-(Gly)3-Pro-(Gly)4-COO-CH2—N
N
N
1. TFA, CH2Cl2
2. 4'-(4-(bromomethyl)phenyl)-2,2':6',2''-
    terpyridine, K2CO3, DMF
24
25  
Scheme 1.6: Terpyridine conjugation at both the termini of a peptide for metal-assisted 
assembly of cyclometallopeptides 
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As described previously, safety catch linkers are also useful in incorporating ligands 
at both termini of peptides (Scheme 1.7).46 A peptide was synthesized via SPPS using a 
safety catch linker and after ligand conjugation at the N-terminus, concomitant copper (II) 
acetate mediated oxidation of hydrazyl amide linker followed by nucleophilic displacement 
provided peptide-ligand conjugates in which ligands are present at both termini of the peptide. 
In the following example an unusual Lewis acid mediated cleavage condition was required to 
cleave methyl ether protecting groups on the catechol side chains. 
Cu(OAc)2, DMF, air
then 2,3-Dimethoxy 
benzylamine
N
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R
26 27  
Scheme 1.7: RGD-bridged catechol ligands for metallomacrocycles 
Apart from ligand conjugation at both termini, synthetic methods that allow selective 
incorporation of ligands at either N- or C-terminus from the same precursor are certainly 
interesting. In the following example, a threonine building block 28 was synthesized so that 
the side chain was attached to the acid labile dihydropyran resin, while N- and C-terminus 
were protected as Fmoc- and allyl groups, respectively (Scheme 1.8).47 For conjugation of 
ligands at the N-terminus, DOTA or HYNIC ligands were incorporated into the peptide using 
traditional N-terminus ligand conjugation methods, except that a palladium-catalyzed allyl 
deprotection was performed prior to the cleavage of peptide from resin (28 to 29 to 30). For 
ligand conjugation at the C-terminus, the peptide chain was synthesized using SPPS and a 
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Nα-Boc protected amino acid was incorporated at the end of the sequence. Palladium-
catalyzed conditions facilitated orthogonal cleavage of the allyl group, and the exposed C-
terminus was coupled with Fmoc-protected ethylenediamine. Fmoc cleavage of the 
ethylenediamine moiety followed by coupling of the resulting amine with ligands bearing 
carboxylic acids provided ligand conjugation at the C-terminus (28 to 31 to 32). In either 
mode of conjugation, an acidolytic cleavage released the peptide from resin with concomitant 
deprotection of the side chain protecting groups. Although not discussed in this work, this 
method could potentially be used to conjugate two structurally different ligands at the C- and 
N-terminus of a peptide chain. 
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Scheme 1.8: General method for C- or N-terminal functionalization of Tyr3-octreotate 
1.1.2 Ligand incorporation within the backbone of peptides 
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The presence of metal-binding sites within the backbone is expected to have a 
significant influence on the peptide folding. Hence, peptide-ligand conjugates that contain 
ligands within their backbones have numerous applications in metal-assisted stabilization of 
peptide-microstructures (Section 1.2.4).12 To incorporate the ligands within the backbone, 
ligand building blocks bearing amino acid functionalities were synthesized and used during 
peptide synthesis as artificial amino acid building blocks. Many of the commonly used ligand 
building blocks are comprised of 2,2’-bipyridine (Bpy) and some representative examples are 
shown in Figure 1.3.48 
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Figure 1.3: Examples of 2,2’-bipyridine derivatives for ligand incorporation into the 
backbone of peptides 
Incorporation of amino groups directly into bipyridine, as in case of H-5Bpy-OH 
(33), is a straightforward modification of Bpy, however poor nucleophilicity of the resulting 
aromatic amine in Fmoc-protection of 33 restricted its use in SPPS. As a solution to this, 
pseudodipeptide derivatives 34 and 35 were synthesized via solution phase synthesis and 
efficiently incorporated into the peptide backbone.48 Alternatively, a methylene group could 
be introduced between the amine and the pyridine ring to obtain 36-37.49 Other derivatives 
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were synthesized from (2,2'-bipyridine)-6,6'-diamine in such a way that Bpy could be 
incorporated into the peptide backbone via 6,6’-substitutions (38-41).50 Peptide-ligand 
conjugates containing 38-41 have been shown to induce β-sheet formation upon metal 
coordination and hence have found applications in de novo β-sheet inducing metallopeptides. 
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Scheme 1.9: Synthesis of imidazolium building blocks (a) and their utility in synthesis of 
carbene-peptide conjugates (b) 
Carbenes are an important ligand for transition metal complexes, thus their 
incorporation into peptide chains has been envisioned as a potential method for synthesis of 
chiral metal complexes. For synthesis of carbene-peptide conjugates, imidazolium ion 
building blocks 44, containing a carboxylic acid moiety and a dormant amine protected as an 
azide group, were synthesized by SN2 displacement of iodides 43 with imidazoles 42 
(Scheme 1.9a).51 Building blocks 44 were coupled to the Nα-amino group of a growing 
peptide chain. Then, additional amino acids were incorporated after unmasking the latent 
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amino group via a DTT/DBU mediated azide reduction (Scheme 1.9b). Finally these 
conjugates were cleaved from resin and N-heterocyclic carbenes (NHC) were generated in 
situ by reaction with 2-(tert-butylimino)-2-(diethylamino)-1,3-dimethylperhydro-1,3,2-
diazaphosphorine (BEMP), which were eventually trapped with [Pd(Cl)2(COD)]. When 
peptide-ligand conjugates containing only one unit of 44 were reacted with BEMP, a β-
enolate is generated that was found to coordinate the palladium center. Interestingly, when 
two units of 44 were incorporated into a peptide chain, their palladium complexes did not 
involve a β-enolate coordination. 
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Scheme 1.10: Method for incorporation of phosphine ligands into the peptide backbone 
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Ligands can also be incorporated within the backbone of peptides that contain one or 
more reduced peptide bond(s), which provide a reactive secondary amine functionality for 
the ligand conjugation (Scheme 1.10).52,53 These secondary amine functionalities of 46 and 
49 were phosphinomethylated to obtain the phosphine-peptide conjugates 47 and 50b 
respectively. Incorporation of cysteine into the peptide chain prior to the reduced double 
bond produced P,S-ligands 50.  In addition, reaction of 49 with diphenylphosphine chloride 
produced a P,S-ligand 50a where phosphorous was directly attached to the backbone 
nitrogen. Palladium complexes were prepared from resin-bound conjugates and used as a 
solid supported catalyst for organic transformations. For ease in characterization, phosphine-
ligand conjugates were oxidized prior to their cleavage from resin (47 to 48). 
1.1.3 Ligands incorporation into the side chain of peptides 
Among all the modes of ligand conjugations, ligand incorporation into the side chains 
is the most advantageous since the ligand can be introduced site-specifically at any position 
of the peptide chain. For incorporation of ligands into side chains, single amino acid chelates 
(SAAC) can be synthesized by appending ligands on the side chain of natural or unnatural 
amino acids. These SAAC could then be directly incorporated into peptides as if they were 
natural amino acid building blocks. Alternatively, ligands can be tethered to the side chains 
via use of on-resin orthogonal protecting group methods. In this method, a natural or 
unnatural amino acid bearing an orthogonal protecting group is introduced during peptide 
synthesis. After constructing the peptide, the orthogonal protecting group can be selectively 
removed in presence of other side chain protecting groups and ligands can be appended 
selectively at this position. 
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1.1.3.1 Ligand incorporation via SAAC 
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Figure 1.4: Examples of SAAC derived from lysine 
Single amino acid chelates can be prepared by appending ligands on the side chains 
of natural or unnatural amino acids. Among all the natural amino acids, lysine is the most 
commonly used amino acid for the synthesis of SAAC’s. Indeed SAAC’s containing N- or 
O-donor ligands such as cyclen (52)54, HYNIC (53)55, DOTA (54)56, Ada (55)57-59 as well as 
the S-donor ligand 5660 were readily prepared (Figure 1.4). In addition, N-heterocyclic 
tridentate ligands, pertaining to this dissertation, were also incorporated into lysine 
derivatives (57-58).61-64 In this method, reactive functionalities present on SAAC are usually 
protected with an acid labile protecting group so they can be unmasked during the final 
acidolytic cleavage from resin. In the case of peptides derived from 56, a separate reduction 
step was needed to generate the reduced thiol groups for coordination to metal centers.60 It is 
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important to note that N-heterocyclic ligands (57 & 58) do not require any protection and 
were well tolerated with SPPS conditions.61-64 Most of the SAAC’s were straightforward to 
incorporate into peptide chains except 52 and 53. Bis-cyclen containing 52 suffered from 
poor coupling efficiency due to the bulkiness of the ligand and required specific coupling 
conditions54, while HYNIC derivative 53 was found to be unstable in the oxidative 
conditions used for S-S bond formation and required an additional Boc protecting group.55 
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Figure 1.5: Examples of SAAC derived from tyrosine, phenylalanine, aspartic acid, tyrosine 
and glutamic acid 
Apart form lysine, other natural amino acids such as tyrosine, phenylalanine, aspartic 
acid and glutamic acid have also been used for the synthesis of SAAC’s where ligands such 
as bis-bpa, DOTA and EDTA were attached to the side chain (Figure 1.5).56,65-70 In the case 
of phenylalanine, which does not have any reactive functionality on the side chain, a p-amino 
substitution was introduced for ligand conjugation (60).56,65 Synthesis of Fmoc-Tyr(bis-bpa)-
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OH (59) via a Mannich reaction66,67 and Boc-DOPA(OTBS)2-OH (62) via oxidation of 
tyrosine derivatives furnished SAAC’s with improved metal-binding affinities.68 
Incorporation of these SAAC derivatives in SPPS was straightforward except for Fmoc-
Phe(DOTA)-OH (60). In this instance, due to the bulkiness of DOTA, chain termination was 
observed after the incorporation of 60. This issue was easily resolved by using 
pentafluorophenyl ester derivatives of the Fmoc amino acids following the incorporation of 
60.56 
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Figure 1.6: Examples of unnatural amino acids as SAAC 
The synthesis of SAAC’s are not limited to natural amino acids as demonstrated by 
the synthesis of unnatural amino acids where metal-binding moieties are directly attached to 
the amino acid skeleton. Representative examples of this class of SAAC’s are shown in 
Figure 1.6. 71-82 Several pyridine-71-76, quinoxaline-77 and phenanthroline-75 based mono- and 
bidentate SAAC were synthesized (64-69), most commonly using the asymmetric alkylation 
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method.83,84 Click chemistry has also been used to synthesize SAAC derivatives where 
NOTA (71) and bpa (72) were attached to the amino acid skeleton via formation of 1,2,3-
triazole.80 To study the chemistry of rhodium-peptide conjugates, synthesis of phosphine-
containing SAAC 73 was also developed.78,79 In this example, an oxidation-prone phosphine 
was protected as a phosphine sulfide, which could be easily removed via reduction prior to 
complex formation. 
1.1.3.2 Ligand incorporation directly onto peptides 
Among all the methods discussed thus far, ligand incorporation directly onto the pre-
synthesized peptide is the most convenient for the library synthesis of peptide-ligand 
conjugates. The only requirement for this method is the availability of an orthogonally 
protected functional group on one of the amino acids in a peptide chain. This group can be 
selectively cleaved and the unveiled reactive functionality can be used for ligand 
conjugation. Similar to SAAC derivatives, lysine is a well-known amino acid for ligand 
conjugation via this method. The enamine-based protecting group Dde  (1-[(4,4-dimethyl-
2,6-dioxocyclohex-1-ylidine)ethyl]) or its hindered version ivDde are often used to 
orthogonally protect Nε-lysine (Scheme 1.11).85,86 In a typical procedure, Fmoc-Lys(Dde)-
OH or Fmoc-Lys(ivDde)-OH building blocks are used during SPPS. After completion of the 
desired peptide sequence, treatment of the peptide with 2-10% hydrazine selectively cleaves 
Dde or ivDde group in the presence of other acid-labile protecting groups. Next, a ligand is 
attached to the Nε-amino group, typically through amide bond formation or by exploiting the 
reactivity of amines towards isocyanates or acyl substitution. 
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Scheme 1.11: Incorporation of DOTA and DTPA into the side chain of oxytocin analogues 
via orthogonally protected lysine  
A rather unique method was developed where a lysine ε-amino group of somatostatin 
analogue 76 was chemoselectively transformed into azide (77, Scheme 1.12).87 This azide 
was subsequently used as a handle to incorporate a DOTA group bearing an alkyne into 
somatostatin analogues via a click reaction. This method allows for the synthesis of 
dendrimeric structures by tethering multiple somatostatin analogues to the single ligand if a 
ligand with multiple alkynes is used. A highlight of this method is the use of protecting group 
free peptides in diazo-transfer as well as click reactions, which underscores the 
chemoselectivity of these reactions. Copper accumulation was a challenge in this example. 
Hence treatment with sodium sulfide (Na2S) was incorporated into the workup but in several 
instances these conditions were detrimental to the resulting bioconjugates. More recently, an 
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alkyne linker named monofluoro-substituted cyclooctyne (MFCO) has been synthesized 
which reacts with an azide moiety under copper-free conditions due to presence of the 
strained alkyne moiety.88 
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Scheme 1.12: Synthesis of Nε-azido peptide from Nε-lysine of cyclic RGD peptide and its 
utility in ligand incorporation via click reaction 
Another chemoselective method for protecting group free peptides utilized a 6π-
azaelectrocyclization reaction between reactive amine groups of a peptide and a pendent 
aldehyde group of a ligand.89 An electron-deficient aldehyde linker 79 was designed, which 
selectively reacted with the amine group of a peptide to form 1-azatriene 80 in situ (Scheme 
1.13). Subsequent intramolecular 6π-azaelectrocyclization resulted in the formation of 1,2-
dihydropyridine. A key feature of this method includes shorter reaction time (less then 30 
min), functional group compatibility and its applicability to short peptides as well as proteins. 
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In addition, although proteins contain multiple amino groups, the ratio of DOTA to protein 
could be controlled by optimization of the reaction conditions. 
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Scheme 1.13: 6π-Azaelectrocyclization for conjugation of ligands at the lysine side chain or 
N-terminus amino functionality of peptides and proteins 
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Scheme 1.14: Synthesis of a four-helix bundle N4Py derivative through ligation to a cysteine 
side chain 
A simple alkylation of an electrophilic functional group on the ligand can be used for 
ligand conjugation (Scheme 1.14).90 In this instance, the nucleophilicity of cysteine was 
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exploited and four electrophilic bromides on the tetradentate N4Py ligand were efficiently 
displaced to produce the ligand with four helixes attached. In this example, a three-carbon 
spacer between the bromide and the pyridine ring was essential for the stability of the 
bromide. Note that even an unprotected lysine was tolerated under those conditions. 
Those unnatural amino acids that do not have highly reactive side chains such as 
glutamic acid, phenylalanine, tyrosine, serine and threonine have also been used for direct 
ligand incorporation into peptides (Scheme 1.15). For example, terpyridine ligands were 
incorporated into the side chain of glutamic acid residues of 85, which employed a benzyl 
ester moiety as an orthogonal protecting group (Scheme 1.15a).91 For incorporation of the 
ligand into the phenylalanine side chain, a p-nitro-phenylalanine derivative was introduced 
during peptide synthesis (e.g. 87), which was found to be compatible with SPPS conditions 
(Scheme 1.15b).92 Next, the nitro group of 87 was reduced orthogonally to expose an amine 
88 through which terpyridine or bpa was attached to peptide nucleic acid (PNA) conjugates. 
DOPA is a derivative of tyrosine and could be obtained by ortho-hydroxylation of a phenol 
ring of the tyrosine. IBX oxidation of tyrosine containing peptide 90 was developed in which 
the tyrosine residue was selectively oxidized to generate DOPA-peptides 91 (Scheme 
1.15c).93 Alternatively, tyrosine of peptide 90 was also transformed into phosphine ligands 
upon reaction with dialkyl or diaryl chlorophosphines to obtain corresponding phosphine 
ligands 92a-c.94 This method is not limited to tyrosine and has also been applied to serine and 
threonine. In one instance, the tyrosine side chain of 93 was transformed into a phosphine 
ligand via a palladium catalyzed cross coupling reaction (Scheme 1.15d).95 
  
 
25 
PNAn
H
N
N
H
PNAn—Lys(Boc)-NH2
O
O
Ac
H
N
L
FmocHN
N
H
PNAn—Lys(Boc)—
O
O
NH2
FmocHN
N
H
PNAn—Lys(Boc)—
O
O
NO2
SnCl2·2H2O,
DMF, 16 h
(2 cycles)
1. L, HATU,
i-Pr2EtN, DMF
2. SPPS
3. Acetylation
3. Cleavage from 
resin
N
O
HO
O
N
N
N
N
N
O
HO
L =
or
RR
BocHN
H
N
N
H
OtBu
O
O
O
COOBn
COOBn
COOBn
1. Pd/C, H2, CH2Cl2
2. L, HATU, i-Pr2Et, DMF
3. TFA, anisole
4. HATU, HOAt, i-Pr2Et, DMF
NH
HN
HN
OO
O
N
H
O
NH
O
O
NH
N
O
NN
N
H
L
L
L
L =
BocHN
N
H
OMe
O
O
OH
OH
1. IBX, THF
2. Na2S2O4
BocHN
N
H
OMe
O
O
OPR'2
ClPR'2, Et3N,
DMAP, CH2Cl2
R' = Ph (92a);   R = Et 
(92b);   R = Cy (92c)
Boc-AA-Tyr-OMe
AA = Gly AA =  Phe
(a)
(b)
(c)
BocHN
N
H
H
N
O
O
O
N
H
H
N
O
O
OBn
OH
BocHN
N
H
H
N
O
O
O
N
H
H
N
O
O
OBn
P
Ph
S
Ph
1. PhNTf2, i-Pr2EtN
2. Ph2PH, 
    Pd(OAc)2(dppb)
    DMSO
3. S8, CH3OH
(d)
85
86
87 88
89
91
93 94
90
 
Scheme 1.15: Transformation of glutamic acid (a), phenylalanine (b), and tyrosine (c) side 
chains into various ligands  
  
 
26 
A method shown in Scheme 1.16 was not intended for the synthesis of peptide ligand 
conjugates, however it is still included in this section since DOTA has been attached to 
phosphopeptides using this method.96 Elimination of phosphorylated serine or threonine 
furnished dehydroalanyl peptide 96 that was eventually trapped via 1,4-addition of DOTA 
bound thiols. In this chemical tagging method the rate of reaction decreases upon changing 
the substrate from phosphoserine to phosphothreonine. 
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Scheme 1.16: Derivatization of phosphopeptides with DOTA through phosphate elimination 
and Michael addition 
Unlike natural amino acids there are very few examples where a side chain of an 
unnatural amino acid could be used to append ligands. One method includes the synthesis of 
peptide 99 containing a propargyl glycine44 or α,α-dialkyne97 substituted unnatural amino 
acids 98, which upon click reaction could furnish 1,2,3-triazole or di-1,2,3-triazole 
functionalities that serve as metal chelating groups (Scheme 1.17). In this method, the use of 
azide-containing ligands instead of azidoacetic acid could allow a rapid synthesis of a library 
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of peptide-ligand conjugates, however such work has not been established yet. In addition, 
alkynes could be directly used as ligands in the synthesis of cobalt hexacarbonyl complexes. 
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Scheme 1.17: Use of propargyl glycine derivatives for construction of 1,2,3-triazole chelates 
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Scheme 1.18: Divergent and dual divergent strategies for synthesis of non-heme ligand-
peptide conjugates 
Two synthetic strategies have been developed by our group, named divergent and 
dual divergent strategies, which constitutes Chapters 2 and 3 of this dissertation. In short, 
unnatural amino acid 101 was synthesized and incorporated into a peptide chain to obtain 
102 (Scheme 1.18). Next, the cleavage of the silyloxy ether followed by chlorination gave 
peptide 104, which contains an electrophilic center on the side chain of a peptide. Finally, the 
ligand structure was elaborated by a one-step displacement of chloride with a variety of 
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secondary amines (Scheme 1.18, Eq 1, Divergent Strategy)98 or stepwise alkylation with 
primary amines and chlorides (Scheme 1.18, Eq 2, Dual Divergent Strategy).99 The 
functional group compatibility and the scope of these strategies were also explored. 
1.2 Applications of Metal Complex-peptide Conjugates 
Metal complexes derived from the peptide-ligand conjugates have numerous 
applications in biomedicinal chemistry, catalysis and de novo designed metallopeptides. This 
section will briefly discuss each of these applications.   
1.2.1 Biomedical applications 
One of the most challenging tasks in medicinal chemistry is to achieve the site-
selective delivery of a medicinally active molecule to targeted locations. A magic bullet 
approach, originally introduced by Paul Ehrlich in the late 19th century, was considered as a 
potential solution to this problem.2,5 Initially, medicinally active molecules have been 
attached to antibodies or proteins for site-selective delivery, however the most success has 
been achieved when small receptor-binding peptides are used as carrier vehicles. Conjugation 
of the metal complexes to receptor-binding peptides has become a common practice to 
achieve target specificity in radiopharmaceuticals, imaging, and anticancer or antibacterial 
applications as well as in cellular uptake and internalization studies.11 
1.2.1.1 Radiopharmaceuticals and imaging agents 
Radiopharmaceuticals and imaging agents are drugs that use radioactive metal 
complexes as therapeutics or biosensors. In a typical approach, radioactive metal complexes 
are tethered to a target-selective organic molecule or a peptide for delivery.3 Such conjugates 
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have found numerous applications in radiopharmaceuticals or biosensors for imaging 
thrombi, tumors and infection/inflammation. Several conjugates of this type are currently in 
clinical trials.2 Metal complexes used in such applications are sensitive, reactive and usually 
possess short half-lives, hence the post-conjugation method is often used for their synthesis. 
Success of the peptide-based radiopharmaceuticals and imaging agents depends on the choice 
of three components: a radioactive metal, a ligand and a suitable peptide. 
Several radiometals such as 99mTc, 111In, 64Cu, and 66/67/68Ga have been used as 
radionuclei in these applications.3 Among all the radiometals technetium is cheap, convenient 
in handling, possesses excellent imaging characteristics and does not produce α or β 
radiation. These qualities make technetium the most used radiometal in these applications. 
However for delayed imaging studies, technetium is not suitable due to its moderate half-life 
(6 h). For such applications long-lived 111In (half life = 2.8 days) is more suitable. Some of 
the drawbacks of 111In complexes include high cost, limited availability and relatively high 
radiation burden. In addition to technetium and indium, 64Cu(II) and 66/67/68Ga have also 
found application in PET imaging radiotherapy. 
Stability of radiometal complexes is an important factor in the success of 
radiopharmaceuticals and imaging agents. The stability of radiometal complexes is governed 
by the ligand structure and hence a choice of ligand depends on the type of radiometal used. 
A variety of ligands such as N3S, N2S2, tetraamine, DADT, and HYNIC are conveniently 
used in technetium labeled radiopharmaceuticals, while for 111In labeling DTPA, EDTA, 
NOTA and DOTA are more suitable.3 For 64Cu complexes unconventional ligands such as 
TETA and CPTA are developed while Ga-peptide conjugates utilize DFO (desferrioxamine), 
NOTA and DOTA ligands.3 
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The most critical component that is responsible for the selectivity of 
radiopharmaceuticals and imaging agents is the structure of the peptide. Since the selectivity 
is achieved through an affinity of the peptide vector to the appropriate receptor, the choice of 
peptide vector solely depends on the biological target. For instance, radiopharmaceuticals 
containing RGD sequences have been used for thrombus imaging.3 The more prevalent 
peptides carriers are somatostatin analogues, bombesin analogues and analogues of 
gonadotropin releasing hormone (GnRH) or luteinizing hormone releasing hormone 
(LHRH).100 Somatostatin receptors are overexpressed in several tumors of neuroendocrine 
origin, neuroblastomas, medullary thyroid cancers, pheochromocytomas and small cell lung 
cancers.101 Octreotide is an octapeptide analogue of the somatostatin that has been evolved as 
the most successful delivery vector (Figure 1.7). Ligands are usually attached to the N-
terminus of an octreotide during its biomedicinal applications. For instance, octreotide 
derivative 105 containing 111In·DTPA complex at its N-terminus is the first peptide 
radiopharmaceutical approved for clinical use.5 
Bombesin analogues are also used extensively as delivery vectors (106, Figure 1.7). 
Bombesin receptors are overexpressed in lung, prostate, breast, gastric, colon and pancreatic 
cancers as well as glioblastoma.102 SAR studies have established the importance of the C-
terminal sequence of the natural bombesin and the linker length in receptor binding 
process.32,103 Based on the SAR studies, several analogues of bombesin have been developed 
by maintaining the C-terminus sequence of the natural bombesin and appending ligands in 
the N-terminus region. Moreover, N3S-bombesin conjugates containing 0, 3, 5, 8 and 11 
carbon linkers have shown that derivatives with 3, 5 and 8 carbon spacers possess better 
binding affinity compared to the corresponding 0 or 11 carbon spacers.32 
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Figure 1.7: Representative examples of somatostatin-, bombesin- and LHRH-metal complex 
conjugates 
The most successful peptide delivery vector is derived from LHRH (107, Figure 1.7). 
Receptors for LHRH are overexpressed in ovarian, prostate and breast cancers.100 Several 
cytotoxic agents have been incorporated into LHRH analogues leading to successful 
anticancer agents. However, there are very few examples for LHRH analogues containing 
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metal complexes. 99mTc complex of LHRH was synthesized from P2S2-LHRH conjugates as 
described in Scheme 1.2, however its utility was not discussed.40 In another study, an LHRH 
analogue containing two thiols at its termini was prepared. Upon complexation with rhenium 
or technetium the metal-mediated cyclization of LHRH was induced.104 However, the cyclic 
analogues were found to be less effective in the binding assay then native LHRH. In another 
example when 68Ga·DOTA was directly attached to the LHRH through ε-amino moiety of 
lysine, no receptor binding or internalization was observed.33  
Apart form somatostatin, bombesin and LHRH, several other peptide vectors such as 
vasoactive intestinal peptide (VIP), alpha-melanocyte stimulation hormone peptide analogues 
(α-MSH), neurotensin (NT) peptide analogues, alpha-M2 peptide analogues (α-M2), and 
cholecystokinin (CCK) peptide analogues are also used as delivery vectors however they are 
less popular.3 Besides imaging cancers, the potential of peptide-based radiopharmaceuticals 
to image infection and inflammation have also been investigated.3 
1.2.1.2 Inactivation of biomolecules 
Inactivation of biomolecules such as DNA, RNA or proteins is an attractive mode of 
action for therapeutics. A conventional drug inactivates biomolecule by stoichiometric 
binding. In contrast, a catalytic inhibitor can inactivate multiple copies of target molecules 
(Figure 1.8).105 An obvious advantage of catalytic inhibitors is that they have the potential to 
require low dosage and hence side effects could be significantly reduced. The role of metal 
complexes has been extensively investigated as potential catalytic inactivating agents for 
DNA, RNA and proteins. Franz et al. has recently reviewed applications of metal complexes 
as enzyme inhibitors and DNA probes.106 
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Figure 1.8: Comparison of conventional inhibitors with catalytic inhibitors 
To achieve selectivity in a catalytic inhibition mode, metal complexes are usually 
tethered to peptides, peptidomimetics, peptide nucleic acid conjugates (PNA) or small 
organic molecules that recognize the target biomolecules. For simplicity, only those 
examples that include peptide or peptidomimetic conjugates are discussed here. Inhibition of 
biomolecules usually occurs through three common modes of inactivation such as metal 
complex induced oxidative damage, hydrolytic cleavage or cross-linking of the biomolecules.  
Metal complexes-peptide conjugates are most extensively studied for their potential 
in targeting and inactivating DNA through hydrolytic cleavage, oxidative damage or cross-
linking.  A family of rhodium and ruthenium-peptide conjugates was explored for DNA 
hydrolysis, DNA cross-linking as well as to enhance DNA sequence selectivity. For example 
[Rh(bpy3C)(chrysi)(phen)]Cl3 complex functionalized with basic cell-penetrating peptides 
(CPP) induced site-specific cleavage of duplex DNA.107 In another instance photochemically 
controlled inactivation of DNA was achieved by series of short peptides containing 
[Rh(phi)2phen]3+.108 A selective and efficient cleavage of HIV-1 TAR-RNA has been 
achieved with metal free cyclen-polyarginine peptide conjugate.24 However the cleavage was 
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attributed to the pH-dependent hydrolysis of DNA since the cleavage was inhibited in 
presence of EuIII or ZnII. In contrast to metal complex-peptide conjugates, metal complex-
PNA conjugates have emerged as a unique DNA recognition motif that is stable towards 
nucleases and proteases. In addition, they have low binding affinity for proteins but still 
maintain high binding affinity for DNA. In particular, PNA conjugates containing Co2+, Cu2+ 
and Zn2+ complexes of dipeptides [H-Cys(uracil)-AA-cyclen] efficiently catalyzed DNA 
hydrolysis.10 Likewise, PNA conjugates of mononuclear lanthanide complexes cleaved 
single-stranded DNA via ZrIV or CeIV catalyzed reactions.8,109 Besides this, traditional metal 
complex-peptide conjugates derived from ATCUN110-113 and zinc finger motifs or de novo 
designed 32- and 33-residue helix-turn-helix metallopeptides8 have also demonstrated their 
capabilities in of DNA and viral RNA cleavage. 
Unlike DNA cleavage, protein inactivation mediated by metallopeptides is relatively 
unexplored. Similar to DNA cleavage, protein inactivation also occurs through hydrolytic 
cleavage, oxidative damage or cross-linking.105 A class of metal complexes that inactivates 
protein via hydrolytic cleavage, known as artificial proteases, has been extensively 
investigated. For example, artificial proteases derived from Cu2+ and Co3+ complexes of 
PNA-cyclen conjugates catalyzed the hydrolysis of myoglobin however only at higher 
concentrations (> 3 µM) and longer reaction times (> 100 h).114,115 In order to improve the 
catalytic efficiency of artificial proteases, several CoIII(cyclen)-peptidomimetic conjugates 
were investigated for their hydrolytic capability on deformylase (PDF) and amyloid β-42 
targets.105 
Oxidative damage of proteins is a complementary approach for protein inactivation 
when compared to hydrolytic cleavage. Oxidative damage of proteins occurs through either 
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backbone cleavage or side chain oxidation. When iron(II) or copper(II) complexes were 
tethered to known inhibitors such as biotin,116 benzene sulfonamides117 or trifluoperazine,118 
the conjugates oxidatively cleaved the target protein in the presence of oxygen and reductant. 
Examples of protein inactivation through side chain oxidation include ATCUN·Cu2+ 
catalyzed inhibition of angiotensin-converting enzyme and endothelin-converting 
enzyme.7,119 In a remarkable example, chromophore assisted light inactivation (CALI) of 
vascular endothelial growth factor (VEGF) was achieved using ruthenium peptoide 
conjugate.120 In this example the inhibition potency of ruthenium-peptoide conjugate was 
increased from nM to pM in presence of light. In line with this example, our group is 
exploring the use of high valent iron complexes, called ferryl complexes, for amino acid and 
protein oxidation. We have shown ferryl complexes tethered to guanidine-based inhibitors 
inactivate chymotrypsin and trypsin selectively.17 With the aim of developing site-selective 
iron based protein inactivating agents, such complexes have been recently attached to short 
peptides.121 The detailed study for the synthesis and stability of such ferryl-peptide 
conjugates is described in Chapter 4. 
Apart from the traditional oxidative cleavage and side chain oxidation, rather unique 
oxidative damage has been observed when proteins containing N-terminal aspartate were 
treated with cyclen-peptidomimetic conjugates. In this instance, an oxidative damage of the 
N-terminal aspartate leads to the formation of pyruvate.122 Although catalytic damage of the 
protein is a more attractive mode of inactivation, metal complex-peptide conjugates could 
also be used as stoichiometric inhibitors. When a CoIII Schiff base complex was tethered at 
the N-terminus of a thrombin binding peptide, suicide inhibition was achieved, where one of 
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the labile ligand of the CoIII Schiff base complex was exchanged with the histidine side chain 
of thrombin.123 
1.2.1.3 Anticancer activity, antibacterial activity, cellular uptake and 
internalization 
Apart from the applications of metal complex-peptide conjugates in 
radiopharmaceuticals and DNA/protein inactivation, their utility as traditional 
anticancer/antibacterial agents as well as in cellular uptake and internalization studies has 
also been investigated.11 Ferrocene-dipeptide conjugates or cisplatin-tripeptide conjugates 
have shown antiproliferative activity at low micromolar concentrations.124-126 Similarly, the 
conjugation of a cymantrene complex to a cell-penetrating peptide hCT displayed a high 
cytotoxicity to MCF-7 breast cancer cells.127 Furthermore, cisplatin and trans-
bis(salicylaldoximato)copper(II) complexes were appended on a well-known LHRH peptide 
vector was appended with at its D-Lys6 side chain.128 A cisplatin-LHRH conjugate displayed 
50 times higher potency than the native hormone, while a conjugate derived from 
bis(salicylideneimine) complex caused 100% inhibition of ovulation. In addition to the 
conventional anticancer activity, light mediated activation of metal carbonyl complexes have 
also been explored, which not only opens a coordination site on a metal complex-peptide 
conjugate but also releases toxic CO or singlet oxygen.11,129  
In contrast to anticancer activity, antibacterial activity of metal complex-peptide 
conjugates has been investigated over the last two decades, however only moderate success 
has been achieved to date.11 In this application, antimicrobial peptides are expected to 
interfere with the bacterial membrane.130 Some success has been achieved when metallocenes 
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were incorporated into small peptides, which not only increased the activity but also altered 
the specificity for Gram-positive or Gram-negative bacteria.131,132 In this example, alteration 
in peptide chain or charge on metal complexes was detrimental to the selectivity of 
conjugates. 
The directing ability of peptides was also utilized in studies of cellular signaling 
peptides. This application requires that conjugates recognize the target biomolecule in a 
biological process without inhibiting it. For example, metallocene conjugates of nuclear 
localization signal (NLS) peptides were efficiently translocated into the nuclei of HepG2 cell 
and were readily taken up by the cells without displaying any cytotoxicity up to 1 mM.133 
With the aim of developing metallochaperones, bis-(2-picolylamine) ligands were also 
incorporated at the N-terminus of the nuclear localization signal (NLS) peptide.28 
1.2.2 Metal-assisted stabilization of peptide-microstructures 
Metal mediated peptide folding plays a critical role in achieving the desired properties 
and functions of metal complex-peptide conjugates.  Zinc-fingers are an interesting example 
of how metal-binding amino acids can influence protein folding. Inspired by such examples, 
metal-assisted stabilization of synthetic peptide-ligand conjugates have been explored.12,13 
Such studies are important since stabilization of peptide-microstructures might help 
developing more active and/or selective secondary structures that eventually could be used in 
artificial metalloproteins, or to obtain materials with impressive biological activity and novel 
properties. 
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Figure 1.9: Metal-assisted stabilization of peptide-microstructures via formation of α-helix, 
β-sheet or turn/loop 
Peptide-ligand conjugates for this application usually contain multiple ligands in a 
single peptide, and upon binding to metals they fold into an α-helix, a β-sheet or a metal-
assisted turn/loop (Figure 1.9).12 For such applications, N-donor, P-donor as well as O-donor 
ligands have been attached within the backbone or at the N- and C-terminus of peptides. For 
example, incorporation of multiple copies of 2,2’-bipyridine derivative (33-37, Figure 1.3) 
within the backbone of a peptide have induced the ruthenium-assisted peptide folding48,49, 
while incorporation of a 6,6’-substituted 2,2’-bipyridine derivatives into a peptide (38-41, 
Figure 1.3) have induced a β-sheet structures upon binding to Cu(II) salts.50 Additionally, 
incorporation of a terpyridine derivative at the N- and C-terminal is also known to stabilize 
the corresponding metal complex-peptide conjugates through metal-induced loop/turn 
formation (Scheme 1.6).45 Likewise, when phosphine containing SAAC’s (73, Figure 1.6) 
were incorporated at i and i+4 positions of a peptide, the resulting peptide folded into an α-
helix structure upon reaction with rhodium salts.95 Besides N- and P-donor ligands, O-donor 
catechols are also known to stabilize metal-assisted secondary structures. Amino acid or 
peptide bridged dicatechol ligands (Scheme 1.7) bind titanium or molybdenum and induce 
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metal-assisted folding.46 The orientation of dicatechol-peptide conjugate during complex 
formation complicated its chemistry in solution phase, however isomeric complexes 
converted into thermodynamically favored major isomers over several days. Overall, metal-
assisted stabilization of peptide-microstructure is a growing application of synthetic peptide-
ligand conjugates. 
1.2.3 Catalysis in organic transformations 
Inspired by the efficiency of metalloenzymes, catalytic potential of small metal 
complex-peptide conjugates for organic transformations was also explored.95,134 The ultimate 
goal was to develop the recycling catalysts or continuous flow reactors, which requires 
synthetic methods that are suitable for library synthesis via SPPS and produce the material 
with quantitative yields. To fulfill this requirement, a polyethylene glycol-based resin 
(PEGA) has been developed, which possesses an open structure, excellent swelling in polar 
and non-polar solvents and extreme mobility.135 These properties facilitate the peptide 
folding on resin that is essential for obtaining a chiral environment around the metal center. 
Phosphines and carbenes were chosen as ligands for this application due to their ability to 
form the stable organometallic complexes. Moreover in this application, ligands were placed 
in close proximity of the peptide backbone in order to transfer the chirality of a secondary 
structure into the catalytic center. 
For the synthesis of chiral metal complex-peptide conjugates, phosphine ligands were 
initially incorporated within the backbone or through a side chain of peptides. For example, 
several phosphine based ligands such as diphosphine ligand, P,S-ligand, and phosphine-
oxazoline ligand were incorporated into the backbone of peptides (Scheme 1.10).52,53 
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Palladium complexes of these phosphine-peptide conjugates not only served as an excellent 
catalyst for the Suzuki reaction but the activity of solid supported catalyst was retained even 
after five recycles. These conjugates were also used in enantioselective C-allylation, however 
in this instance the efficiency was significantly dependent on the type of resin and the 
stability of the catalyst structure. Interestingly, moving from six-membered (51a, Scheme 
1.10) to seven-membered (51b, Scheme 1.10) palladium complexes, an inversion in the 
enantioselectivity (from S to R) was observed.53 
Palladium complexes of phosphine-peptide conjugates, derived from serine, threonine 
and tyrosine (Scheme 1.15c), served as excellent catalysts in the palladium-catalyzed 
asymmetric Heck reaction.94 Alternatively, phosphine-peptide conjugates have also been 
synthesized by incorporation of phosphine derived SAAC’s (73, Figure 1.6) into 
peptides.78,79 Upon complexation with rhodium and ruthenium, these complexes generated an 
α-helix or a β-turn sheet structural assembly.134 Among these, β-turn assembly has relatively 
better selectivity in alkylation reactions, although the selectivity varied with the substrates. 
Unfortunately, corresponding rhodium catalysts suffered from poor selectivity in 
hydrogenation reactions. Moreover, in either case enantioselectivities varied when moving 
from solid phase to solution phase reactions. 
Carbene-peptide conjugates have recently emerged as an alternative to phosphine-
peptide conjugates. Carbenes have been incorporated into the peptide backbone51 (Scheme 
1.9) or at the N-terminus.26 The strong interaction of carbenes with transition metals 
enhances the stability of the resulting catalysts. Although higher reaction temperatures are 
required due to their stability, their utility in Sonogashira and Suzuki reactions were 
remarkable as indicated by the short reaction times, low catalyst loading and broad substrate 
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scope. More interestingly, a reaction can be performed in water and a quantitative conversion 
could be achieved with solid supported catalyst.134 The efficiency of the catalyst was 
demonstrated by carrying out the solution phase reaction with as little as 0.00005 mol% 
catalyst loading. In contrast, solid supported catalyst required higher loading however they 
can be recycled up to as many as eight times without affecting the activity. 
1.2.4 Miscellaneous 
Apart from specialized applications discussed above, metal complex-peptide 
conjugates have found several other applications. For example, coordination of an amino acid 
residue of a target protein to the metal center of the metal complex-peptide conjugate can 
result in a stable coordinative cross-linkage between synthetic conjugate and a biomolecule. 
This concept has been used in developing protein tags for protein-protein interaction studies 
as shown by incorporating duplicate copies of 59 (Figure 1.5) into a peptide chain.67 The zinc 
complex derived from these conjugates selectively recognized oligo-aspartate sequences and 
hence served as a D4 tag. Similarly, a zinc complex of a peptide-ligand conjugate containing 
a single copy of 59 has been used to study the anion-mediated translocation process.66 A 
rather unique application in material chemistry is reported where cyclic-tri-β-peptide 
(Scheme 1.15a) was prepared and its ability to form columnar assemblies was explored.91 A 
rigid and planar skeleton of this peptide facilitated the rod-shaped molecular assembly while 
the copper ion provided the electronic conductivity and hence the resulting conjugate is 
expected to have applications in the electronics field. Another application for self-assembling 
molecules was demonstrated by the synthesis of light-harvesting nanomaterials.136 In this 
example, [Ru(bpy)3]2+ has been attached to the N-terminus of a peptide via an amino 
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hexanoic acid linker. An appropriate mixture of Ru-peptide conjugate and a peptide 
containing molecular probe has displayed light capturing capacity. 
1.3 Ferryl Chemistry 
Iron-enzymes have gained significant attention due to their potential as biological 
oxidants. Heme- and non-heme ferryl species have been proposed as reactive intermediates 
in such enzymes. Inspired by the selectivity and specificity of these enzymes, several 
research groups have explored the chemistry of synthetic ferryl complexes over the last two 
decades.14,15,137,138 This research has focused mainly on two parent ligand structures, either 
heme or non-heme ferryl complexes.14,15 The first well-characterized mononuclear non-heme 
ferryl complex was reported in 2003. Since then a variety of non-heme ferryls have been 
synthesized and their utility in oxidation chemistry has been explored. Que and Nam et al. 
have reviewed chemistry of heme and non-heme ferryl complexes.14,15 In addition, Dr. 
Abouelatta139 and Dr. Campanali140, former Kodanko group members, have recently 
discussed the progress of ferryl chemistry in their Ph.D. theses. Hence in the following 
sections synthesis, characterization and applications of the synthetic mononuclear non-heme 
ferryls will be briefly discussed in the context of the synthetic ferryl-peptide conjugates.  
1.3.1 Synthesis and characterization of the synthetic non-heme 
ferryl complexes 
The first mononuclear non-heme ferryl complex was synthesized by reaction of 
[FeIII(cyclam-acetato)(CF3SO3)]2+ with oxone at –80 °C and characterized by Mössbauer 
spectroscopy.138 Several years later two more ferryl complexes, [FeIV(O)(TMC)(MeCN)]2+ 
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and [FeIV(O)(N4Py)]2+, were synthesized and characterized by X-ray crystallography.141,142 
Typical synthesis procedures include the reaction of non-heme iron(II) complexes with 
oxidant such as peracids,141,143-146 PhIO,147 KHSO5,145 O3,148 NaOCl,149 NaOBr,149 
hydroperoxide141,145,150 or molecular oxygen151 (Figure 1.10). In the case of single oxygen 
atom donors, two-electron oxidation of Fe(II) to Fe(IV) is responsible for the ferryl 
generation, while in the presence of hydroperoxide, either homolytic O-O bond cleavage of 
FeIII-OOR species, or alternatively heterolytic cleavage of FeII-OOH to form FeIV(O) are 
proposed as the reaction mechanism.152 Analytical techniques such as UV-vis spectroscopy, 
electrospray ionization mass spectrometry, EPR spectroscopy, Mössbauer, resonance Raman 
and magnetic circular dichroism have been used to characterize these ferryl complexes.14 
Typically ferryl species contain a low-spin (S = 1) iron center with a short Fe–O bond (~1.64 
Å) that resembles a Fe–O double bond.14 
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Figure 1.10: Catalytic cycle for formation and reaction of mononuclear non-heme ferryl 
complexes 
1.3.2 Stability and reactivity of non-heme ferryl complexes 
The stability and reactivity of the non-heme ferryls depends on ligand structure, pH of 
the reaction and the type of the axial ligand bound trans to the Fe–O bond. For example, 
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[FeIV(O)(TMC)(MeCN)]2+ and [FeIV(O)(N4Py)]2+ are stable at room temperature while, 
[FeIV(O)(TPA)(MeCN)]2+ is stable only at –40 °C.141,143,153 Likewise [FeIV(O)(N4Py)]2+ is 
stable at lower pH (pH = 5-6) and the stability gradually decreases with the increase in the 
pH of the solution.145 Moreover, ligand structure also has a significant influence on the 
reactivity of the ferryls as indicated by the difference between the reactivity of 
[FeIV(O)(TPA)(MeCN)]2+ and [FeIV(O)(N4Py)]2+.  These complexes oxidize phosphines, 
sulfides and strong C-H bonds.141,153,154 
1.3.3 Non-heme ferryl complexes in oxidation reactions 
1.3.3.1 Oxidation of organic substrates 
One aspect of the reactivity of the non-heme ferryl complexes is their capability to 
oxidize various organic substrates (Figure 1.11).14 Primarily the oxidation potential of ferryl 
complexes has been explored in the oxidation of functional groups such as phosphines,141 
sulfides151 and alkenes,143 which are prone to oxidation. However, an impressive reactivity 
was revealed when ferryls were found to oxidize strong C-H bonds such as those present in 
cyclohexane or ethyl benzene.153 Following these results, it has also been established that the 
ferryls can catalyze aromatic hydroxylation,155 alcohol oxidation,156 alkylaromatic oxidation 
and N-dealkylation reactions.146 In addition to the oxidation of organic substrates, ferryls are 
also capable of transferring oxygen atoms from FeIV(O) to FeII(L) complexes.157 The 
oxidation power of ferryl complexes has a strong influence on their capability as oxygen 
atom transfer reagent. The order of the oxidation power is determined as [FeIV(O)(Bn-
TPEN)]2+ > [FeIV(O)(N4Py)]2+ > [FeIV(O)(TMC)(MeCN)]2+.158 Our group has explored the 
reactivity of ferryl complexes towards oxidation of more complex and biologically important 
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molecules, namely amino acids, peptides and proteins. It has been demonstrated that ferryl 
complexes oxidize amino acid substrates leading to either backbone cleavage (Gly) or side 
chain oxidation (Cys, Tyr, Trp, Met).159,160 Recently ferryl complexes were found to oxidize 
glutathione, which is a biologically important tripeptide antioxidant.161 
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Figure 1.11: Reactivity of mononuclear ferryl complexes with various organic substrates 
1.3.3.2 Mechanism of oxidation reactions 
Along with the exploration of the reactivity of ferryl complexes, mechanistic 
investigations have also been carried out. A striking finding born from these studies was the 
high kinetic isotope effect (KIE > 30) obtained in the ferryl-mediated oxidation of alkanes 
and alcohols.153 This suggested that non-heme ferryls oxidize strong C-H bonds via a 
hydrogen atom abstraction (HAT) mechanism where C-H bond cleavage is the rate-
determining step. Unlike the alkane and alcohol oxidation, hydroxylation of aromatic 
compounds gave KIE’s as low as ~0.9 and the rates of hydroxylation were strongly 
influenced by the electron-donating ability of the substituents as indicated by the larger 
negative Hammett ρ values (–3.9).155 Based on these data an electrophilic aromatic 
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hydroxylation was proposed as a possible mechanism. A rather unique mechanism was 
established when ferryl complexes were used in N-dealkylation reactions. In this instance, 
KIE (< 5), relatively low but negative Hammett ρ values (~ –2.5) and product analysis with 
mechanistic probes were consistent with an electron-transfer, proton-transfer (ET-PT) 
mechanism.146 In light of these mechanistic investigations, our group has established the 
mechanism for the reaction of ferryls with various amino acid substrates as well as 
glutathione. Our findings suggest that Cys, Tyr, Trp and Gly react with ferryls via ET-PT or 
HAT mechanisms while Met undergoes an oxygen atom transfer reaction.160 Through 
detailed kinetic studies and product analysis, the Kodanko group has also demonstrated that 
ferryls react more selectively with certain amino acids than ·OH, which is only mildly 
selective in amino acid and protein oxidation.162,163 
1.3.3.3 Intermolecular vs. intramolecular oxidation 
The oxidation reactions of mononuclear non-heme ferryl complexes reported to date 
can be divided into two reaction modes, an intermolecular and an intramolecular pathway. In 
most cases ferryl mediated oxidation is performed under pseudo-first order conditions, in 
which a large excess of substrate is added and the oxidation occurs in an intermolecular 
fashion. Alternatively, when ligands have been appended with certain functionality such as 
aromatic rings, an alternate intramolecular oxidation mode was observed. However such 
examples are relatively rare (Scheme 1.19).164,165 Reaction of [FeII(6-
PhTPA)(MeCN)2](ClO4)2 with tert-butylhydroperoxide or PhIO yields ortho-hydroxylation 
of α-phenyl moiety (Scheme 1.19a).164 Under similar reaction conditions the use of PhINTs 
inserts the NTs group into an aromatic ring. However in either instance the nature of the 
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oxidant was not identified directly. In another example, reaction of [FeII(TPA)(MeCN)2]2+ 
with m-CPBA furnished 5-chlorosalicylate, which is derived via ortho-hydroxylation of m-
CPBA (Scheme 1.19b).165 In this work the formation of a ferryl was well characterized 
however the mechanistic investigation suggested that the initially generated ferryl was not 
directly responsible for the aromatic hydroxylation. The m-chlorobenzoic acid derived from 
m-CPBA coordinated to the iron center via the carboxylic group, which eventually 
underwent an intramolecular hydroxylation. It is important to note that in both examples, 
non-heme ferryls were generated from tetradentate ligands. 
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Scheme 1.19: Intramolecular oxidation or amination of aryl functionalized TPA (a) and 
ortho hydroxylation of m-CPBA (b) 
1.3.4 Applications of synthetic non-heme ferryl complexes 
Dr. Abouelatta has recently discussed applications of synthetic non-heme ferryl 
complexes in his Ph.D. thesis and hence only a summary of this topic has been presented 
here.139 Apart from the utility of the ferryl complexes in oxidizing organic substrates as 
discussed in Section 1.3.3.1, the parent ferrous complexes that can generate reactive oxidants 
are also useful reagents for oxidation of biomolecules.166,167 Several bleomycin mimics have 
been demonstrated to cleave the double stranded DNA in presence of oxygen. Although the 
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transient ferryl species was proposed as a key oxidant in DNA cleavage, its existence was not 
proven. Me-TPEN in presence of H2O2 and N4Py-acridine conjugate in presence of oxygen 
were found to participate in DNA scission process.168,169 
Our group is exploring the utility of ferryl complexes in amino acid, peptide and 
protein oxidation. To date we have shown that the ferryl complexes can oxidize glutathione 
(GSH) to its disulfide dimmer (GSSG) as well as oxidize various amino acid substrates 
leading to either side chain oxidation or backbone cleavage.161 We have also demonstrated 
that ferryl complexes are capable of oxidizing chymotrypsin and trypsin, and hence can be 
utilized as protein inactivating agents.17 
1.4 Thesis Statement 
The chemistry of metal complex-peptide conjugates and synthetic ferryl complexes 
has arisen simultaneously but independently over the last two decades. Metal complex-
peptide conjugates have evolved as target specific therapeutics while ferryls are emerging as 
selective metal-based oxidants. Merger of these two well-explored research areas is an 
attractive idea. However it has not been pursued to date, which may in part be due to the lack 
of the methods for the synthesis of non-heme ligand-peptide conjugates and challenges 
associated with the synthesis of ferryl-peptide conjugates. The Kodanko group identified this 
unexplored area in the literature and aspired to integrate these two research areas by 
exploring the chemistry of ferryl-peptide conjugates and utilizing them for various biological 
applications.  This dissertation is aimed at developing divergent methods for the synthesis of 
non-heme ligand-peptide conjugates and exploring their utility in library synthesis of 
biologically important molecules as well as chemistry of ferryl-peptide conjugates. The 
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overall goals of this dissertation are as follows. (i) Development of a divergent strategy for 
the synthesis of non-heme ligand-peptide conjugates (Chapter 2); (ii) Applications of the 
divergent and dual divergent strategies for library synthesis of metal-binding LHRH 
analogues (Chapter 3) and (iii) Synthesis, characterization and mechanistic studies of the 
synthetic ferryl-peptide conjugates. 
The first goal of this dissertation was to develop a synthetic strategy that allows the 
rapid and efficient synthesis of non-heme ligand-peptide conjugates (Chapter 2). First, an 
unnatural amino acid 86 containing a silyloxy ether group was synthesized. Next, the 
divergent strategy was developed using a model dipeptide substrate derived from amino acid 
86. As a proof of concept three peptide-ligand conjugates were prepared from the model 
dipeptide substrate via solution phase method. Finally, the extension of this method to solid 
phase synthesis is discussed. 
The second goal of this dissertation was to apply the divergent strategy for library 
synthesis of peptide-ligand conjugates (Chapter 3). Prior to proceeding with the library 
synthesis, an extension of the divergent strategy was envisioned. Towards this, a dual 
divergent strategy was developed where ligands were synthesized in a stepwise fashion. For 
library synthesis, a decapeptide (LHRH: luteinizing hormone releasing hormone) was chosen 
as a target peptide. The choice of LHRH peptide was made because of its biological 
significance as a delivery vector, as well as the diverse array of functional groups that it 
contains. Despite its success as a drug delivery agent there are very few example of metal-
binding LHRH analogues, which motivated us to explore their chemistry. In this goal we 
aspired to append the diverse array of metal-binding ligands onto LHRH using divergent and 
dual divergent strategies. 
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The final goal of this dissertation was to use the peptide-ligand conjugates to explore 
the chemistry of synthetic ferryl-peptide conjugates (Chapter 4). The project was initiated 
because our group planned to attach reactive ferryl species to peptide-binding motif for 
selective protein oxidation. However synthetic ferryl-peptide conjugates were not known in 
the literature. Hence it was necessary to develop a synthesis of ferryl-peptide conjugate on a 
model system and establish its stability and reactivity, prior to its incorporation into a 
complex peptide-binding motif. The knowledge gained about synthetic ferryl-peptide 
conjugates has potential to be extremely valuable for the synthesis of stable catalysts or 
artificial oxygenases. In this chapter, synthesis, characterization and reactivity of the first 
ferryl-peptide conjugate was discussed. During this work we observed that the ferryl-peptide 
conjugate was decomposing faster then the parent ferryl complex, which led us to investigate 
the detailed mechanism for its decomposition. The findings of this mechanistic investigation 
are presented at the end of this chapter. 
Experimental procedures and characterization of new compounds as well as tabulated 
data are presented at the end of Chapters 2, 3 and 4. The dissertation ends with Conclusions 
and Future Directions (Chapter 5).  
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Chapter 2: Divergent Strategy for the Synthesis of 
Peptide-ligand Conjugates       
2.1 Introduction 
For exploring the chemistry of non-heme ligand-peptide conjugates the most essential 
requirement is the rapid access to their library synthesis. Hence we sought to develop the 
divergent strategy for the synthesis of non-heme ligand-peptide conjugates as shown in 
Figure 2.1. To develop the divergent strategy, a pyridine containing unnatural amino acid 
Fmoc-HPA(OTBS)-OH (HPA: 2-Hydroxymethyl Pyridyl Alanine, 1) was designed and 
synthesized that mimics the natural amino acid phenylalanine. Using this unnatural amino 
acid a model dipeptide 2 was synthesized and the divergent strategy was developed using this 
model system. The model system contained a tert-butyldimethylsilyl (TBS) group on the 
hydroxymethyl side chain so that it could be cleaved orthogonally in the presence of 
traditional side chain protecting groups used during Fmoc solid phase peptide synthesis. In 
the first section of this chapter, a retrosynthetic analysis, synthesis of key intermediates, and 
asymmetric synthesis of Fmoc-HPA(OTBS)-OH (1) is presented. In the second section, the 
synthesis of a model dipeptide substrate and a three-step divergent strategy is illustrated. 
Finally, the extension of the divergent strategy to SPPS as well as a study to determine 
functional group compatibility and scope are discussed. 
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Figure 2.1: Schematic diagram for the divergent strategy 
2.2 Results 
2.2.1 Synthesis of an unnatural amino acid 
2.2.1.1 Retrosynthetic analysis 
Two retrosynthetic pathways were considered for the synthesis of the unnatural 
amino acid 1 (Figure 2.2). The Negishi coupling was an attractive approach because the 
intermediate 4 can be prepared from serine, which would facilitate enantioselective synthesis 
of amino acid 1. This approach was based on the literature precedence for the synthesis of 2-
pyridylalanine.170 Alternatively, an asymmetric alkylation strategy was also possible, which 
was originally developed by O’Donnell and has been emerged as a well-known method for 
the synthesis of unnatural amino acids.83 
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Figure 2.2: Retrosynthetic analysis of Fmoc-HPA(OTBS)-OH 
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2.2.1.2 Synthesis of intermediates 4-7 
Intermediate 4170 and 6171 were prepared according to the procedures reported in the 
literature, while the synthesis of 5 and 7 is described in Scheme 2.1. Initially intermediates 5 
and 7 were prepared from commercially available 2,5-dibromopyridine (8)172 (Scheme 2.1, 
Route 1). The sequence began with a selective lithium halogen exchange reaction of 8, which 
upon in situ formylation followed by reduction furnished 9 in 65% yield. Protection of the 
hydroxymethyl moiety as a silyloxy ether gave 5, which upon a second sequence of lithium 
halogen exchange/formylation/reduction produced alcohol 10. The transformation of 10 to 
bromide 7 was straightforward and achieved through Mitsunobu conditions. Although gram 
quantities of bromide 7 could be prepared via this route in convenient yields, it required 
rigorous dry reaction conditions and column chromatographic purifications. To make the 
synthesis more amenable to scale up, we developed an alternate route for 7 (Scheme 1, Route 
2). In this route, 13 was synthesized from commercially available 11 via selective reduction 
of 11 to 12 followed by silyloxy ether protection as described previously.173,174 Reduction of 
the C5 ester functionality of 13 by bis-(methoxyethoxy) aluminum hydride produced alcohol 
10. This route did not involve any rigorous dry reaction condition or chromatographic 
purification. Finally, the alcohol 10 was transformed into corresponding bromide 7. As a 
keynote, the bromide 7 is unstable and decomposes within few days upon storage; therefore 
it should be prepared and used as soon as possible. 
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Scheme 2.1: Two routes for the synthesis of bromide intermediates 5 and 7 
2.2.1.3 Forward synthesis of Fmoc-HPA(OTBS)-OH (1) 
We began the synthesis of Fmoc-HPA(OTBS)-OH (1) via the Negishi coupling 
between intermediates 4 and 5 using the literature procedure for preparation of 2-
pyridylalanine.170 Unfortunately, the intermediate 4 decomposed under the reaction 
conditions used for the Negishi coupling, presumably via β-hydride elimination to produce 
dehydroalanine as a major product. Even after several trials with various palladium catalysts 
we could not suppress this undesired side reaction. Hence we decided to pursue the 
asymmetric alkylation strategy. 
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Scheme 2.2: Asymmetric alkylation reaction and synthesis of Fmoc-HPA(OTBS)-OH 
The alkylation strategy began with a reaction between 6a and 7 in the presence of a 
base and a phase transfer catalyst (PTC, Scheme 2.2). A racemic alkylation of 6a with 
bromide 7 using the achiral PTC tetrabutyl ammonium hydrogen sulfate was straightforward 
and furnished racemic 14a in 88% yield (Table 1, entry 1).74,83 Unfortunately alkylation 
reactions between 6a and 7 with chiral PTCs (15175 or 16176) gave corresponding alkylation 
product 14a in good yield (46-88%) but in low to moderate ee (11-79%) under a variety of 
conditions (Table 1, entries 3-6).177 Fortunately, substitution of the benzyl ester substrate 6a 
for its tert-butyl ester congener 6b along with N-(9-methylanthracenyl)-O-allyl-cinchonidine 
bromide (17)176  as a  chiral PTC and CsOH·H2O as a base at –30 °C furnished 14b in 87% 
yield and 92% ee (Table 1, entry 7).83,176 To make the synthesis amenable to scale up, the 
reaction was optimized further where the base and temperature were changed (Table 1, entry 
8-9). Deprotection of the benzyl ester derivative 14a was straightforward and produced 3 in 
77% yield that was transformed into the target 1. In contrast, the deprotection of tert-butyl 
ester moiety of 14b in the presence of acid labile silyloxy ether was troublesome. Therefore, 
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a global deprotection of 14b with 6N HCl, followed by reprotection with TBSCl and Fmoc-
OSu was performed to obtain 1 in 80% yield over the three steps. 
Table 2.1: Optimization of asymmetric alkylation reaction for the synthesis of 14 
Entry PTC (mol%) R Base T (°C) Yield  ee  
1 TBAHa (20) Bn 50% NaOH 0 88%d racemic 
2 TBAIb (20) tBu 50% NaOH 0 70%d racemic 
3 15 (20) Bn 50% NaOH 0 88%d 11% 
4 15 (20) Bn CsOH·H2O –78 10%e ndc 
5 16 (20) Bn CsOH·H2O –78 46%e 79% 
6 16 (20) Bn CsOH·H2O –30 74%e 72% 
7 16 (20) tBu CsOH·H2O –30  87%e 92% 
8 16 (20) tBu 50% NaOH 0 80%d 93% 
9 16 (5) tBu 50% NaOH 0 70%d 93% 
a TBAH: tetrabutyl-ammonium hydrogensulphate (Bu4NHSO4); bTBAI: tetrabutyl-ammonium iodide; cnd = not determined. 
dCH2Cl2/Toluene (3:7); eCH2Cl2 
2.2.1.4 Determination of enantiomeric excess 
Attempts to determine the enantiomeric excess of 14a and 14b using chiral HPLC 
failed due to lack of separation of two enantiomers on a Chiracel-OD column. Therefore a 
benzophenone moiety of 14a and 14b was selectively removed via a transamination reaction. 
The resulting amino esters were converted into diastereomeric products via the reaction with 
α-methylbenzylisocyanate (Figure 2.3). Diastereomeric ratios were determined by 1H NMR 
analysis using integration of peaks at 8.15 and 8.10 ppm for 14a and 8.21 and 8.15 ppm for 
14b. 
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Figure 2.3: Determination of enantiomeric excess. (a) Transformation of 14a or 14b into 
corresponding diastereomers 18a or 18b (b) Determination of diastereomeric ratio by 1H 
NMR 
2.2.2 Development of the divergent strategy 
2.2.2.1 Development of the divergent strategy via solution phase 
synthesis 
The divergent strategy was initially developed on a model dipeptide substrate 2 via 
solution phase synthesis. A model dipeptide 2 was synthesized by the N-acetylation of 
racemic H-HPA(OTBS)-OH (3), followed by coupling the C-terminus with glycine benzyl 
ester, which furnished the target substrate 2 in 60% overall yield (Scheme 2.3). The next 
objective was to develop reaction conditions that could elaborate the pyridyl moiety of 2 into 
various ligands via solution phase syntheses, with the goal that these conditions could be 
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applied towards solid phase peptide syntheses in the future. Towards this goal, a silyloxy 
ether side chain of 2 was deprotected using buffered TBAF to unveil the corresponding 
alcohol, which was transformed into chloride 19 via tosylation followed by its in situ 
displacement with lithium chloride. 
AcHN
H
N
O
N
OTBS
OBn
O
15
1. Ac2O, Et3N, CH2Cl2, 
rt, 3 h 
2. EDAC, HOBt, H-Gly-
OBn, CH2Cl2, rt, 
overnight, 60% (2 steps)
1. TBAF, AcOH, 
THF, rt, 1.5 h
2. TsCl, i-Pr2EtN, 
LiCl, MeCN, 0 °C to 
rt, 6 h, 76% (2 steps)
H2N
OH
O
N
OTBS
2
AcHN
H
N
O
N
Cl
OBn
O
19  
Scheme 2.3: Synthesis of model dipeptide substrate 19 and transformation of the silyloxy 
ether moiety to the chloride 
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Scheme 2.4: Incorporation of TPA, Bn-TPEN and N4Py into chloride substrate 19 
After developing milder conditions for the silyloxy ether cleavage and chlorination, 
the next goal was to elaborate the chloromethyl pyridyl functionality of 19 into a variety of 
non-heme ligands via displacement of the chloride by various secondary amines. The 
reaction of chloride 19 with excess of bis-(2-picolylamine) in acetonitrile furnished a TPA 
attached dipeptide substrate 20a in excellent yield (Scheme 2.4). These conditions were also 
compatible with relatively more complex secondary amines as demonstrated by incorporation 
of Bn-TPEN (20b) and N4Py (20c) into the same dipeptide precursor 19. A catalytic amount 
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of sodium iodide was necessary to obtain a better conversion when a hindered secondary 
amine was used to prepare 20c. 
2.2.2.2 Application of the divergent strategy to solid phase synthesis 
The ultimate goal of this project was to demonstrate the applicability of the divergent 
strategy on SPPS. Towards this goal, a dipeptide substrate  (Ac-HPA(OTBS)-Gly-Wang 
Resin) was constructed in such a way that the C-terminus is attached to resin. Conditions 
developed for the silyloxy ether cleavage and chlorination via solution phase synthesis were 
conveniently performed on SPPS after some optimization, and using these conditions Ac-
HPA(Cl)-Gly-Wang Resin was synthesized. N-alkylation of the Wang resin bound chloride 
followed by acidolytic cleavage from resin gave the corresponding TPA-dipeptide in ~70% 
purity as judged by NMR analysis. Unfortunately, attempts to incorporate N4Py into the 
same chloride precursor gave a complex mixture of products. At this point, other colleagues 
continued the project further and demonstrated that the replacement of the Wang resin with 
the Rink amide resin not only furnishes the corresponding TPA and N4Py dipeptide 
conjugates but also facilitates the purification of the resulting non-heme ligand-peptide 
conjugates (Scheme 2.5). In this study Tomasz Respondek has also demonstrated the 
functional group compatibility of these conditions by synthesizing TPA-heptapeptide 23, 
while Selma Ulku has broadened the scope of the divergent strategy by applying the method 
to peptides containing two other unnatural amino acids (22a-c) as well as by attaching 
multiple copies of TPA into the same peptide chain (24-25).98 
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Scheme 2.5: Synthesis of peptide-ligand conjugates via solid phase peptide synthesis 
2.3 Discussion 
2.3.1 Optimization of key intermediates and Fmoc-HPA(OTBS)-OH 
A fundamental requirement for the divergent strategy was an efficient and scalable 
method for the synthesis of intermediates 6-7 as well as an unnatural amino acid 1. Towards 
this, intermediate 6a and 6b were easily synthesized by transamination between 
benzophenone imine and glycine ester derivatives, while two routes were developed for the 
synthesis of an intermediate 7. In the first route, a selective lithium halogen exchange of 2,5-
dibromopyridine (8) was attributed to a non-coordinative nature of toluene, which facilitated 
the coordination of lithium to the nitrogen of pyridine and eventually resulted in the C2 
selectivity (Scheme 2.1, Route 1). For an alternate route, a selective reduction of dimethyl 
pyridine-2,5-dicarboxylate (11) was performed in THF/MeOH instead of THF/EtOH as 
described in the literature (Scheme 2.1, Route 2). This modification was important during the 
scale up of 12 since it eliminated issues derived from the transesterification of 11 by EtOH. 
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This selective reduction of the C2 ester moiety of 11 was attributed to an increased 
electrophilicity of the C2 ester that was achieved through a chelation of calcium ion to 
nitrogen and C2 carbonyl group. In contrast, the reduction of C5 ester moiety of 13 required 
harsher conditions and was accomplished using sodium bis(2-methoxyethoxy)aluminum 
hydride. In either route, a bromination of 10 was achieved using the Mitsunobu conditions.  
When the Negishi coupling was utilized for the synthesis of Fmoc-HPA(OTBS)-OH 
(1), dehydroalanine was obtained instead of the target amino acid. The slow rate for the 
oxidative addition of palladium to the C-Br bond of 5 compared to the relatively faster β-
hydride elimination of 4 was attributed to this undesired side reaction. Towards the 
asymmetric alkylation route, alkylation of 6 with bromide 7 was straightforward but the 
asymmetric alkylation required some optimization to obtain the acceptable enantioselectivity. 
We began the asymmetric alkylation studies on benzyl ester derivative 6a because it was 
certainly advantageous over its tert-butyl ester congener 6b since the benzophenone imine as 
well as the benzyl ester group of the resulting alkylation product 14a could be cleaved by 
hydrogenolysis. However, none of the conditions produced the acceptable range of ee when 
6a was employed (Table 1, entry 3-6). Interestingly, employing 6b in the similar reaction 
conditions significantly improved the %ee of the alkylation product (Table 1, entry 6 vs. 7), 
which highlights the importance of the steric bulk of the ester moiety in this reaction. 
Furthermore, the enantioselectivity of 14b was unaffected when the reaction was performed 
with NaOH as the base at 0 °C that made the synthesis of 14b amenable to scale up (Table 1, 
entry 8-9).  
During the synthesis of 1 from 14b, the selective deprotection of the tert-butyl group 
in 14b was challenging due to the presence of an acid labile silyloxy ether moiety. An 
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attempt to deprotect benzophenone imine of 14b with NH2OH·HCl178 followed by a selective 
cleavage of tert-butyl ester with TMSOTf/2,6-lutidine179 furnished the desired amino acid 3, 
however in very low yields. Therefore, a three-step global deprotection/reprotection/Fmoc 
protection sequence was adopted, which produced 1 in 80% overall yield and hence was not 
optimized further.  
2.3.2 Development of the divergent strategy 
We began our investigations for the divergent strategy via solution phase synthesis, 
since the solution phase synthesis allows the isolation and characterization of key 
intermediates. A model dipeptide 2 used in this study was embraced with benzyl ester at C-
terminus and acetyl functionality at N-terminus to mimic the peptide chain bound to the 
Wang resin. The first step of the divergent strategy, deprotection of the silyloxy ether moiety 
to obtain the corresponding alcohol, was straightforward but the transformation of an alcohol 
to a better leaving group required some optimization (Scheme 2.3, 2 to 19). After several 
attempts to tosylate or brominate the hydroxymethyl moiety of 2, the chlorination was found 
to be an ideal leaving group and provided an appropriate balance between the reactivity and 
the stability of 19. 
An elaboration of the chloromethyl pyridyl moiety of 19 into a variety of pyridyl 
containing non-heme ligands was the key step of the divergent strategy and achieved by 
heating 19 with excess secondary amines (Scheme 2.4). Excess of secondary amine was used 
in this reaction considering that these conditions would eventually be applied to SPPS and it 
would be advantageous to study the effect of excess reagents on this transformation. During 
optimization we also identified that the N-alkylation is sluggish with hindered secondary 
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amines (e.g. synthesis of 20c). Incorporation of a catalytic amount of sodium iodide 
significantly improved the conversion, presumably through in situ iodination of 19. However, 
we also noticed that the use of excess sodium iodide was detrimental and resulted into a 
complex mixture of products. Apart from the difficulties associated with synthesis, the 
purification of peptide-ligand conjugates prepared by solution phase synthesis was also 
challenging. In a typical procedure, after completion of the reaction, a reaction mixture was 
concentrated, an excess of secondary amine was removed by alumina column 
chromatography and a second purification was usually performed on preparative HPLC using 
0.1%TFA:MeCN as a mobile phase. Isolation of the purified conjugates by evaporation of 
the acidic HPLC fractions caused the decomposition of the product, presumably through a 
hydrolysis of benzyl ester moiety of 20. Therefore, peptide-ligand conjugates were isolated 
by neutralization of HPLC fractions followed by extraction with organic solvent. 
Efforts to extend the divergent strategy from solution phase synthesis to SPPS were 
initiated on a model dipeptide bound to Wang resin, since its C-terminus was analogues to 
the model substrate 2. Two cycles of the buffered TBAF were required to ensure the 
complete cleavage of silyloxy ether on SPPS. In addition, acetonitrile was found to be a 
critical solvent for the chlorination reaction, as the reaction performed in DMF furnished a 
complex mixture of products. Moreover, we were surprised to note that dry reaction 
conditions were not necessary while performing the chlorination on SPPS. In some instances 
it was necessary to repeat the chlorination step to obtain the efficient conversion on SPPS. 
Unfortunately, the N-alkylation reaction to incorporate N4Py into Wang resin bound peptide 
precursor resulted in a mixture of unidentifiable products. This result was indicative of the 
slow alkylation of the hindered amines observed in solution phase synthesis. Fortunately 
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replacement of the Wang resin with Rink amide resin, which possesses a stable amide 
linkage between peptide and resin, allowed the incorporation of N4Py as well as other non-
heme ligands into peptides via SPPS (Scheme 2.5). 
2.4 Conclusion 
A divergent strategy for the incorporation of pyridyl containing non-heme ligands 
into peptides has been developed. To facilitate the development of the divergent strategy, two 
routes for the synthesis of an intermediate 7 were established. Straightforward access to this 
intermediate set up a foundation for the synthesis of an unnatural amino acid 1. The amino 
acid 1 was synthesized via asymmetric alkylation to access the enantiomerically enriched 
building block for the divergent strategy. During optimization of an asymmetric alkylation 
route it has been established that the tert-butyl ester moiety in 6b is critical to obtain high 
enantioselectivity of 14b. Although, the transformation of 14b to 1 required a sequence of 
deprotection/reprotection steps, convenient conditions were developed to access multi-gram 
quantities of the target Fmoc-HPA(OTBS)-OH (1) in good yields. Next, the development of 
the divergent strategy was demonstrated using the model dipeptide substrate 2 in solution 
phase synthesis. Using this method TPA, Bn-TPEN and N4Py were incorporated into 2. 
These conjugates could be used to study the coordination chemistry of non-heme ligand-
peptide conjugates as well as in models to study the chemistry of ferryl-peptide conjugates. 
The divergent strategy was further extended to SPPS where the functional group 
compatibility and the scope of this method were explored. With these studies, the divergent 
strategy could provide an easy access to the library synthesis of non-heme ligand-peptide 
conjugates. 
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2.5 Experimental Section 
2.5.1 General consideration 
All reagents were purchased from commercial suppliers and used as received. Rink 
amide MBHA resin (200-400 mesh, 0.75 mmol/g, 1% DVB) was purchased from Chem-
Impex International Inc. NMR spectra were recorded on a Varian FT-NMR Mercury-300 or 
400 Spectrometer. Mass spectra were recorded on a Waters ZQ2000 single quadrupole mass 
spectrometer using an electrospray ionization source. IR spectra were recorded on a Nicolet 
FT-IR spectrophotometer. HPLC was performed on an Agilent 1200 Preparative Purification 
System equipped with a multi-wavelength detector. Column purifications were performed 
using flash chromatography technique and silica gel as a stationary phase unless mentioned 
otherwise. All reactions were performed under ambient atmosphere unless otherwise noted. 
Anaerobic reactions were performed in Schlenk tubes. MALDI-TOF analysis was performed 
on a MALDI-TOF mass spectrometer using the reflectron mode.  
2.5.2 Experimental procedures and tabulated characterization data 
for new compounds 
(6-(((tert-butyldimethylsilyl)oxy)methyl)pyridin-3-yl)methanol (10). 
N
OTBS
OH
Chemical Formula: C13H23NO2Si
Molecular Weight: 253.41
 
Route 1: 
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A solution of compound 5172,180 (8.50 g, 2.81 mmol) and distilled toluene (255 mL) 
was purged with argon for 10 min. The reaction mixture was cooled to –78 °C and n-BuLi 
(1.6M solution in hexanes, 21.0 mL, 3.37 mmol) was added dropwise over 30 min, during 
which the color of the reaction mixture changed from colorless to reddish orange. The 
reaction mixture was maintained for 1.5 h at –78 °C and N,N-dimethyl formamide (2.83 mL, 
3.66 mmol) was added over 5 min. The reddish orange solution was maintained at –78 °C for 
other 1.5 h. The reaction mixture was warmed to 0 °C and methanol (42 mL) was added 
dropwise over the period of 10 min. NaBH4 (1.06 g, 2.81 mmol) was added to it and the 
resulting red solution was maintained for 1 h at 0 °C, during which the color of the solution 
changed from red to yellow. A solution of 0.1M NaOH (100 mL) was added and the reaction 
mixture was warmed to rt. The reaction mixture was maintained at rt for 15 min and mixed 
with water (300 mL). After extraction of the aqueous layer with ethyl acetate (4 × 50 mL), 
the combined organic layer was dried over anhydrous Na2SO4 and concentration to obtain 
crude product. The crude product was recrystallized from cold hexanes to obtain 10 as off-
white solid (4.65 g, 65%). 
Route 2: 
A mixture of 12173 (10.0 g, 59.2 mmol), imidazole (6.05 g, 88.8 mmol) and DMF 
(130 mL) was maintained at rt under a nitrogen atmosphere for 5 min. TBSCl (9.80 g, 65.1 
mmol) was added and the reaction mixture was maintained at rt for 2 h. After consumption of 
the starting material, as judged by TLC analysis, the reaction mixture was mixed with H2O 
(250 mL). The aqueous layer was extracted with EtOAc  (3 × 75 mL). The combined organic 
layer was dried over anhydrous Na2SO4 and concentrated to obtain the crude product 13 as a 
yellow viscous oil (16.6 g, quant.) 
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A solution of 13174 (5.00 g, 17.8 mmol) and dry THF (125 mL) was maintained at 0 
°C under a nitrogen atmosphere for 10 min.  A solution of NaAlH2(OCH2CH2OMe) in 
toluene (65% w/w, 12.7 mL, 40.8 mmol) was added dropwise over 25 min, resulting in an 
orange solution. The solution was maintained at 0 °C for 2 h.  After consumption of the 
starting material, as judged by TLC analysis, the reaction mixture was quenched by dropwise 
addition of MeOH (4.5 mL) and a solution of 0.1M NaOH (10 mL) was added.  The reaction 
mixture was combined with H2O (200 mL) and the aqueous layer was extracted with EtOAc 
(3 × 75 mL). The combined organic layer was dried over anhydrous Na2SO4 and 
concentrated to obtain the crude product which upon crystallization from cold hexanes (10 
mL) furnished 10 as off-white crystalline solid (3.50 g, 78%).  mp = 50-51 °C; 1H NMR (400 
MHz, CDCl3) δ 8.34 (brs, 1H), 7.69 (d, J = 8.1 Hz, 1H), 7.46 (d, J = 8.1 Hz, 1H), 4.76 (s, 
2H), 4.64 (s, 2H), 3.57 (b, 1H), 0.91 (s, 9H), 0.07 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 
160.4, 147.2, 135.8, 134.7, 119.9, 65.7, 62.2, 25.9, 18.3, –5.4; IR (thin film) 3211 (b), 2953, 
2927, 2856, 1604, 1573, 1491, 1458, 1399, 1377, 1358, 1341, 1255, 1102, 1060, 1031, 1006, 
860, 839, 776, 670, 647 cm-1; LRMS (ESMS) calcd for C13H24NO2Si (M+H)+ 254, found: 
254. 
5-(bromomethyl)-2-(((tert-butyldimethylsilyl)oxy)methyl)pyridine (7). 
N
OTBS
Br
Chemical Formula: C13H22BrNOSi
Molecular Weight: 316.31
 
A mixture of (6-((tert-butyldimethylsilyloxy)methyl)pyridin-3-yl)methanol 10 (4.65 
g, 18.4 mmol) and CH2Cl2 (93 mL) was maintained at 0 °C under a nitrogen atmosphere for 
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10 min. N-bromosuccinimide (3.60 g, 20.2 mmol) and triphenylphosphine (5.30 g, 20.2 
mmol) were added successively over 15 min.  The yellow solution was maintained at 0 °C 
for 2 h.  After consumption of the starting material, as judged by TLC analysis, the reaction 
mixture was concentrated without warming and the crude product was purified by silica gel 
chromatography (5% to 15% EtOAc:hexanes) to obtain compound 7 as a pink oil (5.33 g, 
92%). Note: Compound 7 decomposes upon storage, hence should be used immediately. 1H 
NMR (400 MHz, CDCl3) δ 8.48 (s, 1H), 7.71 (d, J = 8.1 Hz, 1H), 7.48 (d, J = 8.1 Hz, 1H), 
4.80 (s, 2H), 4.44 (s, 2H), 0.93 (s, 9H), 0.09 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 161.6, 
148.7, 137.3, 131.7, 120.0, 65.8, 29.8, 25.9, 18.3, –5.4; IR (thin film) 2954, 2929, 2885, 
2857, 1600, 1571, 1487, 1471, 1393, 1369, 1252, 1101, 1026, 1006, 938, 838, 778, 725, 670 
cm-1; LRMS (ESMS) calcd for C13H23BrNOSi (M+H)+ 316, found: 316. 
General Procedures for Preparation of 14a and 14b. 
General Procedure A: A mixture of 6a171 or 6b171 (16.7 mmol), PTC (See Table 2.1) and 
7:3 toluene:CH2Cl2 (72 mL) was cooled to 0 °C under a nitrogen atmosphere. A 50% 
aqueous NaOH solution (24.5 mL) was added at 0 °C. 5-(bromomethyl)-2-((tert-
butyldimethylsilyloxy)methyl)pyridine 7 (5.30 g, 16.7 mmol) was dissolved in 7:3 
toluene:CH2Cl2 (11 mL) and this solution was added dropwise to the reaction mixture at 0 °C 
over 10 min. The reaction mixture was stirred vigorously at 0 °C for 3-12 h. After 
consumption of the starting material as judged by TLC analysis (20% EtOAc:hexanes), the 
reaction mixture was combined with cold H2O (40 mL). The organic layer was separated and 
the aqueous layer was extracted using CH2Cl2 (3 × 20 mL). The combined organic layer was 
dried over anhydrous Na2SO4 and concentrated to obtain a brown viscous oil.  The crude 
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product was purified by silica gel chromatography (5% to 15% EtOAc:hexanes) to afford the 
corresponding product 14a or 14b. 
General Procedure B: A mixture of 6a171 or 6b171 (0.79 mmol), 15 or 16  (See Table 2.1), 5-
(bromomethyl)-2-((tert-butyldimethylsilyloxy)methyl)pyridine 7 (250 mg, 0.79 mmol) and 
CH2Cl2 (2.3 mL)  was cooled to the appropriate temperature (See Table 2.1) under a nitrogen 
atmosphere. Solid CsOH·H2O (1.32 g, 7.89 mmol) was added and the reaction mixture was 
stirred vigorously for 3-12 h. After consumption of the starting material as judged by TLC 
analysis (20% EtOAc:hexanes), the reaction mixture was diluted with Et2O (20 mL) and then 
combined with cold water (30 mL). The organic layer was separated and the aqueous layer 
was extracted with CH2Cl2 (3 × 15 mL).  The combined organic layers were dried over 
anhydrous Na2SO4 and concentrated to get a brown viscous oil.  The crude product was 
purified by silica gel chromatography (5% to 15% EtOAc:hexanes) to afford 14a or 14b. 
(S)-benzyl 3-(6-(((tert-butyldimethylsilyl)oxy)methyl)pyridin-3-yl)-2-((diphenyl 
methylene)amino)propanoate (14a). 
N
OBn
O
N
OTBS
Ph
Ph
Chemical Formula: C35H40N2O3Si
Molecular Weight: 564.79
 
Compound 14a was synthesized according to general procedure A (Table 2.1, entry 1, 
3) or general procedure B (Table 2.1, entry 4-6). 1H NMR (400 MHz, CDCl3) δ 8.20 (s, 1H), 
7.55 (d, J = 7.3 Hz, 2H), 7.38-7.22 (m, 13H), 6.63 (d, J = 7.3 Hz, 2H), 5.19 (d, J = 13.0 Hz, 
1H), 5.12 (d, J = 13.0 Hz, 1H), 4.76 (s, 2H), 4.26 (dd, J = 8.9, 4.9 Hz, 1H), 3.27-3.16 (m, 
2H), 0.91 (s, 9H), 0.72 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 171.5, 171.1, 159.3, 149.7, 
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139.0, 138.0, 135.9, 135.7, 131.4, 130.5, 128.8, 128.5, 128.5, 128.3, 128.2, 128.1, 128.0, 
127.4, 119.5, 66.7, 66.6, 65.9, 36.4, 25.9, 18.3, –5.4; IR (thin film) 3061, 3032, 2954, 2928, 
2885, 2856, 1741, 1622, 1599, 1574, 1489, 1471, 1446, 1397, 1372, 1314, 1287, 1252, 1163, 
1128, 1104, 1029, 1004, 939, 910, 838, 779, 696, 640 cm-1; LRMS (ESMS) calcd for 
C35H41N2O3Si (M+H)+ 565, found: 565. 
(S)-tert-butyl 3-(6-(((tert-butyldimethylsilyl)oxy)methyl)pyridin-3-yl)-2-((diphenyl 
methylene)amino)propanoate (14b). 
N
OtBu
O
N
OTBS
Ph
Ph
Chemical Formula: C32H42N2O3Si
Molecular Weight: 530.77  
Compound 14b was synthesized according to general procedure A (Table 2.1, entry 
2, 8-9) or general procedure B (Table 2.1, entry 7). 1H NMR (400 MHz, CDCl3) δ 8.23 (s, 
1H), 7.58 (d, J = 7.3 Hz, 2H), 7.43-7.26 (m, 8H), 6.72 (d, J = 6.5 Hz, 2H), 4.79 (s, 2H), 4.13-
4.10 (m, 1H), 3.20-3.14 (m, 2H), 1.43 (s, 9H), 0.92 (s, 9H), 0.08 (s, 6H); 13C NMR (100 
MHz, CDCl3) δ 170.4, 170.0, 158.8, 149.4, 138.9, 137.7, 135.9, 131.5, 129.9, 128.4, 128.0, 
127.9, 127.6, 127.1, 119.1, 88.0, 66.9, 65.6, 36.1, 27.6, 25.5, 18.0, –5.7; IR (thin film) 3059, 
2955, 2929, 2885, 2856, 1734, 1624, 1599, 1574, 1488, 1472, 1462, 1446, 1394, 1368, 1314, 
1288, 1253, 1151, 1104, 1030, 1006, 977, 938, 910, 840, 815, 779, 731, 696, 670, 641 cm-1; 
[α] = –132° (c = 1.0, MeOH); HRMS (ESMS) calcd for C32H43N2O3Si (M+H)+ 531.3043, 
found: 531.3037. 
General Procedure for the Determination of Enantiomeric Excess. 
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 A mixture of compound 14a or 14b (1 eq), 1:1 THF:H2O and NH2OH·HCl (3 eq) 
was stirred at rt for 3 h. After consumption of the starting material, as judged by TLC 
analysis, the reaction mixture was combined with H2O. The aqueous layer was extracted 
using hexanes followed by CH2Cl2. The combined CH2Cl2 layer was dried over anhydrous 
Na2SO4 and concentrated to obtain the crude amino ester. 
A solution of (S)-α-methylbenzylisocyanate (1.2 eq), amino ester and CHCl3 was 
maintained at rt for 3 h under a nitrogen atmosphere. The reaction mixture was concentrated 
under vacuum to obtain a crude oil that was analyzed by 1H NMR spectroscopy. Ratios of 
diastereomers were determined as discussed in section 2.2.1.4. 
 (S)-2-amino-3-(6-((tert-butyldimethylsilyloxy)methyl)pyridin-3-yl)propanoic acid (3). 
H2N
OH
O
N
OTBS
Chemical Formula: C15H26N2O3Si
Molecular Weight: 310.46
 
A mixture of 14a (6.15 g, 10.9 mmol), MeOH (123 mL) and 10% Pd/C (50% w/w 
moisture, 615 mg) was stirred at rt under H2 (1 atm) atmosphere for 5 h. After consumption 
of the starting material, as judged by TLC analysis, the reaction mixture was filtered through 
celite and the celite bed was washed with methanol. The combined filtrate was concentrated 
to obtain a sticky white solid, which upon triturating with Et2O for 10 min furnished 3 as a 
white amorphous solid.  The white solid was isolated by filtration and washed with Et2O 
(2.60 g, 77%). 1H NMR (400 MHz, CD3OD) δ 8.38 (s, 1H), 7.81 (dd, J = 8.1, 2.4 Hz, 1H), 
7.54 (d, J = 7.3 Hz, 1H), 4.78 (s, 2H), 3.81 (dd, J = 8.1, 4.9 Hz, 1H), 3.30-3.10 (m, 2H), 0.96 
(s, 9H), 0.13 (s, 6H); 13C NMR (100 MHz, CD3OD) δ 173.2, 161.1, 150.0, 139.8, 132.0, 
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121.9, 66.5, 57.0, 35.0, 26.3, 19.2, –5.3; IR (KBr) 3405 (b), 2956, 2930, 2887, 2858, 1604, 
1524, 1492, 1472, 1463, 1442, 1398, 1361, 1333, 1254, 1108, 838, 778 cm-1; LRMS (ESMS) 
calcd for C15H27N2O3Si (M+H)+ 311, found: 311. 
(S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-(6-((tert-butyldimethylsilyloxy) 
methyl)pyridin-3-yl)propanoic acid (1). 
FmocHN
OH
O
N
OTBS
Chemical Formula: C30H36N2O5Si
Molecular Weight: 532.70
 
From compound (3): A mixture of compound 3 (1.00 g, 3.22 mmol), Na2CO3 (324 mg, 3.06 
mmol) and H2O (10 mL) was maintained at 0 °C for 5 min. The suspension of FmocOSu 
(1.09 mg, 3.22 mmol) in acetone (8 mL) was added and the reaction mixture was maintained 
at 0 °C for 1 h. The reaction mixture was allowed to warm up to rt and maintained overnight. 
Throughout the reaction period the reaction mixture was maintained at pH 7-8. After the 
consumption of the starting material, as judged by TLC analysis, the reaction mixture was 
combined with H2O (130 mL) and the aqueous layer was washed with hexanes (2 × 30 mL). 
The aqueous layer was acidified to pH 4-5 by slow addition of 10% aqueous citric acid and 
extracted with EtOAc (5 × 30 mL). The combined EtOAc layers were washed with saturated 
NaCl (aq). The EtOAc layer was dried over anhydrous Na2SO4 and concentrated to obtain 
the crude product (1.14 g, 67%).  
From compound (14b): A solution of compound 14b (700 mg, 1.32 mmol) and 6N HCl (3.5 
mL) was refluxed for 6 h. The reaction mixture was combined with H2O (5 mL) and 
extracted with Et2O (2 × 10 mL). The aqueous layer was concentrated under high vacuum to 
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obtain a crude product. The crude product was dissolved in H2O (10 mL) and concentrated 
under high vacuum (twice) to remove excess HCl. The crude product was dried on high 
vacuum for 3-4 h to obtain an off-white solid, which was found to be hygroscopic and stored 
under nitrogen or used immediately for the next reaction. 
A mixture of the off-white solid (325 mg, 1.20 mmol), Et3N (2.8 mL, 19.8 mmol) and 
DMF (11.5 mL) was maintained at rt under nitrogen atmosphere for 5 min. TBSCl (2.00 g, 
13.2 mmol) was added and the reaction mixture was maintained for 2 h under nitrogen 
atmosphere. The reaction mixture was combined with 0.1% aq Na2CO3 (50 mL) and washed 
with Et2O (3 × 15 mL). An off-white solid formed that was isolated and combined with the 
aqueous layer. A mixture of an off-white solid and aqueous layer was cooled to 0 °C and a 
solution of FmocOSu (489 mg, 1.45 mmol) in 1,4-dioxane (7 mL) was added over 5 min. 
The reaction mixture was maintained at 0 °C for 1 h and then allowed to warm up to rt. The 
reaction mixture was maintained at rt overnight, combined with H2O (50 mL) and extracted 
with hexanes (2 × 50 mL). The aqueous solution was acidified to pH 4-5 by slow addition of 
citric acid (10% aq). The aqueous solution was extracted with EtOAc (4 × 25 mL). The 
combined EtOAc layers were dried over anhydrous Na2SO4 and concentrated to obtain the 
product. The crude product was further purified by silica gel chromatography (0% to 5% 
MeOH:CH2Cl2)  (605 mg, 86%). A small sample was recrystallized from MTBE:hexanes 
(1:2) for analysis. mp = 81-83 °C; 1H NMR (400 MHz, CD3OD) δ 8.34 (s, 1H), 7.76-7.70 
(m, 3H), 7.57-7.43 (m, 3H), 7.38-7.24 (m, 4H), 4.72 (s, 2H), 4.46-4.41 (m, 1H), 4.34-4.28 
(m, 1H), 4.19-4.07 (m, 2H), 3.30-3.20 (m, 1H), 3.03-2.93 (m, 1H), 0.91 (s, 9H), 0.06 (s, 6H); 
13C NMR (100 MHz, CD3OD) δ 175.2, 160.2, 158.2, 149.8, 145.2, 142.5 139.8, 133.7, 128.7, 
128.1, 126.3, 126.2, 121.5, 120.9, 67.9, 66.3, 56.6, 35.7, 26.3, 19.2, –5.3; IR (KBr) 3419 (b), 
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3065, 2953, 2928, 2887, 2856, 1713, 1606, 1536, 1450, 1401, 1335, 1253, 1106, 1053, 1007, 
839, 779, 759, 740, 671, 621 cm-1; [α] = –2.5° (c = 1.1, MeOH); HRMS (ESMS) calcd for 
C30H37N2O5Si (M+H)+ 533.2472, found: 533.2481. 
Benzyl 2-(3-(6-((tert-butyldimethylsilyloxy)methyl)pyridin-3-yl)-2-ethanamido 
propanamido)ethanoate (2). 
AcHN
H
N
O
N
OTBS
OBn
O
Chemical Formula: C26H37N3O5Si
Molecular Weight: 499.67
 
Acetic anhydride (0.4 mL, 3.86 mmol) was added to a mixture of compound 3 (1.00 
g, 3.22 mmol), CH2Cl2 (25 mL) and Et3N (2.20 mL, 16.1 mmol). The reaction mixture was 
maintained at rt under a nitrogen atmosphere for 3 h. After consumption of the starting 
material, as judged by TLC analysis, the reaction was combined with H2O (40 mL).  The 
aqueous layer was acidified to pH ~5 by slow addition of citric acid (10% aq).  The organic 
layer was separated and the aqueous layer was extracted with CH2Cl2 (3 × 25 mL). Note: 
Extracting the organic layer with sat. NaCl at this stage results in precipitation and hence 
the organic layer should never be washed with sat. NaCl. The combined organic layers were 
dried over anhydrous Na2SO4 and concentrated to obtain crude Ac-HPA(OTBS)-OH as a 
yellow viscous semisolid (1.14 g, quantitative).  
A mixture of crude Ac-HPA(OTBS)-OH (1.14 g, 3.32 mmol), H-Gly-OBn181,182 (721 
mg, 4.37 mmol), CH2Cl2 (35 mL), Et3N (0.7 mL, 5.03 mmol), and HOBt (610 mg, 3.98 
mmol)  was maintained at rt under a nitrogen atmosphere for 5 min. EDAC (763 mg, 3.98 
mmol) was added and the mixture was stirred vigorously overnight.  The reaction mixture 
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was combined with CH2Cl2 (25 mL) and extracted with 5% aq NaHCO3 (3 × 15 mL), sat. aq 
NH4Cl (3 × 15 mL) and sat. aq NaCl (3 × 15 mL) respectively.  The organic layer was 
separated, dried over anhydrous Na2SO4 and concentrated to obtain the crude 2 as viscous 
oil. Upon triturating with Et2O at –20 °C, a white solid formed that was isolated by filtration 
and washed with cold Et2O (1.17 g, 72%).  mp = 98-100 °C; 1H NMR (400 MHz, CDCl3) δ 
8.28 (s, 1H), 7.53 (d, J = 8.1 Hz, 1H), 7.39 (d, J = 8.1 Hz, 1H), 7.34-7.30 (m, 5H), 7.12 (brs, 
1H), 6.57 (d, J = 8.1 Hz, 1H), 5.12 (s, 2H), 4.80-4.76 (m, 3H), 4.01-3.98 (m, 2H), 3.09 (dd, J 
= 14.6, 6.5 Hz, 1H), 2.90 (dd, J = 13.8, 7.3 Hz, 1H), 1.90 (s, 3H), 0.92 (s, 9H), 0.08 (s, 6H); 
13C NMR (100 MHz, CDCl3) δ 171.1, 170.4, 169.2, 160.0, 149.2, 137.5, 135.0, 130.0, 128.6, 
128.5, 128.3, 119.8, 67.2, 65.8, 53.6, 41.2, 34.9, 25.9, 23.0, 18.3, –5.4; IR (thin film) 3286 
(b), 3067, 2954, 2929, 2886, 2856, 1751, 1649, 1546, 1471, 1456, 1374, 1254, 1188, 1105, 
1030, 1005, 839, 778, 734, 697, 670 cm-1; LRMS (ESMS) calcd for C26H38N3O5Si (M+H)+ 
500, found: 500. 
Benzyl 2-(3-(6-(chloromethyl)pyridin-3-yl)-2-ethanamidopropanamido)ethanoate (19). 
AcHN
H
N
O
N
Cl
OBn
O
Chemical Formula: C20H22ClN3O4
Molecular Weight: 403.86
 
A mixture of compound 2 (300 mg, 600 µmol), acetic acid (34 µL, 600 µmol) and 
THF (4.2 mL) was maintained under a nitrogen atmosphere for 5 min. A 1M solution of 
TBAF in THF (1.8 mL, 1.80 mmol) was added and the reaction mixture was maintained for 
1-1.5 h. After consumption of the starting material, as judged by TLC analysis, the reaction 
mixture was combined with H2O (50 mL) and the solution was adjusted to pH ~ 8 using 
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Na2CO3 (sat. aq).  The aqueous layer was extracted with CH2Cl2 (7 × 20 mL).  The combined 
organic layers were dried over anhydrous Na2SO4 and concentrated to obtain the 
corresponding alcohol as a white solid.  After triturating the solid with Et2O overnight a 
white solid was isolated by decantation and used for the next reaction without purification 
(176 mg, 76%). 
A mixture of the crude alcohol (50.0 mg, 0.13 mmol), flame dried LiCl (55 mg, 1.30 
mmol), i-Pr2EtN (46 µL, 0.26 mmol) and MeCN (1.9 mL) was maintained under a nitrogen 
atmosphere at 0 °C for 5 min and TsCl (37 mg, 0.19 mmol) was added under a nitrogen 
atmosphere. The reaction mixture was stirred at 0 °C for 1.5 h and then warmed to rt. The 
color of the reaction mixture changed from colorless to red. The red suspension was 
maintained at rt for 4 h. After consumption of the starting material, as judged by TLC 
analysis, the reaction mixture was decanted and the residues were rinsed with MeCN (5 mL). 
The combined MeCN layer was concentrated and the crude product was combined with 
CH2Cl2 (15 mL). The CH2Cl2 layer was extracted with an aq NaHCO3 (pH ~ 9) solution (3 × 
10 mL).  The organic layer was dried over anhydrous Na2SO4 and concentrated to furnish the 
crude product 19 as a red oil. The crude product was purified by silica gel chromatography 
(0% to 5% MeOH:CH2Cl2) to obtain an orange oil (37 mg, 70%). 1H NMR (400 MHz, 
CDCl3) δ 8.35 (s, 1H), 7.55 (dd, J = 8.1, 1.6 Hz, 1H), 7.35-7.25 (m, 7H), 6.74 (d, J = 8.1 Hz, 
1H), 5.12 (s, 2H), 4.83 (dd, J = 14.6, 7.3 Hz, 1H), 4.58 (s, 2H), 4.00 (d, J = 4.6 Hz, 2H), 3.11 
(dd, J = 13.8, 6.5 Hz, 1H), 2.95 (dd, J = 13.8, 7.3 Hz, 1H), 1.90 (s, 3H); 13C NMR (100 MHz, 
CDCl3) δ 170.9, 170.4, 169.2, 155.2, 150.1, 138.0, 135.0, 131.6, 128.7, 128.6, 128.4, 122.6, 
67.3, 53.5, 46.4, 41.3, 34.9, 23.0; IR (thin film) 3284 (b), 3065, 1748, 1650, 1544, 1440, 
1384, 1190, 753, 697 cm-1; LRMS (ESMS) calcd for C20H23ClN3O4 (M+H)+ 404, found: 404. 
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General Procedure for N-Alkylation of 19. 
A mixture of compound 19, corresponding secondary amine, MeCN, and i-Pr2EtN 
was heated at 55 °C for 18-20 h. The reaction mixture was concentrated and the crude 
product was dissolved in CH2Cl2. The organic layer was extracted with 5% aq NaHCO3 (2 × 
5 mL). The organic layer was dried over anhydrous Na2SO4 and concentrated to obtain the 
crude product as brown viscous oil. 
Benzyl 2-(2-acetamido-3-(6-((bis(pyridin-2-ylmethyl)amino)methyl)pyridin-3-
yl)propanamido)acetate (20a). 
AcHN
H
N
O
N
OBn
O
N
N
N
Chemical Formula: C32H34N6O4
Molecular Weight: 566.65
 
Compound 20a was prepared by general procedure for N-alkylation using 19 (33 mg, 
81.6 µmol), MeCN (1.5 mL), i-Pr2EtN (22 µL, 122 µmol) and bis-(2-picolylamine)175 (21 
mg, 106 µmol). A crude product was purified by column chromatography on basic alumina 
(0% to 5% MeOH:EtOAc) for analysis (29 mg). The yield was calculated by 1H NMR 
analysis of a crude product using methyl-m-toluate as an internal standard (95%). 1H NMR 
(400 MHz, CDCl3) δ 8.48 (d, J = 4.0 Hz, 2H), 8.29 (s, 1H), 7.63-7.59 (m, 2H), 7.53-7.46 (m, 
4H), 7.33-7.26 (m, 5H), 7.11-7.02 (m, 3H), 6.52 (d, J = 8.1 Hz, 1H), 5.07 (s, 2H), 4.73 (dd, J 
= 14.6, 6.5 Hz, 1H), 4.06-3.91 (m, 2H), 3.82-3.80 (m, 6H), 3.07 (dd, J = 13.6, 7.3 Hz, 1H), 
2.94 (dd, J = 13.6, 7.3 Hz, 1H), 1.88 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 171.0, 170.4, 
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169.2, 159.2, 158.0, 149.6, 149.0, 137.3, 136.4, 135.0, 130.3, 128.6, 128.5, 128.3, 122.9, 
122.7, 122.0, 67.2, 60.0, 59.7, 53.6, 41.2, 34.8, 29.6, 23.0; IR (thin film) 3283 (b), 2926, 
1749, 1654, 1590, 1569, 1434, 1370, 1188, 994, 756, 698 cm-1; HRMS (ESMS) calcd for 
C32H35N6O4 (M+H)+ 567.2720, found: 567.2706. 
Benzyl 2-(2-acetamido-3-(6-(((2-(benzyl(pyridin-2-ylmethyl)amino)ethyl) (pyridin-2-
ylmethyl)amino)methyl)pyridin-3-yl)propanamido)acetate (20b). 
AcHN
H
N
O
N
OBn
O
N
N
N
N
Chemical Formula: C41H45N7O4
Molecular Weight: 699.84
 
Compound 20b was prepared by general procedure for N-alkylation using compound 
19 (20 mg, 49.5 µmol), MeCN (0.9 mL), i-Pr2EtN (35 µL, 198 µmol), and N1-benzyl-N1,N2-
bis(pyridin-2-ylmethyl)ethane-1,2-diamine183 (50 mg, 148 µmol). A sample was purified by 
preparative HPLC for analysis (14 mg). The yield was calculated by 1H NMR analysis of a 
crude product using methyl-m-toluate as an internal standard (79%). HPLC Conditions: 
column: Zorbax XDB-C18, 21.2 × 150 mm, 5 micron equipped with guard column; flow rate 
= 20 mL/min; gradient elution 0-5 min 0-5% MeCN in 0.1% aq TFA, 5-15 min 5-95% 
MeCN in 0.1% aq TFA; RT = 10.2 min.184 1H NMR (400 MHz, CDCl3) δ 8.45 (d, J = 4.0 
Hz, 2H), 8.26 (s, 1H), 7.58-7.53 (m, 2H), 7.46-7.41 (m, 3H), 7.34-7.08 (m, 14H), 6.44 (b, 
1H), 5.10 (s, 2H), 4.70-4.65 (m, 1H), 3.95 (dd, J = 13.0, 5.7 Hz, 2H), 3.73-3.69 (m, 4H), 
3.58-3.52 (m, 4H), 3.05 (dd, J = 13.9, 6.5 Hz, 1H), 2.96 (dd, J = 13.9, 6.5 Hz, 1H), 2.69-2.55 
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(m, 4H), 1.90 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 171.0, 170.3, 169.1, 160.2, 159.6, 
158.5, 149.5, 148.9, 148.8, 139.1, 137.2, 136.5, 136.4, 135.1, 130.2, 128.6, 128.5, 128.3, 
128.2, 126.9, 122.8, 122.6, 121.9, 67.2, 60.8, 60.5, 60.1, 58.9, 53.9, 51.7, 41.2, 34.9, 23.0; IR 
(thin film) 3286(b), 2917, 2849, 1749, 1653, 1591, 1539, 1435, 1373, 1260, 1188, 1029, 756, 
699, 665 cm-1; HRMS (ESMS) calcd for C41H46N7O4 (M+H)+ 700.3611, found: 700.3604. 
Benzyl 2-(2-acetamido-3-(6-(((dipyridin-2-ylmethyl)(pyridin-2-ylmethyl)amino) 
methyl)pyridin-3-yl)propanamido)acetate (20c). 
AcHN
H
N
O
N
OBn
O
N
N
N
N
Chemical Formula: C37H37N7O4
Molecular Weight: 643.73
 
Compound 20c was prepared by general procedure for N-alkylation using compound 19 (52 
mg, 130 µmol), MeCN ( 2.6 mL), i-Pr2EtN (93 µL, 519 µmol), sodium iodide (5 mg, 25.9 
µmol) and 1,1-di(pyridin-2-yl)-N-(pyridin-2-ylmethyl)methanamine [NH(PyCH2)(CHPy2); 
where Py = 2-pyridyl]168 (107 mg, 389 µmol). The crude product was purified first by 
column chromatography on basic alumina (0% to 5% MeOH:CH2Cl2) and then by 
preparative HPLC for analysis (21 mg). The yield was calculated by 1H NMR analysis of a 
crude product using cyclooctadiene as an internal standard (90%).  Note: A catalytic amount 
of sodium iodide is necessary for the better conversion in this reaction. HPLC Conditions: 
column: Zorbax XDB-C18, 21.2 × 150 mm, 5 micron equipped with guard column; flow rate 
= 20 mL/min; gradient elution 0-5 min 0-20% MeCN in 0.1% aq TFA, 5 -15 min 20-65% 
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MeCN in 0.1% aq TFA; RT = 8.5 min.184 1H NMR (400 MHz, CDCl3) δ 8.51 (d, J = 4.9 Hz, 
2H), 8.44 (d, J = 4.9 Hz, 1H), 8.28 (s, 1H), 7.65-7.56 (m, 6H), 7.50-7.34 (m, 2H), 7.32-7.26 
(m, 5H), 7.12-7.04 (m, 3H), 6.94 (brs, 1H), 6.46 (brs, 1H), 5.30 (s, 1H), 5.08 (s, 2H), 4.72-
4.65 (m, 1H), 3.99-3.90 (m, 6H), 3.05 (dd, J = 14.6, 6.5 Hz, 1H), 2.95 (dd, J = 14.6, 6.5 Hz, 
1H), 1.88 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 170.9, 170.3, 169.2, 159.9, 159.7, 158.4, 
149.6, 149.2, 149.0, 137.3, 136.4, 136.3, 135.0, 130.2, 128.6, 128.5, 128.3, 123.9, 122.9, 
122.8, 122.1, 71.9, 67.2, 57.0, 56.7, 53.7, 41.2, 34.7, 23.0; IR (thin film) 3285, 3062, 2928, 
1749, 1656, 1588, 1569, 1470, 1433, 1372, 1188, 1030, 996, 911, 732, 698, 645 cm-1; HRMS 
(ESMS) calcd for C37H38N7O4 (M+H)+ 644.2985, found: 644.2988. 
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Chapter 3: Application of the Divergent and Dual 
Divergent Strategies for a Library Synthesis of Luteinizing 
Hormone Releasing Hormone (LHRH) Analogues 
3.1 Introduction 
One goal of the Kodanko group is to investigate the potential of non-heme ligands 
and their metal complexes as anticancer agents. The most essential requirement for this study 
is the rapid synthesis of the library of non-heme ligand-peptide conjugates where ligand 
structures could be rapidly altered to tune the reactivity. The peptide vectors in such 
conjugates are expected to serve as carriers for the target specific delivery of the metal 
complexes. The divergent strategy described in Chapter 2 has a potential to elaborate the 
metal-binding units at the late stage and hence facilitates a straightforward access to the 
diverse ligand structures.98 With this strategy, the size of the library would depend only on 
the number of the available secondary amines. Thus 100 secondary amines would be needed 
if a library of 100 analogues, each possessing a different ligand, was to be constructed. This 
could be a major limitation for the rapid synthesis of larger libraries because secondary 
amines are usually prepared by solution phase synthesis, which is associated with 
purification and isolation issues. Therefore a modification of the existing divergent strategy 
was sought prior to utilizing the strategy for library synthesis. A stepwise elaboration of the 
ligand structure, named dual divergent strategy, was envisioned as a viable alternative to the 
divergent strategy (Scheme 1.18, Eq 2). This modification would reduce the number of 
starting material from 100 secondary amines to 10 primary amines and 10 chlorides for the 
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library of 100 analogues. Moreover, the method could not only avoid a tedious solution phase 
synthesis but could also be suitable for the split-pool synthesis technique185 commonly 
employed in the construction of larger libraries.  
The second requirement to explore the utility of non-heme ligands as anticancer 
agents is the choice of suitable peptide vector that could selectively deliver non-heme ligand 
to the target site. For this study we chose a decapeptide, luteinizing hormone releasing 
hormone (LHRH), which is a well-known delivery vector and selectively delivers cytotoxic 
agents to tumors in vivo. The selectivity is ascribed to the presence of LHRH receptors on 
various cancer cell lines such as breast, ovarian and prostate cancer cells.186,187 The research 
over last two decades have established that the replacement of Gly at position 6 of the natural 
LHRH with D-lysine provides a point of attachment for cytotoxic agents and improves the 
serum half-life188 of the resulting conjugates without affecting the binding affinity (Figure 
3.1).128 For example, analogue such as AN-152, which contains a cytotoxic agent 
doxorubicin (DOX) at the D-Lys side chain of LHRH, is in phase II clinical trials for the 
treatment of ovarian cancer.189 
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Figure 3.1: Schematic diagram for conjugation of cytotoxic agents to the D-Lys6[LHRH] 
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In this chapter the development of the dual divergent strategy on a model substrate is 
presented. In addition, the scope, limitation and functional group compatibility of the dual 
divergent strategy are also demonstrated by constructing a small library of metal-binding 
LHRH analogues. Towards this, an unnatural amino acid Fmoc-HPL(OTBS)-OH (1, Figure 
3.1) was synthesized in such a way that it possesses a hydroxymethyl pyridyl moiety at the 
Nε-amine of the D-lysine. Amino acid 1 was incorporated into the LHRH analogue, which 
provided a suitable functionality through which diverse array of ligand structures were 
constructed via divergent as well as dual divergent strategy. 
3.2 Results 
3.2.1 Development of the dual divergent strategy 
3.2.1.1 Synthesis of a model substrate on resin 
To develop the dual divergent strategy, a model dipeptide substrate 2 was synthesized 
from commercially available Fmoc-Gly-Rink amide resin using standard SPPS conditions 
(Scheme 3.1). Transformation of the silyloxy ether side chain of 2 into the corresponding 
chloride 3 was achieved using a two-step sequence developed during the divergent strategy. 
98 The sequence involved the treatment of 2 with buffered TBAF to obtain the corresponding 
alcohol, which was eventually chlorinated using a combination of tosyl chloride and lithium 
chloride. A small portion of the peptide 3 was cleaved from resin and the completion of the 
chlorination reaction was verified using 1H NMR spectroscopic analysis, prior to proceeding 
with the alkylation reactions. If partial chlorination was observed, the chlorination conditions 
were repeated. 
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Scheme 3.1: Synthesis of a model substrate and transformation of the silyloxy ether side 
chain into chloride 
3.2.1.2 Development of dual divergent strategy on the model substrate 
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Figure 3.2: (a) Development of the dual divergent strategy on the model substrate (b) HPLC 
chromatogram of crude 5 prepared by the divergent and the dual divergent strategy 
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The dual divergent strategy was investigated (Scheme 3.2) by the N-alkylation of the 
chloride 3 with excess primary amine using the conditions developed for the divergent 
strategy (MeCN, 55 °C, 18 h). The N-alkylation gave the desired secondary amine 4, albeit in 
low purity. Delightfully, performing the reaction in DMF at rt instead of heating in MeCN 
significantly minimized the side reactions and furnished the desired secondary amine 4 as the 
major product (Figure 3.2a). The second alkylation of 4 was straightforward and achieved by 
heating 4 with 10 equiv of 2-picolylchloride. Interestingly, the HPLC chromatogram of the 
crude TPA-dipeptide 5 obtained via this route was indistinguishable to the conjugate 
obtained via the divergent strategy (Figure 3.2b). 
3.2.2 Application of the divergent and dual divergent strategies to 
a library synthesis of LHRH analogues 
3.2.2.1 Synthesis of Fmoc-HPL(OTBS)-OH 
To investigate the scope and the functional group compatibility of the dual divergent 
strategy, an unnatural amino acid Fmoc-HPL(OTBS)-OH (1, HPL: Hydroxymethyl Pyridyl 
Lysine) was designed in such a way that the hydroxymethyl pyridyl moiety containing the 
silyloxy ether side chain was connected on the side chain of D-lysine. The synthesis of 1 
began with a hydrolysis of intermediate 6 to obtain 7, which was transformed into an 
activated ester 8 upon coupling with N-hydroxysuccinimide. Selective substitution at the Nε-
position of D-lysine was achieved using the literature procedure for the Nε-protection of 
lysine (Scheme 3.2). The synthesis involved the protection of an α-amino acid group of D-
lysine as a CuII chelate, followed by amidation of the Nε-amine with 8. Isolation of the 
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resulting copper complex by centrifugation followed by decomplexation using EDTA and 
subsequent Fmoc protection furnished the target amino acid 1 in 62% overall yield. 
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N
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O
OH
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Scheme 3.2: Synthesis of the unnatural amino acid Fmoc-HPL(OTBS)-OH (1) 
3.2.2.2 Library synthesis via divergent and dual divergent strategies 
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Scheme 3.3: Incorporation of 1 into LHRH and transformation of the silyloxy ether side 
chain into chloride 
With an amino acid 1 in hand, we embarked on constructing the metal-binding 
analogues of LHRH. A decapeptide 9 was synthesized by incorporating 1 at position 6 of 
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LHRH via standard SPPS synthesis (Scheme 3.3). Transformation of the silyloxy ether side 
chain of 9 to chloride 11 was straightforward and achieved using conditions employed in the 
model substrate. MALDI analysis of the crude chloride, obtained from the cleavage of a 
small amount of the peptide from resin 11, suggested that the alcohol 10 was completely 
consumed under the chlorination conditions. 
To explore the scope of the dual divergent strategy, a mini-library of LHRH 
analogues was synthesized from 11 using two primary amines and three chlorides that 
provided a diverse array of O-donor and N-donor metal-binding units (Scheme 3.4). The 
synthesis began with two parallel first alkylations of the chloride 11, one with 2-picolylamine 
(12a-c) and the other with N-(2-aminoethyl)picolinamide (12d-f). The first alkylation 
products were split into three portions and reacted with 2-(chloromethyl)pyridine, 2-
(chloromethyl)pyrazine or tert-butyl 2-chloroacetate, thus producing six (2 primary amines × 
3 chloride) metal-binding LHRH analogues (Scheme 3.4, Dual divergent strategy). This 
clearly demonstrates that the conditions used for the dual divergent strategy are compatible 
with O-donor carboxylates as well as several N-donors such as pyridine, pyrazine and basic 
amine groups. A limitation to this strategy was also revealed when the first alkylation was 
attempted with N-benzyl ethylenediamine. The first alkylation using this amine, which would 
provide Bn-TPEN derivatives, gave a mixture of products under these conditions presumably 
due to a lack of selectivity between alkylation of primary and secondary amines. Since the 
pentadentate ligands such as Bn-TPEN and N4Py have shown promising results during the 
HeLa cell studies,16 we incorporated these two ligands (13a-b) into the LHRH peptide via the 
divergent strategy (Scheme 3.4, Divergent Strategy). These eight analogues were cleaved 
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from resin and purified by reverse phase HPLC to obtain a small library of metal-binding 
LHRH analogues. 
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Scheme 3.4: Synthesis of mini-library of metal-binding LHRH analogues via divergent and 
dual-divergent strategy 
3.2.2.3 Metal-binding studies of LHRH analogues 
The next goal was to demonstrate that LHRH analogues have similar metal-binding 
properties to their parent ligands. For this study we choose TPA·LHRH analogue 12a and 
PaPy3·LHRH analogue 12d since the metal-binding properties of parent TPA and PaPy3 
ligands were well established. Initial attempts to characterize FeII or FeIII complexes of TPA 
and 12a were unsuccessful, however by the virtue of diamagnetic zinc complexes, the 
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reaction of 12a with ZnCl2 could be monitored by 1H NMR spectroscopic analysis (Figure 
3.3). Addition of 0, 0.5 and 1 equiv of ZnCl2 to the solution of TPA in D2O have shown a 
gradual shift towards the downfield region (e.g. a to a’ in Figure 3.3a). Similar shifts were 
also observed when the experiment was performed with a solution of 12a (a/b to a’/b’ in 
Figure 3.3b). Interestingly, the part of the ligand not participating in the complex formation 
either retains the chemical shift (e.g. c to c’) or experiences minor chemical shifts (e.g. d/e to 
d’/e’) as shown in Figure 3.3b. 
  
(a) (b)
 
Figure 3.3: 1H NMR spectra of TPA (a)  and 12a (b) after addition of 0, 0.5 and 1 equiv (top 
to bottom) of ZnCl2 in D2O 
Ferric complexes of PaPy3 exhibit characteristic UV-vis absorption bands in water as 
well as in methanol media. Affinities of PaPy3 and 12d for FeIII were confirmed by titrating 
the aqueous solutions of PaPy3 and 12d with a solution of FeIII(ClO4)3. Although, the 
titration curve for 12d was found to plateau at higher amounts of FeIII than corresponding 
PaPy3 (Figure 3.4, left), UV-vis spectra (λmax = 500 nm, ε = 1830 M–1cm–1 for PaPy3 and 
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λmax = 505 nm, ε = 1520 M–1cm–1 for 12d) of the newly formed red species were in well 
agreement with the literature data (Figure 3.4, right).190 The difference of 5 nm in their 
absorption maxima was attributed to the electron-withdrawing amide group present on the 
pyridyl ring of 12d.  
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Figure 3.4: Titration of PaPy3 (red) and 12d (blue) with Fe(ClO4)3·xH2O (left) and; UV-vis 
spectra of PaPy3 (red) and 12d (blue) upon addition of Fe(ClO4)3·xH2O (right) 
3.3 Discussion 
3.3.1 Optimization of the dual divergent strategy 
The fundamental goals of this project were to expand the divergent strategy by 
investigating the dual divergent strategy and apply both strategies for the library synthesis of 
biologically important molecules. Towards this goal, a model dipeptide substrate 2 was 
chosen to investigate the dual divergent strategy. Since the divergent strategy was established 
on the same substrate98, the comparison between the divergent and the dual divergent 
strategy would be straightforward. During initial attempts to alkylate the chloride 3 (3 to 4, 
Scheme 3.2) with 2-picolylamine in MeCN, a complex mixture of products was obtained 
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including an apparent product derived from the undesired reaction between 4 with 3 as 
judged by MALDI and 1H NMR spectroscopic analysis. The undesired product was most 
likely derived from the reaction between 3 and 4 of the same resin bead, what is essentially 
an intramolecular reaction. In contrast, an intermolecular reaction between two resin beads 
containing 3 and 4 is less likely since it would require a reaction to occur between two solid 
particles. If this assumption is true, reducing the effective concentration of 3 and 4 on the 
resin beads is expected to lower the rate of intramolecular type of reactivity. The use of lower 
initial loading or improving the swelling of the resin should reduce the concentration of 3 and 
4 on resin. Indeed, performing the reaction in DMF, a superior solvent for SPPS and 
facilitates excellent bead swelling, minimized the side reaction and furnished the desired 
secondary amine 4 at room temperature. Initial attempts to reduce the equivalents of primary 
amine (100 eq.) in the first alkylation were unsuccessful and no further studies were 
conducted. As expected the alkylation of the secondary amine 4 required relatively higher 
temperature but could be achieved with only 10 equiv of 2-picolylchloride. 
3.3.2 Library synthesis and metal-binding studies of LHRH 
analogues 
For the library synthesis of metal-binding LHRH analogues, an unnatural amino acid 
Fmoc-HPL(OTBS)-OH (1) was designed and synthesized (Scheme 3.2). The synthesis began 
with the hydrolysis of a known intermediate 6, in which lower temperatures for the reaction 
as well as work up were critical to obtain a higher yield. When the hydrolysis reaction was 
allowed to warm up to room temperature, cleavage of the silyloxy ether was observed, 
probably due to the high pH of the reaction media. While designing 1, a stable amide bond 
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was chosen to connect the hydroxymethyl pyridyl moiety to D-lysine, since the amide 
linkage is stable in both the divergent and the dual divergent strategies as well as acidolytic 
cleavage conditions. Incorporation of 1 into LHRH analogue and deprotection of the silyloxy 
ether side chain was uneventful (9 to 10). The alcohol was transformed into the 
corresponding chloride 11, which was reacted with 2-picolylamine and then with 2-
picolylchloride to construct TPA onto the LHRH analogue (12a, Scheme 3.4, Dual divergent 
strategy). The chlorination as well as the first and second alkylation reactions were monitored 
by MALDI and 1H NMR analysis. Based on the MALDI data, an additional peak was 
observed during chlorination that was transformed into a new peak upon reaction with 2-
picolylamine. The new peak suggested the addition of two units of 2-picolylamine into 11. 
This newly formed peak remained unchanged during the reaction with 2-picolylchloride. 
This undesired side reaction could be explained if the pyroglutamic acid (Glp) moiety of the 
chloride 11 undergoes N-tosylation under chlorination conditions. Subsequently, a 
nucleophilic addition of 2-picolylamine to the N-tosylated Glp would result in the undesired 
product that should be inert towards the second alkylation. Incorporating Glp containing an 
electron rich protecting group could minimize this side reaction. However, since this side 
reaction was only a minor pathway, as judged by HPLC analysis, we decided to employ the 
present conditions for the library synthesis (Scheme 3.4). Selective alkylation of the chloride 
11 using N-benzyl ethylendiamine was unsuccessful due to the poor selectivity between 
primary and secondary amines of N-benzyl ethylendiamine under the reaction conditions, 
which required us to use the divergent strategy for the incorporation of Bn-TPEN and N4Py 
into LHRH analogue. 
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To establish the metal-binding capabilities of the LHRH analogues, 12a and 12d were 
chosen since the metal-binding properties of the parent ligands were well established. The 
characterization of FeII·12a was limited due to the sensitivity/stability of the complex while 
FeIII·12a was spectroscopically silent when analyzed by UV-vis spectrophotometer. 
Fortunately, 1H NMR analysis of the ZnII·12a complexes has displayed a clear change in the 
chemical shifts when the ligand was bound to zinc. Moreover, the change in the chemical 
shifts is identical between 12a and the parent TPA ligand suggested that TPA and 12a bind to 
zinc in a similar fashion. For the characterization of FeIII·PaPy3 and FeIII·12d complexes, 
their characteristic absorption maxima were compared. Although the complex formation 
could not be monitored in buffered solution due to the absence of characteristic UV-vis 
absorption in MOPS buffer (pH =6.9), the use of distilled water in identical reaction 
conditions furnished characteristic red species for each complex that could be monitored by 
UV-vis spectroscopy. 
3.4 Conclusion 
The dual divergent strategy has been developed by extension of the divergent 
strategy. The reaction conditions were optimized using a model substrate and the scope as 
well as functional group compatibility of the method were established by synthesizing a 
small library of metal-binding LHRH analogues. By virtue of the dual divergent strategy, the 
library synthesis of peptide-ligand conjugates could be rapidly accessed, since the tedious 
solution phase synthesis and purification of secondary amines could be avoided. Moreover, 
various N-donor and O-donor ligand structures could be rapidly synthesized in a stepwise 
fashion. This is particularly beneficial to study the effect of electronics and overall charge of 
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the complex on the biological properties of the resulting conjugates. In addition, the dual 
divergent strategy would allow the use of split-pool method for the library synthesis that 
exponentially increases the size of the library. During this study a limitation of the dual 
divergent strategy was also revealed when primary amines could not be selectively alkylated 
in the presence of secondary amine. Due to this limitation, Bn-TPEN could not be 
incorporated into LHRH using the dual divergent strategy. Hence, relatively more complex 
Bn-TPEN and N4Py ligands were incorporated into LHRH via the traditional divergent 
strategy. This indicates that, although the dual divergent strategy is more ideal, the divergent 
strategy is also important in the synthesis of certain higher dentate ligands. 
3.5 Experimental Section 
3.5.1 General consideration 
See section 2.5.1 for the general considerations. Compounds bis(pyridin-2-
ylmethyl)amine,191 2-(chloromethyl)pyrazine,192 N-(2-aminoethyl)picolinamide,190 298and 598 
used in this report were synthesized according to previously reported literature procedures. 
3.5.2 Experimental procedures and tabulated characterization data 
for new compounds 
6-(((tert-butyldimethylsilyl)oxy)methyl)nicotinic acid (7). 
N
OTBS
O
OH
Chemical Formula: C13H21NO3Si
Molecular Weight: 267.40
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A solution of ester 6 (3.00 g, 10.7 mmol) in THF (60 mL) was cooled to 0 °C. A 1M 
aqueous solution of LiOH (64.0 mL, 64.0 mmol) was added dropwise over the period of 50 
min while maintaining the temperature below 5 °C. The reaction mixture was maintained at 
0-5 °C for 45 min. After consumption of the starting material, as judged by TLC analysis, the 
reaction mixture was acidified to pH ~6.5 by dropwise addition of 5% citric acid (aq) over a 
period of 25 min during which the temperature of the reaction mixture was maintained below 
5 °C. The aqueous layer was extracted using EtOAc (3 × 50 mL). The combined organic 
layer was dried over anhydrous Na2SO4 and evaporated under vacuum to obtain 7 as a white 
solid (2.15 g, 75%). A portion of 7 was purified by silica gel chromatography (50% to 100% 
EtOAc:hexanes) for analysis. 1H NMR (400 MHz, CDCl3) δ 11.8 (brs, 1H), 9.25 (d, J = 1.6 
Hz, 1H), 8.44 (dd, J = 8.1, 2.4 Hz, 1H), 7.69 (d, J = 8.1 Hz, 1H), 4.96 (s, 2H), 0.95 (s, 9H), 
0.13 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 168.9, 165.8, 149.8, 139.1, 124.9, 120.0, 65.3, 
25.8, 18.3, –5.4; IR (thin film) 2955, 2928, 2891, 2857, 1720, 1608, 1389, 1295, 1260, 1127, 
1104, 1035, 850, 838, 776, 758, 641 cm–1; HRMS (ESMS) calcd for C13H22NO3Si (M+H+) 
268.1369, found: 268.1376. 
2,5-dioxopyrrolidin-1-yl 6-(((tert-butyldimethylsilyl)oxy)methyl)nicotinate (8). 
N
OTBS
O
O
Chemical Formula: C17H24N2O5Si
Molecular Weight: 364.47
N
O
O
 
A mixture of crude 7 (2.00 g, 7.48 mmol), N-Hydroxysuccinimide (1.03 g, 8.97 
mmol), HOBt (1.37 g, 8.97 mmol) and Et3N (1.56 mL, 11.2 mmol) in CH2Cl2 (60 mL) was 
maintained at rt for 5 min under nitrogen atmosphere. EDAC (1.72 g, 8.97 mmol) was added 
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and the mixture was maintained under nitrogen atmosphere for 3 h. After consumption of the 
starting material, as judged by TLC analysis, the reaction mixture was mixed with CH2Cl2 
(40 mL) and extracted with sat. NH4Cl solution (3 × 20 mL), 5% NaHCO3 solution (3 × 20 
mL) and brine solution (1 × 20 mL). The combined organic layer was dried over anhydrous 
Na2SO4 and evaporated under vacuum to obtain 8 as a white solid (2.45 g, 90%). A portion 
of 8 was purified by silica gel chromatography (20% to 40% EtOAc:hexanes) for 
characterization. 1H NMR (400 MHz, CDCl3) δ 9.17 (d, J = 1.6 Hz, 1H), 8.37 (dd, J = 8.1, 
2.4 Hz, 1H), 7.67 (d, J = 8.1 Hz, 1H), 4.88 (s, 2H), 2.89 (s, 4H), 0.93 (s, 9H), 0.10 (s, 6H); 
13C NMR (100 MHz, CDCl3) δ 169.0, 168.4, 160.9, 150.5, 138.6, 119.8, 119.7, 65.9, 25.8, 
25.6, 18.3, –5.4; IR (thin film) 3518, 2952, 2930, 2894, 2857, 1773, 1744, 1647, 1598, 1568, 
1484, 1471, 1463, 1445, 1426, 1394, 1386, 1362, 1309, 1285, 1259, 1210, 1137, 1105, 1072, 
1048, 1040, 1001, 945, 938, 909, 844, 814, 778, 744, 670, 650, 635, 601 cm–1; HRMS 
(ESMS) calcd for C17H25N2O5Si (M+H+) 365.1533, found: 365.1533. 
(R)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-6-(6-(((tert-butyldimethylsilyl) 
oxy)methyl)nicotinamido)hexanoic acid (1). 
FmocHN
OH
O
HN
Chemical Formula: C34H43N3O6Si
Molecular Weight: 617.81
O
N
OTBS
 
A mixture of H-D-Lys-OH·HCl (100 mg, 0.55 mmol), CuSO4·5H2O (68.0 mg, 0.27 mmol), 
NaHCO3 (92.0 mg, 1.10 mmol) and H2O (1.5 mL) was refluxed for 2 h. The mixture was 
cooled to 0 °C and a solution of 8 in DMF (1 mL) was added dropwise over the period of 1 h. 
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After addition, the reaction mixture was allowed to warm to rt and stirred vigorously 
overnight during which a blue solid was formed. The reaction mixture was combined with 
H2O (10 mL) and the resulting blue solid was isolated by centrifugation. The solid was 
washed with H2O (2 × 10 mL), acetone (1 × 5 mL) and dried under high vacuum for 3-4 h 
(230 mg).  
This solid was stirred with an aqueous solution (10 mL H2O) of EDTA (1.20 g, 2.74 
mmol) containing NaHCO3 (92.0 mg, 1.10 mmol) for 2 h during which the colorless solution 
turned blue and the blue solid changed to white. The pH of this reaction mixture was adjusted 
to ~7.7 by dropwise addition of 5% NaHCO3. The reaction mixture was cooled to 0-5 °C and 
a solution of FmocOSu (183 mg, 0.55 mmol) in 1,4-dioxane (2 mL) was added dropwise 
over the period of 1 h. The reaction mixture was allowed to warm to rt and maintained 
overnight. The reaction mixture was combined with H2O (30 mL) and acidified to pH ~6 by 
dropwise addition of 15% citric acid. The aqueous layer was extracted with Et2O (7 × 10 
mL). The combined organic layer was dried over anhydrous Na2SO4 and evaporated under 
vacuum to obtain the crude product as a white solid. The crude product was purified by silica 
gel chromatography (0% to 15% MeOH:CH2Cl2) to afford 1 (210 mg, 62%). 1H NMR (400 
MHz, CD3OD) δ 8.86 (s, 1H), 8.19 (dd, J = 8.1, 1.6 Hz, 1H), 7.72 (d, J = 7.3 Hz, 2H), 7.59-
7.54 (m, 3H), 7.32 (t, J = 7.3 Hz, 2H), 7.23 (t, J = 7.3 Hz, 2H), 4.76 (s, 2H), 4.30-4.21 (m, 
2H), 4.13-4.10 (m, 2H), 3.40-3.30 (m, 2H), 1.88-1.46 (m, 6H), 0.93 (s, 9H), 0.09 (s, 6H); 13C 
NMR (100 MHz, CD3OD) 167.7, 165.1, 158.6, 148.5, 145.3, 145.1, 142.5, 137.5, 130.3, 
128.7, 128.1, 126.2, 121.2, 120.9, 67.8, 66.5, 56.0, 48.4, 40.8, 32.8, 29.9, 26.3, 24.3, 19.2, –
5.3; IR (thin film) 3328 (br), 3067, 2953, 2929, 2857, 1704, 1644, 1600, 1547, 1462, 1450, 
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1379, 1320, 1258, 1105, 1051 1007, 938, 839, 778, 758, 739 cm–1; [α] = –2.7° (c = 1.0, 
CHCl3); HRMS (ESMS) calcd for C34H44N3O6Si (M+H+) 618.2999, found: 618.2998. 
General Procedure for Peptide Syntheses. 
All coupling reactions were performed on a 0.15-0.4 mmol scale by standard SPPS 
method using Fmoc amino acid with HBTU-activated ester chemistry in a Peptide Synthesis 
Vessel (manual synthesis). Typical protocols for coupling steps involved 1-4 h coupling 
cycles with 2-4 eq of Fmoc amino acid. However, for the unnatural amino acids 1, only 2 eq 
of 1 were used. During coupling reactions Fmoc amino acids were pre-activated by stirring 
their solution in DMF with HBTU and i-Pr2EtN for 1-2 min. The Fmoc deprotection was 
performed using 20% piperidine in DMF with two cycles 20-30 min each. After each 
reaction step, the resin was washed with DMF (2 × 2 mL), i-PrOH (2 × 2 mL) and CH2Cl2 (2 
× 2 mL). Kaiser test was used to monitor the coupling reactions and deprotection of the Fmoc 
group. Standard SPPS steps and equivalence of the reagents are summarized in Table 3.1. 
Note: No capping was performed after any coupling step. 
Table 3.1: Conditions for SPPS and divergent/dual divergent strategy 
Operation Reagent Vol Time/temp Scale 
Fmoc 
deprotection 20% Piperidine in DMF 5 mL 
2 × 20 min 
(each)/rt 0.3 mmol 
Drain and wash DMF, i-PrOH, CH2Cl2 
2-4 mL 
(each) 
2 × 2 min 
(each)/rt  
Coupling of 
Fmoc-AA-OH 
Fmoc-AA-OH (0.6 mmol), 
HBTU (0.6 mmol), i-Pr2EtN 
(0.6 mmol) 
5 mL, 
DMF 1 × 2-3 h/rt 0.3 mmol 
Coupling of 
Fmoc-D-
HPL(OTBS)-OH 
Fmoc-AA-OH (0.6 mmol), 
HBTU (0.6 mmol), i-Pr2EtN 
(0.6 mmol) 
5 mL, 
DMF 1 × 4-5 h/rt 0.3 mmol 
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TBS cleavage TBAF (1M, 1.2 mmol), AcOH (0.3 mmol) 
5 mL, 
THF 2 × 1 h/rt 0.3 mmol 
Chlorination 
LiCl (3.75 mmol), i-Pr2EtN 
(1.13 mmol), TsCl (0.75 
mmol) 
2.7 mL, 
MeCN 1 × ~24 h/rt 75 µmol 
1st Alkylation R1NH2 (6.0 mmol) 
1.6 mL, 
DMF 1 × 2 h/rt 60 µmol 
2nd Alkylation R
2Cl (0.2 mmol), i-Pr2EtN 
(0.45 mmol) 
1.1 mL, 
DMF 1 × 18 h/55 °C 20 µmol 
 
Cleavage of the TBS group: A mixture of the peptide (0.3 mmol scale), TBAF (1M in THF, 
1.2 mmol), acetic acid (0.3 mmol) and THF was shaken in a peptide synthesis vessel for 1 h 
at rt. Two cycles were performed to confirm the complete cleavage of TBS group. The resin 
was successively washed with DMF (2 × 2 mL), i-PrOH (2 × 2 mL) and CH2Cl2 (2 × 2 mL) 
dried under vacuum and stored at –30 °C. 
Chlorination: The mixture of peptide (75 µmol), lithium chloride (3.75 mmol), i-Pr2EtN 
(1.13 mmol), tosyl chloride (0.75 mmol) and MeCN (1.7 mL) was shaken in peptide 
syntheses vessel for 20-24 h at rt. The resin was washed successively with DMF (2 × 1 mL), 
i-PrOH (2 × 1 mL) and CH2Cl2 (2 × 1 mL) dried under vacuum and used for alkylation 
reactions. 
Alkylation: In a typical procedure for alkylation, a mixture of chloride (60 µmol), primary 
amine (6 mmol) and DMF (1.6 mL) was shaken in peptide syntheses vessel for 2 h at rt. The 
resin was washed successively with DMF (2 × 1 mL), i-PrOH (2 × 1 mL) and CH2Cl2 (2 × 1 
mL) dried under vacuum, split into three portions (20 µmol each) and transferred into vials. 
This resin was mixed with i-Pr2EtN (0.45 mmol), the corresponding chloride (0.2 mmol) and 
DMF (1.1 mL) and stirred slowly (< 200 rpm) at 55 °C for 18-20 h. The resin was 
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successively washed with DMF (2 × 1 mL), i-PrOH (2 × 1 mL) and CH2Cl2 (2 × 1 mL) and 
dried under vacuum. 
Cleavage of the peptides from resin: The peptide-ligand conjugate were cleaved from the 
resin by stirring the resin (25-30 mg) with a 27:1:2 mixture of TFA:anisole:thioanisole (2mL) 
for 2 h at rt. The resin was removed by filtration and the filtrate was mixed with cold Et2O 
(10 mL). The resulting precipitate was isolated by centrifugation. The residue was washed 
with cold ether (2 × 4 mL) dried under vacuum and used for purification/analysis. 
MALDI analysis: MALDI-TOF data were acquired on a MALDI-TOF mass spectrometer 
using the reflectron mode. Samples for MALDI analysis of peptide-ligand conjugates were 
prepared according to the following procedure. 5-10 mg of peptide-ligand conjugate was 
dissolved in 2 mL of MeOH:H2O (1:1). 2 µL of this sample solution was diluted in 40 µL 
MeOH. 2 µL of this diluted sample was mixed with 4 µL matrix solution (α-Cyano-4-
hydroxy cinnamic acid in 7:3 MeCN:0.1% aq TFA) and spotted on MALDI plate for 
analysis. The nitrogen containing ligands used herein have strong affinities for Zn2+ and 
hence showed M+Zn species in addition to M+Na adducts due to trace amounts of Zn2+ 
present in the buffer solution. Addition of 4 µL of sat EDTA (aq) to the sample solutions 
before spotting on MALDI plate reduced the abundance of M+Zn peak. 
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Peptide-ligand conjugate 12a. 
H
N
N
H
H
N
N
H
H
N
N
H
N
O
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O
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O
N
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O O
N
H
NH
H2N
OH
OH
NH
NHN
H
N
O
NH2
NH2
NHO
N
N
N N
Chemical Formula: C78H101N22O14
Exact Mass: 1569.79
Molecular Weight: 1570.77
 
The crude product was purified by preparative HPLC. HPLC Conditions: column: XDB-C18 
(ZORBAX) 21.2 × 150 mm, 5 micron; Mobile phase: 0.1% aq TFA and MeOH; Flow rate = 
20 mL/min; Gradient elution: 0-5 min 5-40% MeOH in aq TFA, 5-14 min 40-65% MeOH in 
aq TFA, 14-15 min 65-100% MeOH in aq TFA, 15-20 min 100% MeOH in aq TFA, 20-21 
min 5% MeOH in aq TFA; RT = 8.5 min. Desired fractions were evaporated under high 
vacuum (at rt) and analyzed by HPLC to confirm the purity (Mobile phase: 0.1% aq TFA and 
MeOH; Flow rate = 20 mL/min; Gradient elution: 0-5 min 10-40% MeOH in aq TFA, 5-16 
min 40-60% MeOH in aq TFA, 16-17 min 60-100% MeOH in aq TFA; RT = 8.9 min; purity 
= 96%). MALDI-TOF MS (ESMS) calc’d for C78H101N22O14 (M+) 1569.79, found: 1569.40.  
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Peptide-ligand conjugate 12b. 
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Chemical Formula: C77H100N23O14
Exact Mass: 1570.78
Molecular Weight: 1571.76
 
The crude product was purified by preparative HPLC. HPLC Conditions: column: XDB-C18 
(ZORBAX) 21.2 × 150 mm, 5 micron; Mobile phase: 0.1% aq TFA and MeOH; Flow rate = 
20 mL/min; Gradient elution: 0-5 min 5-40% MeOH in aq TFA, 5-14 min 40-65% MeOH in 
aq TFA, 14-15 min 65-100% MeOH in aq TFA, 15-20 min 100% MeOH in aq TFA, 20-21 
min 5% MeOH in aq TFA; RT = 8.9 min. Desired fractions were evaporated under high 
vacuum (at rt) and analyzed by HPLC to confirm the purity (Mobile phase: 0.1% aq TFA and 
MeOH; Flow rate = 20 mL/min; Gradient elution: 0-5 min 10-40% MeOH in aq TFA, 5-16 
min 40-60% MeOH in aq TFA, 16-17 min 60-100% MeOH in aq TFA; RT = 9.5 min; purity 
= 95%). MALDI-TOF MS (ESMS) calc’d for C77H100N23O14 (M+) 1570.78, found: 1570.44. 
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Peptide-ligand conjugate 12c. 
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Chemical Formula: C74H98N21O16
Exact Mass: 1536.75
Molecular Weight: 1537.70
 
The crude product was purified by preparative HPLC. HPLC Conditions: column: XDB-C18 
(ZORBAX) 21.2 × 150 mm, 5 micron; Mobile phase: 0.1% aq TFA and MeOH; Flow rate = 
20 mL/min; Gradient elution: 0-5 min 5-40% MeOH in aq TFA, 5-14 min 40-65% MeOH in 
aq TFA, 14-15 min 65-100% MeOH in aq TFA, 15-20 min 100% MeOH in aq TFA, 20-21 
min 5% MeOH in aq TFA; RT = 8.5 min. Desired fractions were evaporated under high 
vacuum (at rt) and analyzed by HPLC to confirm the purity (Mobile phase: 0.1% aq TFA and 
MeOH; Flow rate = 20 mL/min; Gradient elution: 0-5 min 10-40% MeOH in aq TFA, 5-16 
min 40-60% MeOH in aq TFA, 16-17 min 60-100% MeOH in aq TFA; RT = 8.8 min; purity 
= 99%). MALDI-TOF MS (ESMS) calc’d for C74H98N21O16 (M+) 1536.75, found: 1536.63. 
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Peptide-ligand conjugate 12d. 
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Chemical Formula: C80H104N23O15
Exact Mass: 1626.81
Molecular Weight: 1627.83
 
The crude product was purified by preparative HPLC. HPLC Conditions: column: XDB-C18 
(ZORBAX) 21.2 × 150 mm, 5 micron; Mobile phase: 0.1% aq TFA and MeOH; Flow rate = 
20 mL/min; Gradient elution: 0-5 min 5-40% MeOH in aq TFA, 5-16 min 40-60% MeOH in 
aq TFA, 16-17 min 60-100% MeOH in aq TFA, 17-22 min 100% MeOH in aq TFA, 22-23 
min 5% MeOH in aq TFA; RT = 9.9 min. Desired fractions were evaporated under high 
vacuum (at rt) and analyzed by HPLC to confirm the purity (Mobile phase: 0.1% aq TFA and 
MeOH; Flow rate = 20 mL/min; Gradient elution: 0-5 min 10-40% MeOH in aq TFA, 5-16 
min 40-60% MeOH in aq TFA, 16-17 min 60-100% MeOH in aq TFA; RT = 10.5 min; 
purity = 95%). MALDI-TOF MS (ESMS) calc’d for C80H104N23O15 (M+) 1626.81, found: 
1626.72. 
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Peptide-ligand conjugate 12e. 
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Chemical Formula: C79H103N24O15
Exact Mass: 1627.80
Molecular Weight: 1628.81
 
The crude product was purified by preparative HPLC. HPLC Conditions: column: XDB-C18 
(ZORBAX) 21.2 × 150 mm, 5 micron; Mobile phase: 0.1% aq TFA and MeOH; Flow rate = 
20 mL/min; Gradient elution: 0-5 min 5-40% MeOH in aq TFA, 5-16 min 40-60% MeOH in 
aq TFA, 16-17 min 60-100% MeOH in aq TFA, 17-22 min 100% MeOH in aq TFA, 22-23 
min 5% MeOH in aq TFA; RT = 10.1 min. Desired fractions were evaporated under high 
vacuum (at rt) and analyzed by HPLC to confirm the purity (Mobile phase: 0.1% aq TFA and 
MeOH; Flow rate = 20 mL/min; Gradient elution: 0-5 min 10-40% MeOH in aq TFA, 5-16 
min 40-60% MeOH in aq TFA, 16-17 min 60-100% MeOH in aq TFA; RT = 10.4 min; 
purity = 98%). MALDI-TOF MS (ESMS) calc’d for C79H103N24O15 (M+) 1627.80, found: 
1627.56. 
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Peptide-ligand conjugate 12f. 
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Chemical Formula: C76H101N22O17
Exact Mass: 1593.77
Molecular Weight: 1594.75
 
The crude product was purified by preparative HPLC. HPLC Conditions: column: XDB-C18 
(ZORBAX) 21.2 × 150 mm, 5 micron; Mobile phase: 0.1% aq TFA and MeOH; Flow rate = 
20 mL/min; Gradient elution: 0-5 min 5-40% MeOH in aq TFA, 5-16 min 40-60% MeOH in 
aq TFA, 16-17 min 60-100% MeOH in aq TFA, 17-22 min 100% MeOH in aq TFA, 22-23 
min 5% MeOH in aq TFA; RT = 9.7 min. Desired fractions were evaporated under high 
vacuum (at rt) and analyzed by HPLC to confirm the purity (Mobile phase: 0.1% aq TFA and 
MeOH; Flow rate = 20 mL/min; Gradient elution: 0-5 min 10-40% MeOH in aq TFA, 5-16 
min 40-60% MeOH in aq TFA, 16-17 min 60-100% MeOH in aq TFA; RT = 10.0 min; 
purity = 95%). MALDI-TOF MS (ESMS) calc’d for C76H101N22O17 (M+) 1593.77, found: 
1593.55. 
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Peptide-ligand conjugate 13a. 
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Chemical Formula: C87H112N23O14
Exact Mass: 1702.88
Molecular Weight: 1703.97
 
The crude product was purified by preparative HPLC. HPLC Conditions: column: XDB-C18 
(ZORBAX) 21.2 × 150 mm, 5 micron; Mobile phase: 0.1% aq TFA and MeOH; Flow rate = 
20 mL/min; Gradient elution: 0-5 min 10-40% MeOH in aq TFA, 5-16 min 40-60% MeOH 
in aq TFA, 16-17 min 60-100% MeOH in aq TFA, 17-22 min 100% MeOH in aq TFA, 22-23 
min 10% MeOH in aq TFA; RT = 11.4 min. Desired fractions were evaporated under high 
vacuum (at rt) and analyzed by HPLC to confirm the purity (Mobile phase: 0.1% aq TFA and 
MeOH; Flow rate = 20 mL/min; Gradient elution: 0-5 min 10-40% MeOH in aq TFA, 5-16 
min 40-60% MeOH in aq TFA, 16-17 min 60-100% MeOH in aq TFA; RT = 11.6 min; 
purity = 95%). MALDI-TOF MS (ESMS) calc’d for C87H112N23O14 (M+) 1702.88, found: 
1702.54. 
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Peptide-ligand conjugate 13b. 
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Chemical Formula: C83H104N23O14
Exact Mass: 1646.81
Molecular Weight: 1647.86
 
The crude product was purified by preparative HPLC. HPLC Conditions: column: XDB-C18 
(ZORBAX) 21.2 × 150 mm, 5 micron; Mobile phase: 0.1% aq TFA and MeOH; Flow rate = 
20 mL/min; Gradient elution: 0-5 min 10-40% MeOH in aq TFA, 5-16 min 40-60% MeOH 
in aq TFA, 16-17 min 60-100% MeOH in aq TFA, 17-22 min 100% MeOH in aq TFA, 22-23 
min 10% MeOH in aq TFA, RT = 9.6 min. Desired fractions were evaporated under high 
vacuum (at rt) and analyzed by HPLC to confirm the purity (Mobile phase: 0.1% aq TFA and 
MeOH; Flow rate = 20 mL/min; Gradient elution: 0-5 min 10-40% MeOH in aq TFA, 5-16 
min 40-60% MeOH in aq TFA, 16-17 min 60-100% MeOH in aq TFA; RT = 9.9 min; purity 
= 96%). MALDI-TOF MS (ESMS) calc’d for C83H104N23O14 (M+) 1646.81, found: 1646.68. 
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Chapter 4: Synthesis, Characterization and Mechanistic 
Studies of Ferryl-peptide Conjugates 
4.1 Introduction 
Mononuclear non-heme ferryl complexes have been proposed as key intermediates in 
several enzymes that carry out oxidation reactions in nature.193 Inspired by the efficiency of 
these enzymes, biomimetic ferryl complexes have been extensively explored over the last 
decade as models for such enzymes.14,15 These synthetic ferryl complexes oxidize organic 
substrates such as phosphines, sulfides, alkenes, aromatics as well as alkanes and alcohols.14 
Our group has investigated the reactivity of ferryl complexes towards the oxidation of amino 
acid substrates,160 peptides161 and proteins.17 By virtue of their oxidation power, mechanistic 
studies of the synthetic ferryl complexes that oxidize organic substrate in an intermolecular 
fashion are also extensively investigated.14 In contrast, intramolecular oxidation of organic 
molecules tethered to ferryl complexes are rare.164 This information is particularly important 
because studies pertaining to the ferryl enzymes suggest that the protein radicals, generated 
during the reactivity of the ferryls, transfer radicals from tryptophan to a remote tyrosine 
residue via intramolecular long-range electron-transfer (LRET) process.194-197 In addition, 
LRET process was also depended on the distance between the radical and the electron-
donating group.197 Moreover, although ferryls are proposed as nature’s oxidants, information 
about which functionalities could be tolerated around them is absent. The fundamental 
knowledge about how ferryls reacts with target substrates without destroying the parent 
protein and how the distance between ferryls and reactive groups affects the stability of 
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ferryls is very important to understand the chemistry of ferryl containing enzymes. This 
knowledge can also be utilized to construct stable catalysts as well as artificial oxygenases. 
Since our group aspires to explore the applications of non-heme ligand-peptide conjugates, 
which could generate ferryl species in bioorganic chemistry, we decided to explore the 
chemistry of ferryl-peptide conjugates. 
In this chapter, synthesis, characterization and reactivity of the first ferryl-peptide 
conjugate are presented. In the first section, synthesis and characterization of ferrous- and 
ferryl-peptide conjugates derived from model N4Py-dipeptide conjugate 1 are described. In 
the second section, the reactivity of ferryl-peptide conjugates and a mechanistic investigation 
are presented. 
4.2 Results 
4.2.1 Ferryl-peptide conjugate 
4.2.1.1 Synthesis and characterization of FeII and FeIV complexes 
AcHN
N
N
N
Fe
N
N
H
N
O
O
O
N
2+
AcHN
N
N
N
Fe NN
H
N
O
O
O
O
2+
KHSO5 (aq)
AcHN
H
N
O
N
O
O
N
N
N
N
FeII(ClO4)2
H2O:MeCN 
(1:1)
1 2 3  
Scheme 4.1: Synthesis of ferrous- and ferryl-peptide conjugates of 1 
Strategies described in the previous chapters produced various non-heme ligand-
peptide conjugates that are capable of generating ferryl complexes. Among the pool of these 
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peptide-ligand conjugates, a N4Py-dipeptide analogue 1 was chosen for this study due to the 
capability of the N4Py ligand to generate stable ferryl complexes in aqueous/aerobic 
conditions. First, the ferrous-peptide conjugate 2 was synthesized in situ by treating the 
solution of 1 in 1:1 H2O:MeCN with an aqueous solution of FeII(ClO4)2 to obtain an orange 
solution (Scheme 4.1). The reaction of this orange species with an aqueous solution of 
KHSO5 generated the corresponding ferryl-peptide conjugate 3 as a pale-green species. 
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Figure 4.1: (A) Comparison between the UV-vis spectra of ferrous-peptide conjugate 2 (red) 
with the parent complex [FeII(N4Py)(MeCN)]2+ (blue); (B) Comparison between the UV-vis 
spectra of ferryl-peptide conjugate 3 (red) with the parent complex [FeIV(O)(N4Py)]2+ (blue) 
Ferrous- and ferryl-peptide conjugates were characterized by comparing their UV-vis 
spectra with the UV-vis spectra of the corresponding parent N4Py complexes. For example, 
the spectral data for the ferrous-peptide conjugate 2 (ε380 = 4200 M-1cm-1 and ε455 = 3600 M-
1cm-1) was in agreement with the data of the parent complex [FeII(N4Py)(MeCN)]2+ (ε380 = 
4200 M-1cm-1 and ε455 = 3700 M-1cm-1) when prepared under identical reaction conditions 
(Figure 4.1A). Similarly, the absorption maximum (λmax = 680 nm) for the ferryl-peptide 
conjugate 3 was identical to the corresponding [FeIV(O)(N4Py)]2+ complex (Figure 4.1B). 
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The absorption at 680 nm decreased prior to complete generation of ferryl-peptide conjugate 
3, which did not allow us to calculate the extinction coefficient from the absorption 
maximum. Instead, a plot of ln(Abs) vs. time (Figure 4.4B) was extrapolated at t = 0 to 
obtain the extinction coefficient (ε680 = 200 M-1cm-1). 
To confirm the formation of ferrous- and ferryl-peptide conjugates, electrospray data 
were acquired. As shown in Figure 4.2A, N4Py-dipeptide conjugate 1 upon reaction with 
Fe(ClO4)2·xH2O furnished a clear molecular ion peak in low resolution ESMS that 
corresponds to a doubly charged [FeII(N4Py)(MeCN)]2+ species. Moreover, when the 
reaction of ferrous-peptide conjugate 2 with KHSO5 was monitored by high-resolution 
ESMS, a dominant molecular ion peak at m/z = 357.6093 was observed (Figure 4.2B). The 
experimentally obtained isotope pattern was in well agreement with the calculated isotope 
pattern and corresponds to the formula [FeIV(O)(N4Py)]2+. Interestingly, this molecular ion 
was not observed in the samples injected after 10 min of the reaction. 
  
[FeII(1)(MeCN)]2+ (2) [FeIV(O)(1)]2+ (3)(A) (B)
 
Figure 4.2: (A) LRMS for [FeII(1)(MeCN)]2+; (B) HRMS of [FeIV(O)(1)]2+ showing the 
calculated (top) and experimental isotope pattern 
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N4Py [FeII(N4Py)(MeCN)]2+
  
N4Py dipeptide conjugates 1 [FeII(1)(MeCN)]2+ (2)(A) (B)
(C) (D)
 
Figure 4.3: (A) 1H NMR of 1 in 1:1 CD3CN:D2O; (B) 1H NMR of 1 + Fe(ClO4)2·xH2O in 
1:1 CD3CN:D2O; (C) 1H NMR of N4Py in 1:1 CD3CN:D2O; (D) 1H NMR of N4Py + 
Fe(ClO4)2·xH2O in 1:1 CD3CN:D2O 
In addition, the reaction of 1 with Fe(ClO4)2·xH2O was also monitored by 1H NMR 
spectroscopy, which showed a clear change in the chemical shifts of 1 upon binding with iron 
(Figure 4.3, A vs. B). It is important to note that the methine proton of N4Py in 1 experienced 
a shift of ~1 ppm upon coordination to iron (proton b), which is similar to that observed in 
[FeII(N4Py)(MeCN)]2+ complex when prepared under identical reaction conditions (Figure 
4.3, C vs. D). In contrast, benzylic protons that do not participate in the coordination process 
remained unchanged (proton a). Furthermore, all the NMR resonances are within 0 to 10 ppm 
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suggesting that the ferrous-peptide conjugate is a low-spin complex. Attempts to characterize 
the ferryl-peptide conjugate 3 by 1H NMR analysis were unsuccessful due to the rapid 
decomposition of 3 at the higher concentration that was needed for NMR studies. 
Overall, the findings suggested that the ferryl-peptide conjugate 3 is more reactive 
than the parent N4Py ferryl complex, which eventually caused its rapid decomposition as 
observed by UV-vis, ESMS and 1H NMR analysis. In fact the ferryl-peptide conjugate 3 was 
stable for ~1 h compared to the parent [FeIV(O)(N4Py)]2+ that is stable for ~3 days. Since the 
Kodanko group is planning to attach ferryls to protein-binding motifs for selective protein 
targeting in the future, the knowledge of its self-decomposition would be valuable for the 
synthesis of stable catalysts. Hence, we directed our studies towards understanding the rapid 
decomposition of the ferryl-peptide conjugate 3. In the following section of this chapter, the 
reactivity of the ferryl-peptide conjugate 3 and a detailed mechanistic investigation to 
understand its decomposition are presented. 
4.2.1.2 Reactivity and mechanistic studies of the ferryl-peptide 
conjugate 
The reactivity of ferryl complexes towards the benzyl group and the glycine residue 
was proposed as the cause of the inherent decomposition of the ferryl-peptide conjugate 3. 
To probe the reactivity of 3, five structurally and electronically different derivatives of 1 
were synthesized. Derivatives 4a-d were prepared via transesterification by heating 1 with 
excess alcohol and a catalytic amount of K2CO3 (Scheme 4.2a), while derivative 4e was 
synthesized from the model dipeptide substrate 5 in five steps (Scheme 4.2b). 
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Scheme 4.2: Synthesis of structurally and electronically diverse ester derivatives of 1 
The derivatives of 3 were prepared from each of the ester derivative 4a-e using the 
procedures for the formation of 3. The reactivity of each ferryl-peptide conjugates was 
determined as shown in Figure 4.4. In a typical procedure, a solution of [FeII(L)(MeCN)]2+ 
(1.67 mM) was treated with 1 equiv of KHSO5 and the change in the absorbance was 
monitored at various time intervals. After initial 10 min the absorbance at 680 nm decreased 
and the absorbance at 450 nm increased indicating the decomposition of ferryl-peptide 
conjugate and the regeneration of ferrous-peptide conjugate, respectively (Figure 4.4A). A 
graph of ln(Abs) vs. time at 680 nm furnished a linear plot after an initial induction period of 
~10 min (Figure 4.4B). Extinction coefficients of the ferryl-peptide conjugates were 
calculated by extrapolation of the linear plot to t = 0 (ε680 = 200 M-1cm-1) and were in good 
agreement with that of the [FeIV(O)(N4Py)]2+ (ε680 = 160 M-1cm-1) when prepared under 
identical conditions. In addition, the slope of the plot also furnished rates of the 
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decomposition for ferryl-peptide conjugates that were used to compare their reactivity (Table 
4.1). 
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Figure 4.4: (A) Example of the UV-vis spectra for the decomposition of ferryl-peptide 
conjugates 3. The decrease in λmax = 680 nm and an increase in λmax = 450 nm indicates the 
decomposition of the ferryl and regeneration of the ferrous complex, respectively; (B) 
Example of ln(Abs) vs. time plot (red) and the linear fit (blue) for the ferryl-peptide 
conjugate 3 at λmax = 680 nm 
Table 4.1: Rates of decomposition obtained from the slopes of the ln(Abs) vs. time plots for 
various ferryl-peptide conjugates 
Entry Ferryl-peptide conjugate rate (s–1)a,b krel 
1 [FeIV(O)(1)]2+ (3) 7.3(6) × 10–4 1.0 
2 [FeIV(O)(4a)]2+ (Me-ester) 6.3(3) × 10–5 0.086 
3 [FeIV(O)(4b)]2+ (Bn-d7-ester) 1.6(2) × 10–4 0.22 
4 [FeIV(O)(4c)]2+ (pOMe-Bn-ester) 1.6(3) × 10–3 2.2 
5 [FeIV(O)(4d)]2+ (pMe-Bn-ester) 1.2(2) × 10–3 1.6 
6 [FeIV(O)(4e)]2+ (pCl-Bn-ester) 3.6(2) × 10–4 0.49 
aRates were determined from the slope of ln(Abs) vs. time plots. bNumber reported is the average of at least 
three runs; error as standard deviation is given in parentheses. 
 
To understand which functional groups within the ferryl-peptide conjugate 3 were 
responsible for its decomposition, the rate of decomposition of [FeIV(O)(4a)]2+ (Me-ester) 
was compared with that of the corresponding [FeIV(O)(1)]2+ (3). The ferryl generated from 
the methyl ester derivative was 12 times more stable than the corresponding benzyl ester  
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Figure 4.5: (A): Comparison between the rate of decomposition of Me-ester (blue) and Bn-
ester (red); (B): Comparison between the rate of decomposition of Bn- d7-ester (blue) and 
Bn-ester (red); (C): Comparison between the rate of decomposition of various ferryl-peptide 
conjugates derived from the para-substituted Bn-esters; (D): Hammett plot derived from the 
rate of decomposition of various ferryls derived from the benzyl ester derivatives 
derivative (Figure 4.5A). This clearly implied the role of the benzyl ester moiety in the 
decomposition of the ferryl species. Furthermore, [FeIV(O)(4b)]2+ (d7-Bn-ester) also 
decomposed more slowly than [FeIV(O)(1)]2+ and furnished the kinetic isotope effect (KIE) 
of 4.5 (Figure 4.5B). To understand the effect of electronics on the decomposition process, 
ferryls were generated from para-substituted benzyl ester derivatives 4c-e and their rates of 
decomposition were obtained (Figure 4.5C). Using these rates, a Hammett plot was 
constructed that displayed a strong linear correlation (r = 0.99) between σp and log krel and 
gave a ρ value of –1.3 (Figure 4.5D). The small negative value suggested that the ferryl 
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reacted with the benzylic hydrogen via a hydrogen atom transfer (HAT) mechanism and not 
via an electron-transfer proton-transfer (ETPT) mechanism, which have given a more 
negative ρ value. 
To probe the reaction further, an effect of the concentration on the decomposition 
process was also investigated. Towards this, absorbance vs. time data were collected for 
variable concentrations of [FeII(1)(MeCN)]2+ (0.8-1.7 mM). Using the DynaFit software, the 
data was fit with various theoretical models by varying the estimated rate constant values 
(Figure 4.6). The best fits were obtained using model 4, which considers the formation of the 
ferryl as a bimolecular process and the decay as a unimolecular process. These fits also 
furnished the second order (k1 = 5.2(4) M-1s-1) and the first order (k2 = 5.9(1) × 10-4 s-1) rate 
constants for the formation and the decay process respectively. Moreover, the addition of 1 
equiv of benzyl alcohol or benzyl acetate did not affect the rate of decomposition of the 
ferryl-peptide conjugate, however the rates did change when the equivalents of these 
substrates were increased (Table 4.2). 
Table 4.2: Comparison of kobs upon addition of benzyl alcohol and benzyl acetate 
Additives Conc. kobs s–1 krel 
None -- 7.3(6) × 10–4 -- 
1 eq. 7.6 x 10–4 1.0 
5 eq 1.3 x 10–3 1.8 Benzyl alcohol 
10 eq. 2.2 x 10–3 3.0 
1 eq. 7.4 x 10–4 1.0 
5 eq 9.8 x 10–4 1.3 Benzyl acetate 
10 eq. 1.1 x 10–3 1.5 
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A + B C : k1 ; formation step
C + C D : k2 ; bimolecular decay+ E
Where A = [FeII(1)(MeCN)]2+; B = KHSO5, C = 
[FeIV(O)(1)]2+; D and E = products
A + B C : k1 ; formation step
C D : k2 ; electron transfer
Where A = [FeII(1)(MeCN)]2+; B = KHSO5, C = [FeIV(O)(1)]2+; 
D = radical cation; E = base or solvent; F and G = products
D + E F : k3 ; proton transfer+ G
A B : k1 ; electron transfer
B + C D : k2 ; proton transfer+ E
Where A = [FeIV(O)(1)]2+; B = radical cation; C = base 
or solvent; D and E = products (Formation step 
excluded in this model)
A + B C : k1 ; formation step
C D : k2 ; unimolecular decay
Model 1
Model 2
Model 3
Model 4
Where A = [FeII(1)(MeCN)]2+; B = KHSO5; C = 
[FeIV(O)(1)]2+; D = decomposition
 
Fit from the DynaFit program using model 4
 
Figure 4.6: Mechanistic models considered in DynaFit; Best fit obtained from DynaFit using 
model 4 for experimental data (dots) vs. estimated fit (lines) for 0.83 mM (yellow), 1.25 mM 
(green), and 1.67 mM (blue) of [FeIV(O)(1)]2+ 
Finally, the products derived from the decomposition of ferryl-peptide conjugates 
were also characterized using 1H NMR and ESMS analysis to support the mechanism 
(Scheme 4.3). Formation of benzaldehyde and the acid derivative 7 in this process were 
indicative of the oxidation of the benzylic position. Moreover, dipyridyl ketone and ~34% of 
the parent ligand were present in the reaction mixture suggesting a side reaction derived from 
the decomposition of the ligand moiety. 
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Scheme 4.3: Characterization of the decomposition products 
4.3 Discussion 
4.3.1 Synthesis and characterization of ferryl-peptide conjugates 
Synthesis and characterization of the ferrous- and ferryl-peptide conjugates were 
straightforward and achieved using the procedures reported for the synthesis of the 
corresponding N4Py complexes. Interestingly, the ferryl-peptide conjugate [FeIV(O)(1)]2+ (3) 
displayed the faster self-decomposition (t1/2 = ~15 min) compared to the corresponding 
[FeIV(O)(N4Py)]2+ complex (t1/2 = ~12 h). Due to this self-decomposition process, a 
simultaneous formation and decay of the ferryl-peptide conjugate 3 were observed at the 
initial time period (Figure 4.4B), which led to several challenges during its characterization 
as well as in the mechanistic studies. For example, the absorption maximum of 3 was lower 
than the one for [FeIV(O)(N4Py)]2+ (Figure 4.1B), which required its extinction coefficient to 
be derived indirectly by extrapolating ln(Abs) vs. time plot at t = 0 (Figure 4.4B). Moreover, 
high-resolution ESMS analysis of 3 has shown the molecular ion only at the initial time 
period (Figure 4.2B), while the 1H NMR analysis of 3 was unsuccessful. Despite these 
challenges, the characterization data obtained for 2 and 3 were in good agreement with 
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[FeIV(N4Py)(MeCN)]2+ and [FeIV(O)(N4Py)]2+ complexes respectively, when prepared under 
identical reaction conditions. The self-decomposition of 3 was attributed to the reactive 
functionalities of the ferryl-peptide conjugates. Since the knowledge about the stability of the 
ferryl-peptide conjugate is critical, we decided to investigate the detailed mechanism for the 
self-decomposition of the ferryl-peptide conjugates. 
4.3.2 Mechanistic studies 
Considering the literature precedence for the reactivity of ferryl complexes, 
mechanistic studies were directed towards understanding whether the decomposition is 
caused by hydroxylation of the phenyl ring or by oxidation of the benzylic or the glycyl 
moieties of 3. Towards this, various ester derivatives (4a-e) were conveniently prepared. 
Transesterification of 1 furnished 4a-d, however attempts to produce the electron 
withdrawing p-nitro benzyl ester or p-chloro benzyl ester derivatives by this method were 
unsuccessful. The poor nucleophilicity of the corresponding alcohol resulted in no reaction at 
the desired position and gave a complex mixture of products. Alternatively the benzyl ester 
moiety of 5 was transformed into p-chloro benzyl ester prior to incorporation of the N4Py 
ligand (Scheme 4.2b, 5 to 4e).  
Reaction of 1 equiv of KHSO5 with a solution of [FeII(L)(MeCN)]2+ (where L = 1, 4a-
e), furnished a pale-green species whose absorption at 680 nm maximized within 10-20 min 
and then decayed (Figure 4.4A). The linear plot of ln(Abs) vs. time at 680 nm furnished the 
rate of the decomposition process as well as suggested that the decay process is first-order 
with respect to the ferryl species (Figure 4.4B). Moreover, an induction period of ~10 min 
also indicated that the decay process began before the ferryl was fully generated. Therefore, 
  
 
122 
the ferryl is never fully generated. Rates of decomposition and the relative rates for the 
ferryls generated from 1 and 4a-e were used to compare their reactivity.  
Twelve times slower decomposition of [FeIV(O)(4a)]2+ (Me-ester) compared to 
[FeIV(O)(1)]2+ (Bn-ester) was clear evidence that the benzyl ester was the primary cause for 
the decomposition (Figure 4.5A). The KIE of 4.5 (Figure 4.5B) and a Hammett value of ρ = 
–1.3 (Figure 4.5D) obtained in this process were analogues to that observed in oxidation of 
ethyl ethers (KIE = 4.4)198 and para-substituted toluene derivatives (ρ = –1.6)199 by 
cytochrome P450. The KIE value of 4.5 suggested that the reaction was occurring at the 
benzylic position and not via aromatic hydroxylation since it would have furnished KIE 
values close to unity. The negative ρ value indicated that the substantial positive charge is 
building at the benzylic position. A smaller magnitude of the negative ρ value proves that the 
hydrogen atom of the benzylic group was abstracted via a hydrogen atom transfer (HAT) 
mechanism. If a reaction were occurring through an electron-transfer, proton-transfer (ETPT) 
mechanism a higher magnitude for the negative ρ value (–2.2 to –3.3) would have been 
observed.146 
The final goal of the mechanistic studies was to identify whether the decomposition 
occurs through an inter- or intramolecular pathway. A linear plot of ln(Abs) vs. time at the 
later time points clearly suggested that the decay process is first-order and hence 
unimolecular with respect to the ferryl species. This was further supported by the fact that the 
absorbance vs. time data obtained at various concentrations of [FeII(1)(MeCN)]2+ fitted best 
into the DynaFit program, when the formation of the ferryl was considered as a bimolecular 
process and the decay being a unimolecular process (Figure 4.6). Interestingly, the first order 
rate constant (k2) obtained from these fits was within the error of the rate constant obtained 
  
 
123 
from the slop of ln(Abs) vs. time plot (Figure 4.4B). In addition, the inability of 1 equiv of 
benzyl acetate or benzyl alcohol to alter the rate of decomposition suggested that the process 
is unimolecular. The slow change in the rate of decomposition upon increasing the amount of 
additional substrates can be explained if a unimolecular reaction was competing with the 
bimolecular reaction at the higher concentration (Table 4.2). 
From the results obtained in these studies, the mechanistic model was proposed for 
the decomposition of the ferryl-peptide conjugate (Scheme 4.4A). Ferrous-peptide conjugate 
2 reacts with KHSO5 in a bimolecular fashion to furnish the ferryl-peptide conjugate 3, which 
upon intramolecular hydrogen atom transfer generates a benzyl radical 9 that eventually 
decomposes. The proposed mechanistic model also explains the formation of oxidation 
products (Figure 4.4B). The reactive benzyl radical 9 undergoes a radical rebound process to 
furnish the corresponding hydroxylated product 10 that eventually collapsed to give 
benzaldehyde (6) and acid 7. The lower percentage of benzaldehyde compared to 7 was 
attributed to the issues associated with its isolation. In addition, reaction of the benzyl radical 
9 with the methine C-H of the N4Py moiety, presumably through an intermolecular pathway, 
led to the hydroxylated product 11 and regenerated 1 (34%). The further decomposition of 11 
explains the formation of 2-dipyridylketone (5) as well as other oxidation products 12-14 that 
were detected in trace amounts by ESMS analysis. 
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Scheme 4.4: (A) Proposed mechanistic model for the decomposition of the ferryl-peptide 
conjugate; (B) Formation of various oxidation products in decomposition process (Note: 
products presented herein are after the work up, therefore iron is omitted) 
4.4 Conclusion 
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The first ferryl-peptide conjugate was synthesized and characterized using 1H NMR 
spectroscopy, UV-vis spectroscopy and HRMS analysis. The ferryl-peptide conjugate was 
more reactive than the corresponding ferryl complex when it was not tethered to a peptide, 
which led to its rapid decomposition. This observation has raised the question about the 
functional group compatibility of the ferryl-peptide conjugates. To understand which 
functionality on the ferryl-peptide conjugate was responsible for its decomposition, a detailed 
mechanistic investigation was carried out. Using various mechanistic tools such as KIE, 
Hammett plot and oxidation product analysis, it has been established that the decomposition 
was caused by an intramolecular oxidation of the benzylic position by the ferryl. Moreover, 
the data also suggested that the reaction occurred via a hydrogen atom transfer mechanism. 
Overall, the knowledge about the functional groups that can be tolerated around ferryls is 
critical and the study presented herein has set up a foundation to investigate the functional 
group compatibility of the ferryl complexes. The information gained from this study will be 
very important to build stable catalysts, and may be applied in the future towards the 
synthesis of artificial oxygenases. 
4.5 Experimental Section 
4.5.1 General consideration 
See section 2.5.1 for the general considerations. UV-vis spectra were recorded on a 
Cary 50 spectrophotometer. Fitting of kinetic data was carried out using the program Igor 
Pro. 
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4.5.2 Experimental procedures and tabulated characterization data 
for new compounds 
General procedure for transesterification of 1.  
A mixture of compound 1, the corresponding alcohol and potassium carbonate was 
heated at 75 °C for 3-4 h.  The crude reaction mixture was dissolved in ethyl acetate (0.5 mL) 
and passed through alumina. The excess of alcohol was removed using ethyl acetate as an 
eluent. The product was then eluted using 2-5% MeOH:CH2Cl2 and was purified again either 
by alumina chromatography or preparative HPLC. 
Methyl 2-(2-acetamido-3-(6-(((dipyridin-2-ylmethyl)(pyridin-2-ylmethyl)amino)methyl) 
pyridin-3-yl)propanamido)acetate (4a). 
AcHN
H
N
O
N
OMe
O
N
N
N
N
Chemical Formula: C31H33N7O4
Molecular Weight: 567.64
 
Compound 4a was prepared by the general procedure for transesterification using 1 (-
30 mg, 46.6 µmol), methanol (0.6 mL), and potassium carbonate (3.2 mg, 23.3 µmol). The 
reaction mixture was concentrated and the crude product was first purified by column 
chromatography (basic alumina, 0% to 5% MeOH:CH2Cl2) and then by preparative HPLC 
(16 mg, 61%). HPLC Conditions: column: Zorbax XDB-C18, 21.2 × 150 mm, 5 micron 
equipped with a guard column; flow rate = 20 mL/min; gradient elution 0-5 min 0-20% 
MeCN in 0.1% aq TFA, 5-15 min 20-65% MeCN in 0.1% aq TFA; RT = 10.2 min.184 1H 
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NMR (400 MHz, CDCl3) δ 8.52 (d, J = 4.0 Hz, 2H), 8.46 (d, J = 4.9 Hz, 1H), 8.30 (s, 1H), 
7.64-7.58 (m, 6H), 7.54-7.47 (m, 2H), 7.13-7.06 (m, 3H), 6.79 (brs, 1H), 6.37 (d, J = 7.3 Hz, 
1H), 5.30 (s, 1H), 4.69 (dd, J = 14.6, J = 7.3 Hz, 1H), 3.94-3.87 (m, 6H), 3.66 (s, 3H), 3.06 
(dd, J = 13.8, 6.5 Hz, 1H), 2.97 (dd, J = 13.8, 6.5 Hz, 1H), 1.92 (s, 3H); 13C NMR (100 MHz, 
CDCl3) δ 171.8, 170.3, 169.7, 159.9, 159.8, 158.6, 149.6, 149.2, 149.0, 137.3, 136.4, 136.3, 
130.1, 123.9, 122.9, 122.7, 122.1, 121.8, 71.7, 57.1, 56.7, 53.7, 52.3, 41.1, 34.8, 23.1; IR 
(thin film) 3288, 3054, 3009, 2951, 2918, 2849, 1752, 1654, 1588, 1569, 1548, 1487, 1471, 
1433, 1400, 1371, 1288, 1261, 1210, 1181, 1149, 1126, 1089, 1049, 1032, 996, 984, 911, 
785, 755, 731, 646 cm-1; LRMS (ESMS) calcd for C31H34N7O4 (M+H)+ 568, found: 568. 
d7-Benzyl 2-(2-acetamido-3-(6-(((dipyridin-2-ylmethyl)(pyridin-2-ylmethyl)amino) 
methyl)pyridin-3-yl)propanamido)acetate (4b). 
AcHN
H
N
O
N
O
O
N
N
N
N
Chemical Formula: C37H30D7N7O4
Molecular Weight: 650.78
D D D
D
D
D
D
 
Compound 4b was prepared by the general procedure for transesterification using 1 (-
30 mg, 46.6 µmol), d7-benzyl alcohol (269 µL, 2.3 mmol), and potassium carbonate (3.2 mg, 
23.3 µmol). The crude product was purified by column chromatography (basic alumina, 
100% EtOAc to elute excess alcohol and then 0% to 5% MeOH:CH2Cl2 to elute product) (19 
mg, 63%). 1H NMR (400 MHz, CDCl3) δ 8.51 (d, J = 4.0 Hz, 2H), 8.44 (d, J = 4.0 Hz, 1H), 
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8.30 (s, 1H), 7.63-7.47 (m, 8H), 7.10-7.03 (m, 4H), 6.54 (brs, 1H), 5.30 (s, 1H), 4.73-4.68 
(m, 1H), 4.03-3.81 (m, 6H), 3.06 (dd, J = 13.8, 6.5 Hz, 1H), 2.96 (dd, J = 13.8, 6.5 Hz, 1H), 
1.88 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 171.0, 170.4, 169.2, 159.9, 159.6, 158.3, 149.6, 
149.2, 149.0, 137.4, 136.4, 136.3, 130.3, 123.9, 122.9, 122.8, 122.1, 121.8, 71.9, 57.0, 56.7, 
53.7, 41.2, 34.7, 23.0; IR (thin film) 3286, 1748, 1656, 1588, 1569, 1433, 1372, 1187, 1031, 
995, 730 cm-1; HRMS (ESMS) calcd for C37H31D7N7O4 (M+H)+ 651.3425, found: 651.3405. 
4-methoxybenzyl 2-(2-acetamido-3-(6-(((dipyridin-2-ylmethyl)(pyridin-2-ylmethyl) 
amino)methyl)pyridin-3-yl)propanamido)acetate (4c). 
AcHN
H
N
O
N
O
O
N
N
N
N
OMe
Chemical Formula: C38H39N7O5
Molecular Weight: 673.76
 
Compound 4c was prepared by the general procedure for transesterification using 1 (-
40 mg, 62.2 µmol), p-methoxy benzyl alcohol (429 mg, 3.1 mmol), and potassium carbonate 
(4.3 mg, 31.1 µmol). The crude product was purified by column chromatography (basic 
alumina, 100% EtOAc to elute excess alcohol and then 0% to 5% MeOH:CH2Cl2 to elute 
product). The resulting product was stirred with 4:6 Et2O:hexanes (3 × 2 mL) and a solid was 
isolated by decantation. The product was further by preparative HPLC (22 mg, 53%). HPLC 
Conditions: column: Zorbax XDB-C18, 21.2 × 150 mm, 5 micron equipped with guard 
column; flow rate = 20 mL/min; gradient elution 0-5 min 0-20% MeCN in 0.1% aq TFA, 5-
15 min 20-65% MeCN in 0.1% aq TFA; RT = 9.0 min.184 1H NMR (400 MHz, CD3CN) δ 
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8.45-8.42 (m, 3H), 8.28 (d, J = 1.6 Hz, 1H), 7.72-7.62 (m, 5H), 7.56 (d, J = 8.1 Hz, 1H), 
7.51-7.44 (m, 2H), 7.28 (d, 2H), 7.20-7.10 (m, 4H), 6.89 (d, J = 8.9 Hz, 2H), 6.73 (d, J = 8.1 
Hz, 1H), 5.23 (s, 1H), 5.04 (s, 2H), 4.59-4.53 (m, 1H), 3.87-3.85 (m, 6H), 3.75 (s, 3H), 3.06 
(dd, J = 14.6, 5.7 Hz, 1H), 2.78 (dd, J = 14.6, 8.9 Hz, 1H), 1.77 (s, 3H); 13C NMR (100 MHz, 
CD3CN) δ 172.4, 170.9, 170.5, 161.4, 160.9, 159.0, 150.6, 149.9, 149.8, 138.0, 137.3, 137.2, 
132.2, 131.1, 129.0, 124.8, 123.8, 123.4, 123.1, 122.9, 118.3, 114.8, 72.8, 67.3, 57.9, 57.6, 
55.9, 54.7, 41.8, 35.3, 22.9; IR (thin film) 3286, 3051, 2933, 2837, 1747, 1658, 1613, 1588, 
1569, 1515, 1469, 1433, 1373, 1249, 1173, 1032, 995, 824, 756, 734, 700 cm-1; HRMS 
(ESMS) calcd for C38H40N7O5 (M+H)+ 674.3091, found: 674.3084. 
4-methylbenzyl 2-(2-acetamido-3-(6-(((dipyridin-2-ylmethyl)(pyridin-2-ylmethyl) 
amino)methyl)pyridin-3-yl)propanamido)acetate (4d). 
AcHN
H
N
O
N
O
O
N
N
N
Me
Chemical Formula: C38H39N7O4
Molecular Weight: 657.76
N
 
Compound 4d was prepared by the general procedure for transesterification using 1 (-
30 mg, 46.6 µmol), p-methyl benzyl alcohol (357 mg, 2.3 mmol), and potassium carbonate 
(3.2 mg, 23.3 µmol). The crude product was heated at 75 °C under high vacuum (~ 0.3 
mm/Hg) to remove excess p-methyl benzyl alcohol. The resulting product was further 
purified by preparative HPLC (13 mg, 43%). HPLC Conditions: column: Zorbax XDB-C18, 
21.2 × 150 mm, 5 micron equipped with guard column; flow rate = 20 mL/min; gradient 
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elution 0-5 min 5-20% MeCN in 0.1% aq TFA, 5-15 min 20-50% MeCN in 0.1% aq TFA, 
15-16 min 50-95% MeCN in 0.1% aq TFA; RT = 10.8 min.184 1H NMR (400 MHz, CDCl3) δ 
8.52 (d, J = 4.9 Hz, 2H), 8.45 (d, J = 4.9 Hz, 1H), 8.29 (s, 1H), 7.64-7.57 (m, 6H), 7.53-7.46 
(m, 2H), 7.18-7.05 (m, 7H), 6.81 (t, J = 4.9 Hz, 1H), 6.36 (d, J = 7.3 Hz, 1H), 5.30 (s, 1H), 
5.05 (s, 2H), 4.71-4.66 (m, 1H), 4.02-3.88 (m, 6H), 3.05 (dd, J = 13.8, 6.5 Hz, 1H), 2.95 (dd, 
J = 13.8, 6.5 Hz, 1H), 2.30 (s, 3H), 1.89 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 170.8, 
170.3, 169.2, 159.9, 159.7, 158.5, 149.6, 149.2, 149.0, 137.3, 136.4, 136.3, 130.1, 129.3, 
128.6, 123.9, 122.9, 122.8, 122.1, 121.8, 71.9, 67.2, 57.0, 56.7, 53.7, 41.3, 34.8, 23.1, 21.2; 
IR (thin film) 3285, 3052, 2925, 1749, 1654, 1588, 1569, 1471, 1433, 1377, 1180, 1031, 995, 
755 cm-1; LRMS (ESMS) calcd for C38H40N7O4 (M+H)+ 658, found: 658. 
4-chlorobenzyl 2-(2-acetamido-3-(6-((tert-butyldimethylsilyloxy)methyl)pyridin-3-yl) 
propanamido)acetate (15). 
AcHN
H
N
O
N
O
O
Cl
Chemical Formula: C26H36ClN3O5Si
Molecular Weight: 534.12
OTBS
 
A mixture of compound 5 (1.3 g, 2.6 mmol), MeOH (39 mL) and 5% Pd/C (130 mg) was 
stirred at rt under H2 (1 atm) for 5 h. After consumption of the starting material, as judged by 
TLC analysis, the reaction mixture was filtered through celite. The filtrate was concentrated 
to obtain a sticky white solid, which upon triturating with Et2O for 30 min furnished Ac-
HPA(OTBS)-Gly-OH as a white solid.  The white solid was isolated by filtration and washed 
with Et2O (1.06 g, quantitative). 
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A mixture of Ac-HPA(OTBS)-Gly-OH (50 mg, 122 µmol), 4-chlorobenzyl alcohol 
(17.4 mg, 122 µmol), CH2Cl2 (1 mL), Et3N (25 µL, 183 µmol), and DMAP (3 mg, 30.5 
µmol)  was maintained at rt under a nitrogen atmosphere for 5 min. EDAC (28 mg, 146 
µmol) was added and the mixture was maintained for 5-6 h.  The reaction mixture was 
combined with CH2Cl2 (25 mL) and the organic layer was extracted with NaHCO3 (5% aq, 3 
× 15 mL), NH4Cl (sat. aq, 3 × 15 mL) and NaCl (sat. aq, 3 × 15 mL) respectively.  The 
organic layer was separated, dried over anhydrous Na2SO4 and concentrated to obtain the 
crude product as a viscous oil (42 mg, 64%). A small portion of the crude product was 
purified by column chromatography (silica gel, 0% to 3% MeOH:CH2Cl2) for analysis. 1H 
NMR (400 MHz, CDCl3) δ 8.31 (s, 1H), 7.56 (d, J = 8.1 Hz, 1H), 7.42 (d, J = 8.1 Hz, 1H), 
7.32-7.23 (m, 4H), 6.85 (brs, 1H), 6.32 (brs, 1H), 5.09 (s, 2H), 4.77-4.71 (m, 3H), 4.06-3.93 
(m, 2H), 3.11 (dd, J = 13.8, 7.3 Hz, 1H), 2.98 (dd, J = 13.8, 7.3 Hz, 1H), 1.93 (s, 3H), 0.92 
(s, 9H), 0.08 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 170.9, 170.4, 169.1, 160.0, 149.0, 
137.8, 134.5, 133.5, 130.1, 129.8, 128.8, 120.0, 66.4, 65.7, 53.7, 41.2, 34.8, 25.9, 23.1, 18.3, 
–5.4; IR (thin film) 3284 (b), 3066, 2954, 2929, 2857, 1752, 1651, 1602, 1548, 1493, 1471, 
1374, 1254, 1187, 1096, 1032, 1017, 839, 809, 779, 732 cm-1; LRMS (ESMS) calcd for 
C26H37ClN3O5Si (M+H)+ 534, found: 534. 
4-chlorobenzyl 2-(2-acetamido-3-(6-(chloromethyl)pyridin-3-yl)propanamido)acetate 
(16). 
AcHN
H
N
O
N
O
O
Cl
Chemical Formula: C20H21Cl2N3O4
Molecular Weight: 438.30
Cl
 
  
 
132 
A mixture of crude compound 15 (42 mg, 78.6 µmol), acetic acid (4.5 µL, 78.6 µmol) and 
THF (0.6 mL) was maintained under a nitrogen atmosphere for 5 min. A 1M solution of 
TBAF in THF (157 µL, 157 µmol) was added and the reaction mixture was maintained for 
1.5 h. After consumption of the starting material, as judged by TLC analysis, the reaction 
mixture was combined with H2O (20 mL) and the solution was adjusted to pH ~8 using 
Na2CO3 (sat. aq).  The aqueous layer was extracted with CH2Cl2 (15 × 5 mL).  The combined 
organic layers were dried over anhydrous Na2SO4 and concentrated to obtain the 
corresponding alcohol as a white solid.  After triturating the solid with Et2O overnight a 
white solid was isolated by decantation (26 mg, 79%). 
A mixture of alcohol (26 mg, 62 µmol), flame dried LiCl (26 mg, 620 µmol), MeCN 
(1 mL), and i-Pr2EtN (22 µL, 124 µmol) was cooled to 0 °C and TsCl (18 mg, 93 µmol) was 
added under a nitrogen atmosphere. The reaction mixture was stirred at 0 °C for 1.5 h and 
then warmed to rt. The color of the reaction mixture changed from colorless to orange. The 
orange suspension was maintained at rt for overnight. After consumption of the starting 
material, as judged by TLC analysis, the reaction mixture was decanted and the residues were 
rinsed with MeCN (5 mL). The combined MeCN layer was concentrated and the crude 
product was combined with CH2Cl2 (15 mL). The CH2Cl2 layer was extracted with an 
aqueous NaHCO3 (pH ~9) solution (3 × 10 mL).  The organic layer was dried over anhydrous 
Na2SO4 and concentrated to obtain crude product as a red oil. The crude product was purified 
by column chromatography (basic alumina, 0% to 5% MeOH:CH2Cl2) to provide an orange 
oil (14 mg, 52%). 1H NMR (400 MHz, CDCl3) δ 8.38 (s, 1H), 7.60 (dd, J = 8.1 Hz, 1H), 7.37 
(dd, J = 7.3 Hz, 1H), 7.32-7.26 (m, 4H), 7.06 (brs, 1H), 6.44 (d, J = 7.3 Hz, 1H), 5.09 (s, 
2H), 4.82-4.76 (m, 1H), 4.62 (s, 2H), 4.00 (d, J = 5.7 Hz, 2H), 3.14 (dd, J = 13.8, 6.5 Hz, 
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1H), 2.99 (dd, J = 13.8, 6.5 Hz, 1H), 1.93 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 170.9, 
170.4, 169.1, 155.1, 149.9, 138.2, 134.5, 133.5, 131.7, 129.8, 128.8, 122.7, 66.4, 53.5, 46.2, 
41.2, 34.9, 23.0; IR (thin film) 3290 (b), 3065, 1749, 1651, 1546, 1493, 1380, 1188, 1093, 
1016, 806 cm-1; LRMS (ESMS) calcd for C20H22Cl2N3O4 (M+H)+ 438, found: 438. 
4-chlorobenzyl 2-(2-acetamido-3-(6-(((dipyridin-2-ylmethyl)(pyridin-2-ylmethyl)amino) 
methyl)pyridin-3-yl)propanamido)acetate (4e). 
AcHN
H
N
O
N
O
O
N
N
N
N
Cl
Chemical Formula: C37H36ClN7O4
Molecular Weight: 678.18  
A mixture of compound 16 (39 mg, 89 µmol), MeCN (2 mL), i-Pr2EtN (64 µL, 0.36 
mmol), sodium iodide (3.3 mg, 18 µmol) and 1,1-di(pyridin-2-yl)-N-(pyridin-2-
ylmethyl)methanamine [NH(PyCH2) (CHPy2); where Py = 2-pyridyl] (74 mg,  0.27 mmol) 
was heated at 55 °C for 24 h. The reaction mixture was condensed under vacuum and the 
resulting oil was dissolved in CH2Cl2 (10 mL). The organic layer was extracted with 
NaHCO3 (5% aq, 3 × 5 mL). The organic layer was dried over anhydrous Na2SO4 and 
concentrated to obtain the crude product. The product was purified first by column 
chromatography (basic alumina, 0% to 5% MeOH:CH2Cl2) and then by preparative HPLC 
(26 mg, 43%). HPLC Conditions: column: Zorbax XDB-C18, 21.2 × 150 mm, 5 micron 
equipped with guard column; flow rate = 20 mL/min; gradient elution 0-5 min 0-20% MeCN 
in 0.1% aq TFA, 5-15 min 20-65% MeCN in 0.1% aq TFA; RT = 9.7 min.184 1H NMR (400 
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MHz, CDCl3) δ 8.52-8.47 (m, 3H), 8.40 (s, 1H), 7.64-7.44 (m, 9H), 7.28-7.19 (m, 4H), 7.12-
7.06 (m, 3H), 6.76 (brs, 1H), 5.31 (s, 1H), 5.07 (s, 2H), 4.71 (dd, J = 14.6, 7.3 Hz, 1H), 4.02-
3.90 (m, 6H), 3.08 (dd, J = 13.8, 6.5 Hz, 1H), 2.98 (dd, J = 13.8, 6.5 Hz, 1H), 1.89 (s, 3H); 
13C NMR (100 MHz, CDCl3) δ 171.0, 170.4, 169.1, 159.8, 159.6, 158.3, 149.4, 149.2, 149.0, 
137.5, 136.4, 136.3, 134.4, 133.6, 130.4, 129.7, 128.8, 123.9, 122.9, 122.8, 122.2, 121.9, 
71.8, 66.2, 57.1, 56.6, 53.8, 41.2, 34.7, 23.0; IR (thin film) 3288 (b), 3054, 2931, 1751, 1655, 
1588, 1569, 1492, 1471, 1433, 1375, 1186, 1093, 996, 910, 731, 645 cm-1; LRMS (ESMS) 
calcd for C37H37ClN7O4 (M+H)+ 678, found: 678. 
Synthesis and Characterization of [FeII(1)(MeCN)]2+ and [FeIV(O)(1)]2+. 
1H NMR Data (Figure 4.3) 
The methine (b) and pyridyl (c) protons of 1 were clearly shifted downfield (Figure 4.3, A 
and B) upon addition of 1 eq of Fe(ClO4)2·xH2O (aq) to the solution of 1 (5-7 mg) in 1:1 
MeCN:H2O. These shifts were inline with the shifts obtained from the corresponding 
methine (b’) and pyridyl protons (c’) of the reference N4Py ligand (Figure 4.3, C and D) 
under identical experimental conditions. 
Mass Spectrometry Data (Figure 4.2) 
Mass spectra were recorded in positive ion mode using Waters ZQ2000 single 
quadrupole mass spectrometer using an electrospray ionization source or Waters-Micromass 
LCT Premier XE time of flight mass spectrometer equipped with an electrospray ionization 
source (ESI). The key parameters used for the experiment are as follows: Capillary voltage 
3.3 kV, Sample cone voltage 5 V, Desolvation temperature 300 °C, Source temperature 120 
°C, Cone gas Flow 200, Desolvation gas flow 700. The instrument was equilibrated with 
MeCN before injecting the sample.  
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360 µL, 2 mM solution of 1 (1:1 MeCN:H2O) was mixed with 36 µL, 20 mM 
solution of FeII(ClO4)2·xH2O (in H2O) to obtain a yellow solution. 5 µL of this solution was 
mixed with 150 µL MeCN and 10 µL of the resulting solution was injected in the Waters 
ZQ2000 single quadrupole mass spectrometer. Mass spectra were processed using MassLynx 
software. The dominant molecular ion was observed at m/z 370, which is consistent with its 
molecular formula [FeII(1)(MeCN)]2+ (Figure 4.2A). 
The species 3 (1.67 mM) was freshly prepared and 5 µL of this solution was mixed with 50 
µL MeCN at various time periods up to 13 min. 10 µL of these solutions were injected each 
time in the Waters-Micromass LCT Premier XE time of flight mass spectrometer. Mass 
spectra were processed using MassLynx software. In the sample injected at the 8th min, the 
dominant molecular ion was observed at m/z 357.6093, along with a suitable isotopic pattern, 
which is consistent with its formula [FeIV(O)(1)]2+ (3) (calc. m/z 357.6103, Figure 4.3B). 
UV-vis Data (Figure 4.1) 
Table 4.3: Extinction coefficients for the ferrous- and ferryl-peptide conjugate and 
corresponding N4Py complexes in identical reaction conditions 
Species ε  (M-1cm-1) λmax(nm) 
[FeII(N4Py)(MeCN)]2+ 4.2 × 103 380 
  3.7 × 103 455 
[FeII(1)(MeCN)]2+ (2) 4.2 × 103 380 
  3.6 × 103 455 
[FeIV(O)(N4Py)]2+ 1.6 × 102 680 
[FeIV(O)(1)]2+ (3) 2.0 × 102 680 
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Product analysis for decomposition of ferryl-peptide conjugate 3. 
A solution of 1 (13 mg, 20 µmol) in 1:1 H2O:MeCN (12 mL) was treated with 1 
equiv. of FeII(ClO4)2·xH2O in H2O (20 µmol) followed by  1 equiv. of KHSO5 in H2O (20 
µmol).  After 1.5 h, the reaction mixture was concentrated to dryness and combined with a 
dilute aqueous NaHCO3 (10 mL) and CH2Cl2 (10 mL). The organic layer was separated and 
the aqueous layer was extracted with CH2Cl2 (2 × 10 mL). The organics were combined, 
dried, filtered and concentrated. The aqueous layer was concentrated. The organic and 
aqueous fractions were analyzed by ESMS and 1H NMR spectroscopy using 4-
methylpyrimidine as an internal standard in CDCl3 and D2O, respectively. Products and 
yields are shown in Scheme 4.4B. The low isolated yield of benzaldehyde (8%) is likely due 
to the volatility of this product. 
General procedure for kinetic studies. 
 The formation and decomposition studies of [FeIV(O)(L)]2+ species (where L = 1, 4a-
e) were conducted at 25 °C under aerobic conditions. Observed rate constants represent the 
average of three runs. The reactions were monitored using a UV-vis spectrophotometer at 
680 nm and were performed using the following standard procedure.  
For determination of KIE and Hammett plot:  
A 2 mM solution of L (Where L = 1, 4a-e) in 1:1 H2O:MeCN (360 µL, 0.72 µmol) 
was treated with a 20 mM solution of FeII(ClO4)2·xH2O in H2O (36 µL, 0.72 µmol) followed 
by a 20 mM solution of KHSO5 in H2O (36 µL, 0.72 µmol).  
In each of the above experiments, upon addition of FeII(ClO4)2·xH2O to the solution 
of L, the resulting solution turned yellowish orange. After addition of KHSO5 this solution 
turned from yellowish orange to green (while mixing the solution). The reactions were 
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monitored by UV-vis spectroscopy (Figure 4.4A). The absorption at 680 nm was found to 
increase approximately for about 10 min, suggesting the formation of the species 
[FeIV(O)(L)]2+, and then started decreasing, indicating the decomposition of [FeIV(O)(L)]2+. 
The natural log of absorbance at λmax = 680 nm was plotted against time and the linear 
portion of the plot was fit with line equation Y = a + bX (Figure 4.4B). The slope (b) of the 
line furnished the observed rate constants. 
DynaFit modeling for concentration dependence studies. 
The absorbance vs. time traces for three concentrations (0.83 mM, 1.25 mM, and 1.67 
mM) of species 3 was used for the calculations. The data was fit with four possible 
mechanistic models (see Models 1 to 4 in Figure 4.6), by varying the estimated rate constant 
values. The fitting parameters were further optimized by varying the initial concentrations of 
[FeII(1)(MeCN)]+2 and KHSO5 within the error range. The best fit was obtained when the 
model 4 was used. 
Table 4.4: Parameters and standard errors obtained from DynaFit 
Parameter Initial (M-1s-1) Unit Fit (M-1s-1) Unit Error %Error 
k1 5.365666667 M-1s-1 5.365 M-1s-1 0.012 3.6 
k2 0.00059175 s-1 0.000618833 s-1 0.00045 1.2 
rC 200 M-1cm-1 190 M-1cm-1 0.0017 0.9 
* rC : Extinction coefficient for C, i.e. [FeIV(O)(1)]2+ 
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Chapter 5: Conclusion 
This conclusion chapter is divided into two sections. The first section includes the 
accomplishments of the research goals and suggestions to improve the present outcome of 
this research. The second section includes conclusion and future directions that demonstrate 
the significance and scope of the research presented in this dissertation. 
5.1 Accomplishments and suggestions 
5.1.1 Development of the divergent and dual divergent strategies 
for the synthesis of non-heme ligand-peptide conjugates 
Applications of metal complex-peptide conjugates have been extensively explored 
over the last two decades. Considering their applications, several synthesis strategies have 
been developed to construct a variety of peptide-ligand conjugates. Despite the wide scope of 
non-heme ligands in bioorganic chemistry, very few methods are known for tethering 
nitrogen-rich non-heme ligands into peptides. Surprisingly, none of these methods allow the 
incorporation of such ligands into peptides in a divergent fashion. This is important because 
lack of such methods has limited the applications of non-heme ligand-peptide conjugates. In 
effort to contribute to this research, we have developed divergent and dual divergent 
strategies via solution and/or solid phase synthesis (Chapter 2 and 3). In addition, functional 
group compatibilities and the scope of these strategies were also explored. The two 
requirements for the strategies were to synthesize unnatural amino acids and to develop 
conditions for these strategies that can be easily performed in solution as well as solid phase 
synthesis. Towards this, I developed scalable routes for the synthesis of key intermediates 
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and synthesized two unnatural amino acids Fmoc-HPA(OTBS)-OH and Fmoc-HPL(OTBS)-
OH. The unnatural amino acid HPA resembles phenylalanine, so that it can be placed into 
peptidomimetic enzyme inhibitors without significantly altering their structures. I also 
developed conditions for the divergent and dual divergent strategy to incorporated non-heme 
ligands into the peptide. Using these methods, various tetra- and pentadentate ligands such as 
TPA, Bn-TPEN, N4Py and PaPy3 were incorporated into peptides. It is important to note that 
several of these ligands generate ferryl complexes, which display a remarkable oxidizing 
power.14,15 Particularly, the ferryl derived from N4Py ligand is stable in aqueous conditions 
and can oxidize various organic substrates,14 amino acid substrates,160 proteins17 and 
glutathione.161 In addition, metal complexes derived from tetradentate ligand TPA have 
shown numerous applications in photo-responsive materials,200 zinc sensing agents201 as well 
as in inhibition studies.202 The pentadentate ligand PaPy3 and derivatives have been used to 
construct CO/NO delivering agents.203,204 Our group has demonstrated the potential of these 
ligands in cancer cell cytotoxicity studies.16 Considering numerous applications of non-heme 
ligands, the synthesis strategies presented herein will be very important in exploring their 
utility in bioorganic chemistry. 
Although the strategies presented herein facilitate easy excess to the synthesis of 
peptide-ligand conjugates via solution as well as solid phase synthesis, the following 
modifications could make these strategies more convenient. For example, the synthesis of 
Fmoc-HPA(OTBS)-OH can produce multigram quantities of the target amino acid. However 
if the Negishi coupling is performed using iodopyridine instead of the bromopyridine 
derivative to produce Fmoc-HPA(OTBS)-OH, a multi-step synthesis presently used for the 
synthesis of  Fmoc-HPA(OTBS)-OH could be avoided. A convenient route for the synthesis 
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of iodopyridine derivative has to be developed prior to attempting the Negishi coupling. 
Incorporation of N4Py onto Wang resin bound peptide was unsuccessful, however N4Py 
containing a SAAC derivative could be used to synthesize corresponding conjugates on 
Wang resin. This is important because certain peptide vectors might require C-terminal acids 
for their biological activity and the ability to incorporate these ligands into peptide-acids 
would expand the scope of these conjugates. 
5.1.2 Applications of the non-heme ligand-peptide conjugates 
Among numerous applications, the utility of the divergent and dual divergent 
strategies to synthesize the library of biologically important peptide-ligand conjugates and to 
explore the chemistry of ferryl-peptide conjugates were explored in this dissertation. A small 
library of LHRH analogues was synthesized by incorporating Bn-TPEN, N4Py, TPA and 
PaPy3 at the side chain of Fmoc-HPL(OTBS)-OH. Biological applications of metal 
complexes are significantly influenced by the nature of donor atom, chelate rings and the 
charge.106 For example, replacement of a pyridyl moiety with quinoline has a significant 
effect on the NO releasing ability of PaPy3.203 Therefore, the ease of varying the ligand 
framework is very important while exploring the biological applications of such conjugates. 
The dual divergent strategy facilitated the manipulation in ligand structures as demonstrated 
by synthesizing pyrazine and carboxylate chelators containing TPA and PaPy3 derivatives. 
During the library synthesis, chlorination conditions were shown to tosylate 
pyroglutamic acid (Glp) of LHRH as a minor reaction. Although the method was not 
optimized further at this point, I suggest protecting Glp by an electron-rich protecting group 
such as trityl for the future libraries. For simplicity, the metal-binding units were directly 
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attached to the Nε-amine of the D-lysine in the library synthesized in this dissertation. 
However linkers between metal-binding ligands and peptide vectors could play a critical role 
in their biological activity. For instance, when DOTA was directly appended on LHRH, the 
conjugate lost the binding affinity to the target cell.33 In another example, the spacer length 
between N3S ligands and bombesin impacts the binding process of the resulting conjugates.32 
Considering the importance of linkers between metal-binding ligand and peptide vectors, in 
the future the role of spacer has to be established. For conveniently varying the linkers, 
LHRH analogues should be synthesized by incorporating Fmoc-D-Lys(PG)-OH where Nε-
amine of the D-lysine is protected by orthogonal protecting groups such as Dde, ivDde or 
allyl. This modification will ease the incorporation of various linkers between pyridyl moiety 
and D-lysine. 
Another significantly recognized application of non-heme ligands is their utility in 
ferryl chemistry. Given the fact that ferryl complexes play critical role in several enzymes, 
synthetic ferryl complexes and their utility in enzyme models as well as in catalysis has been 
well established. However none of the examples has shown the formation of ferryl using 
peptide bound non-heme ligands until we synthesized and characterized the ferryl-peptide 
conjugate from N4Py-dipeptide conjugate (Chapter 4). This work is significant because it 
supports the hypothesis that ferryls can be generated on a peptide-like (i.e. protein) scaffold. 
A detailed mechanistic study that was performed to understand the higher reactivity of these 
conjugates suggested that ferryl reacts with a remote benzyl group via intramolecular 
hydrogen atom transfer reaction. This clearly suggests the importance of the strategic 
arrangement of the reactive functional groups around the ferryl species; however, the 
knowledge about which groups can be tolerated around the ferryl species in enzymes was not 
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known. The studies presented herein have set up a strong foundation to explore the functional 
group compatibility of ferryl-peptide conjugates. The role of protein radicals has been 
studied in view of aging, lipid peroxidation, catalytic mechanisms and various deceases.194 
For example, ferryl myoglobin generates ferryl species upon reaction with H2O2 that 
eventually reacts with distal tyrosine residues to form the corresponding tyrosine radicals.195-
197 A distance dependent intramolecular long-range electron-transfer (LRET) was found to be 
responsible for this process.197 The intramolecular reactivity of ferryl-peptide conjugates 
established in this dissertation is analogues to the LRET process of protein radicals and could 
be used to study the LRET process on small model system.  
While the synthesis and characterization of ferryl-peptide conjugates were 
straightforward, the mechanistic investigations were challenging. Simultaneous formation 
and decomposition of the ferryl species during the initial time period did not allow the kinetic 
analysis of the decay process as an individual step. Moreover, along with the oxidation of the 
benzyl group, a parallel destruction of the metal-binding unit was observed. These issues 
made the kinetic studies challenging and I suggest following modifications for further 
investigation. A stable ligand such as MeN4Py has shown greater stability towards oxidation 
conditions. Therefore, the ferryl-peptide conjugates should be generated from the MeN4Py-
peptide conjugate and their reactivity should be studied in a similar fashion. This modified 
system should be used to address the question: which functional groups can be tolerated on 
ferryl-peptide conjugates? The knowledge gained from this study will be important for the 
utility of these conjugates in the future. In addition, isolation of the ferrous-peptide 
conjugates and establishment of their solid-state structure could give insight into the 3D-
orientation. 
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5.2 Conclusion and future directions 
In conclusion, we have established divergent and dual divergent strategies that allow 
the rapid synthesis of non-heme ligand-peptide conjugates. We have also explored the 
functional group compatibility and scope that suggests a wide applicability of these 
strategies. Easy access to the synthesis of non-heme ligand-peptide conjugates will play a 
critical role in exploring wide variety of applications. In this dissertation we have 
demonstrated the utility of these strategies in the library synthesis of metal-binding LHRH 
analogue and in exploring the chemistry of ferryl-peptide conjugate. 
Considering the applications of metal complexes containing non-heme ligands as 
oxidants,14,15 CO/NO delivering agents129,205 and biomolecule inactivating agents,106,206 the 
methodology described herein has a great potential in bioorganic research. In the future, the 
dual divergent strategy could be used to expand the library of metal-binding LHRH 
analogues by constructing more diverse ligands onto LHRH analogues. By changing the 
ligand framework the reactivity and the specificity of the resulting conjugates could be tuned 
to obtain the conjugates with desired properties. Moreover, similar libraries could be 
constructed on other delivery vectors such as bombesin and somatostatin for different 
biological targets. The dual divergent strategy could also be used to synthesize larger 
libraries via the split-pool method. These studies would facilitate the development of site-
selective catalytic agents for therapeutics. 
The chemistry of ferryl-peptide conjugates also has great scope and must be explored 
further. During our initial studies, we have found that replacement of glycine with alanine did 
not have any influence on the reactivity of ferryl-peptide conjugates.207 In the future, it will 
be very interesting to study the effect of tryptophan or histidine in the vicinity of ferryl 
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species. Such studies will provide further insight into the environment of the natural ferryls 
found in several enzymes. Moreover, multiple glycine spacers could be incorporated between 
benzyl ester moiety and the ferryl species to study the distance dependence on the reactivity 
of ferryl complexes. This will provide a simpler model to study the intramolecular long-range 
electron-transfer processes that are investigated only on protein radicals to date. We have 
already shown the capability of the divergent strategy to incorporate multiple ligands into a 
single peptide chain.98 Such conjugates will have great potential to construct iron µ-oxo 
complexes that could mimic binuclear iron enzymes.208,209 This is particularly important 
because such binuclear complexes can activate dioxygen and serve as oxidants. This idea can 
open a new research area in enzyme model studies as well as in catalytic inhibitions that 
utilize dioxygen for their activity. The knowledge gathered in these studies could eventually 
be used to construct stable catalysts as well as in the research of artificial oxygenases. 
Overall, two synthesis strategies developed in this dissertation will have significant 
influence on how non-heme ligand-peptide conjugates have been synthesized to date. A 
library synthesis of biologically important molecules and chemistry of ferryl-peptide 
conjugates demonstrates the utility of these strategies. Thus, the study presented herein has as 
set up a strong foundation for exploration of the applications of non-heme ligand-peptide 
conjugates as enzyme models, artificial oxygenases, and potentially in the long term, new 
therapeutic strategies. 
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APPENDIX 
 (6-(((tert-butyldimethylsilyl)oxy)methyl)pyridin-3-yl)methanol 
 
 
  
 
146 
5-(bromomethyl)-2-(((tert-butyldimethylsilyl)oxy)methyl)pyridine 
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(S)-benzyl 3-(6-(((tert-butyldimethylsilyl)oxy)methyl)pyridin-3-yl)-2-((diphenyl 
methylene)amino)propanoate 
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(S)-tert-butyl 3-(6-(((tert-butyldimethylsilyl)oxy)methyl)pyridin-3-yl)-2-((diphenyl 
methylene)amino)propanoate 
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(S)-2-amino-3-(6-((tert-butyldimethylsilyloxy)methyl)pyridin-3-yl)propanoic acid 
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(S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-(6-((tert-butyldimethylsilyloxy) 
methyl)pyridin-3-yl)propanoic acid 
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Benzyl 2-(3-(6-((tert-butyldimethylsilyloxy)methyl)pyridin-3-yl)-2-ethanamido 
propanamido)ethanoate 
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Benzyl 2-(3-(6-(chloromethyl)pyridin-3-yl)-2-ethanamidopropanamido)ethanoate 
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Benzyl 2-(2-acetamido-3-(6-((bis(pyridin-2-ylmethyl)amino)methyl)pyridin-3-
yl)propanamido)acetate 
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Benzyl 2-(2-acetamido-3-(6-(((2-(benzyl(pyridin-2-ylmethyl)amino)ethyl) (pyridin-2-
ylmethyl)amino)methyl)pyridin-3-yl)propanamido)acetate 
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Benzyl 2-(2-acetamido-3-(6-(((dipyridin-2-ylmethyl)(pyridin-2-ylmethyl)amino) 
methyl)pyridin-3-yl)propanamido)acetate 
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6-(((tert-butyldimethylsilyl)oxy)methyl)nicotinic acid 
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2,5-dioxopyrrolidin-1-yl 6-(((tert-butyldimethylsilyl)oxy)methyl)nicotinate 
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(R)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-6-(6-(((tert-butyldimethylsilyl) 
oxy)methyl)nicotinamido)hexanoic acid 
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TPA·LHRH conjugate 
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Pyrazine derivative of TPA·LHRH conjugate 
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Carboxylate derivative of TPA·LHRH conjugate  
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PaPy3·LHRH conjugate 
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Pyrazine derivative of PaPy3·LHRH conjugate 
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Carboxylate derivative of PaPy3·LHRH conjugate 
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Bn-TPEN·LHRH conjugate 
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N4Py·LHRH conjugate 
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Methyl 2-(2-acetamido-3-(6-(((dipyridin-2-ylmethyl)(pyridin-2-ylmethyl)amino)methyl) 
pyridin-3-yl)propanamido)acetate 
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d7-Benzyl 2-(2-acetamido-3-(6-(((dipyridin-2-ylmethyl)(pyridin-2-ylmethyl)amino) 
methyl)pyridin-3-yl)propanamido)acetate 
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4-methoxybenzyl 2-(2-acetamido-3-(6-(((dipyridin-2-ylmethyl)(pyridin-2-ylmethyl) 
amino)methyl)pyridin-3-yl)propanamido)acetate 
 
 
  
 
170 
4-methylbenzyl 2-(2-acetamido-3-(6-(((dipyridin-2-ylmethyl)(pyridin-2-ylmethyl) 
amino)methyl)pyridin-3-yl)propanamido)acetate 
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4-chlorobenzyl 2-(2-acetamido-3-(6-((tert-butyldimethylsilyloxy)methyl)pyridin-3-yl) 
propanamido)acetate 
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4-chlorobenzyl 2-(2-acetamido-3-(6-(chloromethyl)pyridin-3-yl)propanamido)acetate 
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4-chlorobenzyl 2-(2-acetamido-3-(6-(((dipyridin-2-ylmethyl)(pyridin-2-ylmethyl)amino) 
methyl)pyridin-3-yl)propanamido)acetate 
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Three research areas pertaining to this dissertation, (i) synthesis strategies of peptide-
ligand conjugates, (ii) their applications and (iii) chemistry of ferryls were surveyed in the 
introduction chapter. Next, the divergent and dual divergent strategies for the synthesis of 
non-heme ligand-peptide conjugates were developed. Using these strategies various peptide-
ligand conjugates were synthesized via solution as well as solid phase synthesis. The scope 
and the functional group compatibility of these strategies were also established. The utility of 
the dual divergent strategy has been demonstrated by synthesizing a small library of metal-
binding LHRH analogues. This work showcased the ability of the dual divergent strategy to 
rapidly construct the diverse array of ligand structures. In another application, the synthesis 
and characterization of the first ferryl-peptide conjugate was presented. In this work the 
reactivity and the mechanistic study for this ferryl-peptide conjugate were also described. 
From the mechanistic studies it has been proven that the remote benzyl group controls the 
stability of ferryl-peptide conjugate via an intramolecular hydrogen atom transfer 
mechanism. 
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